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1A Zusammenfassung 
Um sich an ihre spezielle Situation anzupassen, regulieren Zellen in hohem Maße die 
Proteinproduktion in jedem Schritt der Genexpression. Dazu kontrollieren Zellen die Mengen 
an Boten-RNA (mRNA) nicht nur während der Transkription, sondern auch 
posttranskriptional. In den letzten Jahren wurde eine Reihe von posttranskriptionalen 
Genregulationswegen beschrieben, wobei jedoch in vielen Fällen ein tiefes mechanistisches 
Verständnis dieser Regulationswege auf molekularer Ebene noch nicht erlangt wurde. 
Bisherige Studien haben gezeigt, dass diese Regulationswege trotz ihrer Verschiedenheit ein 
ähnliches Sortiment von generellen Translationsregulatoren und mRNA-Abbaufaktoren als 
Effektormoleküle einsetzen. Eine Untersuchung dieser generellen mRNA-abbauenden 
Proteine verspricht daher, unser allgemeines Verständnis der Regulation der Genexpression 
zu erweitern. 
In meiner Doktorarbeit habe ich den mRNA-Abbauweg als einen Mechanismus von 
posttranskriptionaler Genregulation untersucht. Insbesondere habe ich mich auf die mRNA-
Deadenylierung und die Hydrolyse der mRNA-5‘-Kappenstruktur (Decapping), die 
Schlüsselschritte des mRNA-Abbaus, fokussiert. Trotz ihrer Bedeutung war nur eine 
eingeschränkte mechanistische Erkenntnis in diese mRNA-Abbauprozesse vorhanden, 
insbesondere in Vielzellern. Ich habe daher Drosophila melanogaster (Dm) und Homo 
sapiens (Hs) als Modellsysteme ausgewählt, um sowohl mRNA-Deadenylierung als auch 
Decapping zu untersuchen. Des Weiteren habe ich den microRNA (miRNA)-Weg untersucht 
um eingehend zu verstehen, wie dieser Weg die generellen mRNA-Abbaufaktoren einsetzt. 
Im ersten Teil meiner Doktorarbeit habe ich systematisch die mRNA-Decapping-Proteine und 
ihre Proteinkomplexe, die sie bilden, um den mRNA-Abbau voranzutreiben, an den 
Beispielen von Decapping protein 1 (DCP1), DDX6/Me31B und Pat untersucht. Ich habe die 
Verbindungen, Domänen und funktionalen Sequenzen des Decapping-Komplexes in 
Vielzellern in den Modellsystemen Dm und Hs bestimmt, sowie deren Bedeutung für den 
Aufbau von Decapping-Aktivator-Komplexen und mRNA-Abbau in vitro und in Zellen. Die 
Untersuchung zur Rolle von DCP1 hat eine unerwartete Komplexität und Verbindung im 
Aufbau von Decapping-Aktivator-Komplexen gezeigt. Ein anderes Projekt konzentrierte sich 
auf den Aufbau der sich gegenseitig ausschließenden Komplexe mit der Helikase 
DDX6/Me31B als gemeinsamen Partner und bietet auf molekularer Ebene eine Erklärung 
dafür, wie diese Helikase unterschiedliche Funktionen bei der Regulation von mRNAs 
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ausüben kann. Zusammen mit einer Untersuchung des Decapping-Aktivators Pat hat diese 
Arbeit das bis dahin vorherrschende Modell eines statischen Super-Decapping-Aktivatoren-
Komplexes in Frage gestellt. Diese beiden Studien weisen eher auf verschiedene 
Unterkomplexe von Decapping-Aktivatoren hin, die sich durch sich gegenseitig 
ausschließende Wechselwirkungen dynamisch bilden und auflösen können. 
Im zweiten Teil meiner Doktorarbeit habe ich untersucht, wie der miRNA-Weg die generelle 
mRNA-Abbau-Maschinerie heranzieht, um mRNA-Angriffsziele der miRNAs beschleunigt 
abzubauen. Eine wachsende Zahl an Belegen in der neueren Literatur legte nahe, dass mRNA-
Abbau eine weitverbreitete Folge der Regulation durch miRNAs ist. Jedoch blieb der 
Mechanismus, wie miRNAs ihre Angriffsziele beschleunigt abbauen, unklar. Hier konnte ich 
eine direkte Verbindung zwischen der Kernkomponente des miRNA-Weges und zwei 
Deadenylierungsfaktoren bestimmen. Diese Proteine wiederum bringen ihre jeweiligen 
Deadenylierungs-Komplexe zu mRNA-Angriffszielen heran, um sie zu deadenylieren. Meine 
Arbeit liefert eine mechanistische Verbindung zwischen miRNA-geleiteter 
Angriffszielerkennung und Angriffszielabbau und zeigt, wie zelluläre Wege, die bisher als 
voneinander unabhängig betrachtet wurden, tatsächlich stark miteinander vernetzt sind. 
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1B Summary 
Cells highly regulate protein production at any step of gene expression in order to adapt to the 
specific situation they are in. To this end, cells not only control mRNA levels 
transcriptionally, but also post-transcriptionally. In the last years a multitude of post-
transcriptional gene regulation pathways have been described, but a deep mechanistic 
understanding at the molecular level of these pathways has not been achieved yet in many 
cases. However, a common outcome that emerged from previous studies was that despite their 
diversity, these pathways employ a similar set of general translation regulators and mRNA 
decay factors at the effector steps. Therefore, studying these general mRNA effector proteins 
promises to increase our general understanding of regulated gene expression. 
During my PhD thesis I studied the mRNA decay pathway as a mechanism of post-
transcriptional gene regulation. In particular, I focused on mRNA deadenylation and 
decapping, the key steps of mRNA decay. Despite their importance the mechanistic insight 
into these mRNA degradation processes had been limited, especially in metazoa. Therefore, I 
chose Drosophila melanogaster (Dm) and Homo sapiens (Hs) as model systems to study both 
mRNA deadenylation and decapping. Furthermore, I studied the microRNA (miRNA) 
pathway to understand in detail how this pathway employs the general mRNA degradation 
factors. 
In the first part of my thesis, I systematically dissected the proteins involved in mRNA 
decapping and the protein complexes they form to promote mRNA decay taking as examples 
the Decapping protein 1 (DCP1), DDX6/Me31B and Pat. I mapped the connectivity, domains 
and functional sequences of the metazoan decapping complex in the model systems Dm and 
Hs as well as their relevance for assembly of decapping activator complexes and mRNA 
degradation in vitro and in cells. A study on the role of the DCP1 revealed an unexpected 
complexity and connectivity of decapping activator complexes. Another project focused on 
the assembly of mutually exclusive complexes with the helicase DDX6/Me31B as common 
partner and provided an explanation at the molecular level of how this helicase can exert 
diverse functions in mRNA regulation. Together with a study on the decapping activator Pat, 
this work challenged the so far prevailing concept of a static super-decapping activator 
complex. These two studies rather suggest that distinct sub-complexes of decapping activators 
are formed and disassemble dynamically due to mutually exclusive interactions between the 
decapping factors. 
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In the second part of my PhD project, I studied how the miRNA pathway recruits the general 
mRNA decay machinery to promote degradation of miRNA targets. Growing evidence from 
recent literature suggested that mRNA degradation is a widespread consequence of miRNA 
regulation. However, the mechanism of how miRNAs promote target degradation remained 
elusive. Here, I could identify a direct link between the core silencing machinery and two 
deadenylation factors. These proteins in turn recruit their respective deadenylation complexes 
to the mRNA targets to promote deadenylation. My work provides a mechanistic connection 
between miRNA guided target recognition and target degradation and shows how cellular 
pathways that have been previously seen as distinct are actually highly interconnected. 
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2 Introduction 
2.1 mRNA synthesis and processing in metazoa 
Messenger RNAs (mRNAs) mediate the flow of information from genes to ribosomes, which 
synthesize the proteins. The basic mechanisms of mRNA synthesis and processing as well as 
mRNA degradation are conserved in metazoa. Therefore the following description applies to 
metazoa in general, however regarding protein names and paralogs this description focuses on 
the two model organisms Homo sapiens (Hs) and Drosophila melanogaster (Dm), since I 
worked with Hs and Dm cells in my PhD. 
During transcription mRNAs are capped at the 5’ end with a cap-structure (Figure 1), that 
protects the mRNA from rapid degradation, while the 3’ end is processed and polyadenylated. 
Splicing of the pre-mRNA starts co-transcriptionally resulting in the mature mRNA that is 
subsequently exported from the nucleus into the cytoplasm. 
 
 
Figure 1: A) Scheme of an mRNA; m
7
G, 7-methyl-guanosine; ORF, open reading frame B) The 
mRNA cap structure in eukaryotes: The cap consists of m
7
G linked by an inverted 5’-to-5’ 
triphosphate bridge to the first nucleoside of the mRNA chain (adopted from Gu and Lima, 2005). 
 
In the cytoplasm mRNAs are bound by a number of general as well as mRNA-specific 
proteins to form a dynamic messenger ribonucleoprotein (mRNP) complex. The cap is bound 
by the eukaryotic translation initiation factor 4E (eIF4E) and the poly(A) tail is bound by 
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cytoplasmic poly(A)-binding proteins (PABPCs) (Figure 2). Several paralogs of PABPC have 
been identified, but most studies on PABPC focused on the prototypcical PABPC1 or did not 
discriminate between the different paralogs. Therefore PABP, PABPC and PABPC1 are used 
in a synonymous way in the literature (Smith and Gray, 2010).  Both eIF4E and PABPC 
interact with eIF4G, so the mRNA is circularized promoting efficient translation (Sonenberg 
and Hinnebusch, 2009). 
 
 
Figure 2: The mRNA cap structure binds to eIF4E and the mRNA poly(A) tail binds to PABPC. Both 
eIF4E and PABPC interact with eIF4G allowing the mRNA to adopt a closed loop conformation. 
 
2.2 mRNA degradation in metazoa 
Cytoplasmic mRNA degradation in metazoa is generally initiated by deadenylation of the 
mRNA, i.e. shortening of the poly(A) tail (Figure 3). Deadenylation followed by a loss of 
PABPC interferes with the closed-loop conformation of the mRNA, reduces translation 
efficiency, and increases the accessibility of the mRNA ends to exonucleases. The translation 
initiation factors eIF4E and eIF4G are displaced upon deadenylation during the transition to a 
decapping competent mRNA, but details of this process are currently unclear (Franks and 
Lykke-Andersen, 2008; Goldstrohm and Wickens, 2008). 
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Figure 3: The general mRNA decay pathways in metazoa. mRNA degradation is initiated by 
shortening of the poly(A) tail by the two major cytoplasmic deadenylases: the PAN2-PAN3 complex 
with the components poly(A) specific ribonucleases PAN2 and PAN3 and the CCR4-NOT complex 
with the components Negative regulators of transcription (NOT1-3), Carbon catabolite repressor 
protein 4 (CCR4) and CCR4-associated factor 1 (CAF1). During deadenylation the mRNA loses 
PABPC and can no longer adopt the mRNA protecting closed loop conformation. The  deadenylated 
mRNA can be either decapped and degraded 5’ to 3’ or degraded 3’ to 5’ by the exosome. Pat together 
with the LSm1-7 ring acts s scaffold important for the transition to decapping. The Decapping protein 
2 (DCP2) has the catalytic activity, which is regulated by a set of decapping activators: the Decapping 
protein 1 (DCP1), the Enhancer of decapping 3 (EDC3), the Enhancer of decapping 4 (EDC4) and the 
DEAD box helicase DDX6/Me31B. The exonuclease XRN1 degrades mRNAs that are no longer 
protected by the cap structure. Alternatively to the degradation from the 5’ to 3’ end, the deadenylated 
mRNA can be degraded via the 3’ to 5’ pathway by the exosome assisted by the SKI-complex. The 
resulting 5’ fragment is degraded by the scavenger decapping protein (DCPS). 
 
Two major deadenylation complexes have been identified in the cytoplasm of eukaryotic 
cells: the poly(A) specific ribonuclease (PAN2-PAN3) complex and the Carbon catabolite 
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repressor protein 4 - Negative regulator of transcription (CCR4-NOT) complex (Goldstrohm 
and Wickens, 2008). Deadenylation is started in a distributive manner by the PAN2-PAN3 
complex with PAN2 as the catalytic subunit (Figure 3). PAN3 interacts with PABPC and is 
important for the recruitment of PAN2 to the mRNA (Yamashita et al., 2005). At a certain 
length of the poly(A) tail, that depends on the organism, the CCR4-NOT continues 
deadenylation in a processive manner. However, the first phase of deadenylation catalyzed by 
the PAN2-PAN3 complex is not essential to deadenylate mRNAs, since the CCR4-NOT 
complex is sufficient for deadenylation in cells depleted from the PAN2-PAN3 deadenylation 
activity (Tucker et al., 2001; Yamashita et al., 2005). The CCR4-NOT complex has two 
catalytic subunits: the CCR4 protein (there are two paralogs CCR4a and CCR4b in human 
cells, but only one ortholog CCR4 in Dm) and the CAF1 or the related POP2 protein (in 
human cells there are two proteins CAF1 and POP2, but in Dm there is only one protein 
POP2/CAF1). The CCR4-NOT complex contains also several NOT proteins, that are 
important for the activity of the complex in cells (Collart and Panasenko, 2011). An additional 
cellular deadenylase, the PARN protein, has also been identified. The PARN dedeadenylase 
has been shown to be important for X.laevis development, but no homolog has been identified 
in D. melanogaster suggesting, that PARN activity is not generally required in metazoa 
(Goldstrohm and Wickens, 2008). 
Upon deadenylation the mRNA is either degraded by the 5’ to 3’ pathway or the 3’ to 5’ 
pathway (Figure 3). In the 5’ to 3’ pathway, the mRNA is decapped by the decapping protein 
2 (DCP2), which is activated and regulated by several decapping activators, i.e. the decapping 
protein 1 (DCP1), the metazoa-specific enhancer of decapping 4 (EDC4), the DEAD box 
helicase DDX6 and the enhancer of decapping 3 (EDC3). In yeast, DCP1 directly interacts 
with DCP2 and stimulates decapping activity in vitro and in vivo, but in metazoa an additional 
protein EDC4 is necessary to stabilize this interaction (Fenger-Grøn et al., 2005). The Pat 
protein in complex with the LSm1-7 ring associates with deadenylated mRNAs and is a 
scaffold protein important for the transition of a translationally active mRNA to an mRNA 
subjected to degradation (Tharun et al., 2000; Tharun and Parker, 2001). During the 
decapping reaction the cap-structure (Figure 1B) is hydrolyzed by DCP2 and m
7GDP and 5’ 
monophosphorylated mRNA are released. 
In specific situations deadenylation as a prerequisite for decapping can be bypassed, as shown 
for the degradation of the mRNA coding for ribosomal protein Rps28b. Here the decapping 
machinery is directly recruited to the mRNA (Badis et al., 2004). mRNA decappping can even 
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occur co-translationally (Hu et al., 2009). Recently, an additional decapping protein, Nudt16, 
has been identified in mammals, suggesting redundancy and/or target-specificity also at the 
step of mRNA decapping (Song et al, 2010). 
When the mRNA is no longer protected by the cap-structure, the mRNA body is rapidly 
degraded from the 5’ end by the exoribonuclease 1 (XRN1) (Figure 3). Since there is strong 
evidence that the step of decapping irreversibly commits an mRNA to degradation, the step of 
decapping has to be tightly controlled (Franks and Lykke-Andersen, 2008). 
Alternatively, following deadenylation mRNAs can be degraded from the 3’ end by the 
cytoplasmic exosome assisted by the SKI-complex. The resulting 5’ fragment is hydrolyzed 
by the scavenger decapping protein DCPS (Parker and Song, 2004; Figure 3). 
In addition to the general mRNA decay pathways initiated by deadenylation, there are also 
specific pathways involving an initial cleavage within the mRNA by an endonuclease such as 
in the nonsense-mediated mRNA decay (NMD) or the small interfering RNA (siRNA) 
pathway, and the resulting fragments are further degraded by XRN1 and the exosome 
(Tomecki and Dziembowski, 2010). Replication dependent histone mRNAs do not have a 
poly(A) tail, but a histone stem-loop structure in the 3’ UTR. Histone mRNAs is degraded 
after completion of DNA replication dependent on the stem-loop binding protein (SLBP) 
(Marzluff et al., 2008). 
Interestingly, the proteins involved in mRNA degradation colocalize into so-called processing 
bodies (P bodies), but the function of these RNA granules is currently not completely 
understood (Eulalio et al., 2007). 
 
2.3 Post-transcriptional regulation of gene expression 
2.3.1 Importance of post-transcriptional regulation of gene expression 
The steady-state levels of mRNAs are determined both by the rates of synthesis and 
degradation. For a rapid adjustment of the mRNA levels a short mRNA half-life is critical, but 
longer mRNA half-lives allow for efficient protein synthesis of gene products over a longer 
period of time. Indeed, mRNA half-lives vary from minutes to days, as determined in mouse 
cells (Sharova et al., 2009). Because mRNA abundance and efficiency of translation both 
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define the amount of protein produced by the cell, the step of translation is also regulated by 
multiple mechanisms. Translational activation or repression can be reversible and allow for a 
very rapid adaptation of gene expression to the needs of the cells. 
 
2.3.2 Regulated translation of mRNAs 
A well-studied example of regulated translation of mRNAs involves eIF4E-binding proteins 
(4E-BPs) that regulate the step of translation initiation. 4E-BPs compete with eIF4G for 
binding to eIF4E and thereby inhibit translation initiation since eIF4E-eIF4G interaction is 
important for efficient translation initiation (Figure 2). The kinase mTOR controls the status 
of 4E-BP phosphorylation, which in turn regulates binding to eIF4E. Phosphorylated 4E-BPs 
interact weaker with eIF4E than hypophosphorylated 4E-PBs. Therefore phosphorylation of 
4E-BPs allows cells to adjust translation efficiency to extra- and intracellular stimuli 
(Sonenberg and Hinnebusch, 2009). 
 
2.3.3 Regulated mRNA degradation 
Regulation of mRNA degradation is well-understood for a certain class of short lived 
mRNAs, that are characterized by AU-rich elements (AREs) in their 3’ UTR, such as the 
mRNAs coding for the cytokines IL-2 or TNF-α. AREs are recognized by the RNA-binding 
protein Tristetraprolin that mediates rapid degradation of mRNA targets. Tristetraprolin 
activity depends on its phosphorylation status, which allows regulation of mRNA stability by 
kinases and phosphatases as e.g. in macrophages during inflammation (Sandler and Stoecklin, 
2008). Recently, Tristetraprolin has been shown to interact with NOT1 which in turn recruits 
the deadenylase CAF1 providing a mechanistic basis for how Tristetraprolin mediates CCR4-
NOT complex-dependent degradation of its mRNA target (Sandler et al., 2011). 
For a certain set of mRNAs during development in Dm it has been shown that the CCR4-NOT 
complex is recruited by RNA-binding proteins such as Smaug or the Pumilio-Nanos complex 
(Goldstrohm and Wickens, 2008). 
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2.4 microRNA-pathway 
2.4.1 Biological impact of the microRNA-pathway 
microRNAs (miRNAs) are a class of small RNAs that are endogenously transcribed. In 
mammals several hundreds of miRNAs have been identified. Each animal miRNA is 
predicted to regulate hundreds of targets, so approximately half of the human transcriptome is 
estimated to be fine-tuned by miRNAs. Thus, it is not surprising that miRNAs are implicated 
in a broad range of biological processes, such as growth, development and metabolism 
(Bartel, 2009). 
 
2.4.2 microRNA biogenesis and function 
Animal miRNAs are transcribed as long primary transcripts and processed subsequently by 
the RNases Drosha and Dicer to the mature miRNA duplex. The two strands of the duplex 
each have a length of approximately 21 nucleotides and a phosphate at the 5’ end. One of the 
two strands, the guide strand, is loaded into an Argonaute (AGO) protein, the central 
component of the miRNA-induced silencing complex (miRISC). The guide strand guides the 
miRISC to the mRNA target by partial sequence complementarity (Krol et al., 2010). 
The miRISC causes translational repression and/or mRNA degradation of the mRNA target 
(Huntzinger and Izaurralde, 2011). Initially, animal miRNAs were thought to mainly repress 
translation as shown for the example of lin-4 miRNA (Olsen and Ambros, 1999). 
Subsequently several studies provided evidence, that miRNAs can promote target degradation 
(Bagga et al., 2005; Krützfeldt et al., 2005; Lim et al., 2005; Wu and Belasco, 2005). Recent 
transcriptome-wide studies showed that decreased mRNA levels of miRNA targets explain in 
most of the cases the decreased protein production, so mRNA degradation is a predominant 
effect of miRNA regulation (Baek et al., 2008; Selbach et al., 2008; Hendrickson et al., 2009; 
Guo et al., 2010; Huntzinger and Izaurralde, 2011). 
 
 
 
12  
2.4.3 Mechanism of microRNA-mediated gene silencing 
In contrast to the related siRNA-pathway, in the miRNA-pathway AGO proteins generally do 
not cleave their targets endonucleolytically, but recruit a protein of the GW182 protein family. 
Indeed, GW182 proteins are essential for silencing in animal cells and are considered together 
with the miRNA loaded AGO proteins as the core miRISC (Eulalio et al., 2009a). Only one 
ortholog of GW182 is present in Dm, but in human cells there are three paralogs of GW182: 
the Trinucleotide repeat-containing gene 6 proteins TNRC6A, TNRC6B and TNRC6C, which 
seem to be redundant. The domain organization of GW182 proteins is conserved from human 
to flies (Figure 4). 
 
 
Figure 4: Domain organization of GW182 proteins: Hs, Homo sapiens; Dm, Drosophila 
melanogaster. N-term, Mid and C-term: N-terminal, middle and C-terminal GW-repeat-containing 
regions, respectively (the number of GW-repeats in each region is indicated in brackets). UBA: 
ubiquitin associated-like domain; Q-rich: region rich in glutamine; PAM2: PABPC-interacting motif 
2; RRM: RNA recognition motif. Numbers underneath the protein schematic represent amino acid 
positions at the fragment boundaries for each protein. The AGO-binding and silencing domains are 
indicated (adopted from Eulalio et al., 2009a). 
 
GW182 proteins have multiple Gly-Trp (GW)-repeats in their N-terminal region, which 
mediate direct binding to the AGO proteins. Single GW-repeats have only low affinity for 
AGOs, but together they contribute to efficient AGO-binding. The relative contribution of a 
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GW-repeat to AGO-binding depends on its specific sequence context in the GW182 protein. 
The N-terminal region therefore has been termed AGO-binding domain. The AGO-binding 
domain is followed by a conserved ubiquitin associated-like domain (UBA), a region rich in 
glutamine (Q-rich) and the silencing domain. The silencing domain has been shown to be 
necessary and sufficient for silencing activity in human cells and contains a middle region 
(Mid) and a C-terminal region (C-term). GW182 proteins also contain a conserved RNA 
recognition motif (RRM), but its functional importance is currently not well understood 
(Eulalio et al., 2009a). 
GW182 proteins are the effector proteins of the miRNA pathway and cause translational 
repression and/or mRNA degradation of their targets. Degradation of mRNA targets requires 
the activities of the CCR4-NOT complex and the decapping complex, but also the PAN2-
PAN3 complex has been implicated in the miRNA pathway. The molecular mechanism of 
translational repression by miRNAs is not well understood and several models have been 
proposed: Translational repression could occur at the step of initiation or at the step of 
elongation and even cotranslational degradation of the nascent peptide has been proposed, but 
only the first two models are strongly supported by experimental evidence (Fabian et al., 
2010; Huntzinger and Izaurralde, 2011). 
Recently, GW182 proteins were shown to interact directly with PABPC via a conserved 
PABP-interacting motif-2 (PAM2), and this interaction is important for silencing in vitro and 
in cells (Fabian et al., 2009; Zekri et al., 2009). The interaction of GW182 with PABPC was 
proposed to compete with PABPC-eIF4G-binding and/or to interfere with the protection of 
the poly(A) tail by PABPC and/or to promote deadenylation. In Figure 5 the working model 
from 2010 of the mechanism of miRNA-mediated gene silencing is shown (Fabian et al., 
2010; Huntzinger and Izaurralde, 2011). 
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Figure 5: Mechanism of miRNA-mediated gene silencing: silencing is effected by an Argonaute 
(AGO) protein recruiting a GW182 protein. GW182 proteins in turn interact with PABPC and 
promote translational repression (A) and/or mRNA degradation (B). A) GW182 has been shown to 
compete with the eukaryotic initiation factor 4G (eIF4G) for binding to PABPC to repress translation. 
B) mRNA degradation is initiated by deadenylation dependent on the PAN2-PAN3 and CCR4-NOT 
complexes. The deadenylated mRNA can be stored or degraded by the 5’ to 3’ decay pathway 
(adopted from Tritschler et al., 2010). 
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3 Motivation and aims 
3.1 How do decapping activators assemble to promote mRNA decapping in 
metazoa? 
When I started my PhD in July 2008, proteins involved in the 5’ to 3’ mRNA degradation 
pathway had been identified in genetic screens and biochemical purifications. However, 
functional and mechanistic studies on the 5’ to 3’ mRNA degradation pathway were mainly 
limited to yeast, despite its importance for general mRNA degradation and target specific 
pathways such as the miRNA-pathway. In particular how the decapping activators contribute 
to mRNA decapping was unclear (Franks and Lykke-Andersen, 2008). Furthermore, even for 
proteins that are conserved in yeast, the metazoan homologs contain additional domains and 
extensions adding another layer of complexity to the metazoan mRNA degradation machinery 
(Figure 6). 
 
 
Figure 6: Domain organization of DCP1 proteins: Sp, Schizosaccharomyces pombe and Hs, Homo 
sapiens. The conserved Ena-VASP homology 1 (EVH1) domain and metazoan specific conserved 
sequences are colored. Numbers underneath the protein schematic represent amino acid positions at 
the fragment boundaries for each protein (adopted from Tritschler et al., 2009b). 
 
For most of the mRNA decay factors the specific function during mRNA degradation as well 
as their interaction with other decay factors was not precisely characterized. In the decapping 
field the model of a super-decapping activator complex was favored. According to this 
hypothesis decapping activators bind to the mRNA committed to decay simultaneously or 
subsequently until ultimately a static decapping activator complex comprising the full set of 
protein factors important for decapping is assembled (Parker and Sheth, 2007). Specifically, 
my work addressed 4 main questions: 
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3.1.1 What is the role of metazoan DCP1 and how does it promote mRNA decapping? 
To improve the mechanistic understanding of how decapping activators promote mRNA 
decapping and to test the model of a super-decapping complex I studied how mRNA 
decapping factors assemble precisely and how this is relevant for mRNA decapping. I chose 
to study the role of DCP1 in decapping activator complexes based on the prominent role of 
DCP1 among the decapping activators. Indeed, DCP1 was the first protein identified as being 
required for mRNA decapping even before DCP2 itself (Beelman et al., 1996). Studying the 
role of DCP1 in decapping complexes therefore was expected to yield insights into 
fundamental aspects of mRNA decapping. I focused on metazoan DCP1, since in addition to a 
lack of mechanistic understanding of the process of mRNA decapping itself, it was unclear 
how mRNA decay is integrated by target specific decay pathways involved in post-
transcriptional gene regulation in metazoa. In Figure 6 the domain organization of yeast and 
human DCP1 proteins is shown. Both orthologs have an N-terminal conserved Ena-VASP 
homology 1 (EVH1) domain, but metazoan DCP1 has a long C-terminal extension with 
additional motifs conserved in metazoa. This illustrates the increased complexity of metazoan 
DCP1 and the rationale of studying metazoan DCP1. 
 
3.1.2 How can Pat act as a scaffold to promote mRNA decapping? 
According to the established “super-decapping activator complex model” decapping 
activators assemble during the commitment of an mRNA to decapping. The Pat protein has 
been shown to be important for the transition of a translationally active mRNA to an mRNA 
committed to decapping (Tharun and Parker, 2001; Coller and Parker, 2005). Mapping the 
interactions of Pat with other decapping activators was the next step towards mechanistic 
insights into the scaffold function of Pat. Previously, the yeast ortholog Pat1 had been studied, 
but the mechanistic insights were limited, so there was still much to learn (Pilkington and 
Parker, 2008). Studying this protein also promised to be the key to investigate if decapping 
factors indeed assemble sucessively to a super-decapping complex or if they rather form 
dynamically linked distinct decapping activator complexes. This competing model could not 
be excluded or proven by experimental evidence at that time. 
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3.1.3 How does the DEAD box helicase DDX6/Me31B assemble into distinct complexes 
in translational repression and mRNA decapping? 
Previous data from our lab suggested that DDX6/Me31B assembles into distinct decapping 
activator complexes (Tritschler et al., 2007; Tritschler et al., 2008). Indeed, it had been shown 
that DDX6 associates either into a complex containing DCP1 and the translational repressors 
Trailer Hitch (Tral) and Cup or into another complex containing EDC3, DCP1 and DCP2. 
However insights into the molecular details und functional importance of these interactions 
was only limited (Tritschler et al., 2008). In addition, DDX6/Me31B had been shown to 
interact with Pat (Coller et al., 2001), which raised the question how the complex of 
DDX6/Me31B with Pat was related to these two previously described complexes. Using the 
crystal structure of DDX6/Me31B, which was solved by another PhD student (Felix 
Tritschler) in the lab, I designed and tested mutants to dissect how DDX6/Me31B is recruited 
into distinct functional complexes and to test the relevance of these assemblies for 
DDX6/Me31B function. 
 
 3.2 How are general mRNA decay factors recruited to miRNA targets? 
Pathways of post-transcriptional gene regulation had been described to employ general 
mRNA decay factors, but it remained unclear how these factors are integrated. As an example 
for this, it was of outstanding interest to study the miRNA pathway in detail to understand 
how mRNA degradation is promoted by miRISCs. Several lines of evidence suggested that 
mRNA degradation is a widespread consequence of miRNA regulation (Eulalio et al., 2009b). 
However the mechanism of how miRNAs promote target degradation remained elusive. Even 
the idea that miRNAs promote mRNA target degradation was under debate. The elucidation 
of how the miRNA pathway recruits the general mRNA decay machinery to promote 
degradation of miRNA targets was therefore expected to provide mechanistic insights into the 
mechanism of miRNA-mediated gene silencing in particular, but also how general mRNA 
decay factors are integrated into specialized post-transcriptional gene regulation pathways. 
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4 Results and discussion 
4.1 Decapping activators assemble into distinct mRNA decapping complexes in 
metazoan to promote mRNA decapping. 
To dissect the interaction network of decapping activators, I systematically investigated the 
connectivity, domains and functional sequences of the metazoan decapping activators in the 
model systems Dm and Hs and tested their relevance for decapping and mRNA degradation in 
vitro and in cells.  
Analysis of metazoan DCP1 showed an unexpected complexity and connectivity of the 
metazoan decapping complex (4.1.1), which is important to mechanistically understand the 
process of decapping itself in metazoan and also sheds light on how in metazoa specific 
pathways integrate the general mRNA decay factors at the effector steps. 
Studying how Pat (4.1.2) and DDX6/Me31B (4.1.3) assemble into distinct decapping 
complexes provided a molecular explanation for their functions and challenged the prevailing 
model of a super-decapping complex. 
 
4.1.1 DCP1 self-interacts to assemble into active mRNA decapping complexes in 
metazoa. 
The work described in this chapter has been published in Tritschler et al., 2009b. 
Experimental data and detailed description of experimental procedures are available in the 
attached manuscript. 
In this study, I investigated the role of metazoan DCP1 in the assembly of mRNA decapping 
complexes. The composition of the metazoan decapping complex had been described by 
Fenger-Grøn and colleges in 2005, but it was not clear how this complex assembles and 
which role DCP1 plays in this complex. Structural and functional analysis of DCP1 was 
limited to its EVH1 domain (She et al., 2008). Yeast DCP1 consists only of the EVH1 
domain, but metazoan DCP1 has a C-terminal extension (Figure 6). 
Analyzing this metazoan specific C-terminal extension of DCP1 I could identify two novel 
conserved motifs, motif I and the so called trimerization domain. The trimerization domain 
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was subsequently shown by another PhD student (Felix Tritschler) in the lab to mediate 
homotrimerization, therefore referred to as trimerization domain. In human cells, there are 
two paralogs of DCP1 (DCP1a and DCP1b), and in this study I focused on DCP1a. As the 
first step, I generated expression constructs for wild-type DCP1a and deletion mutants, that 
either lacked motif I (DCP1a-ΔMI) or the trimerization domain (DCP1a-ΔTD). I tested these 
mutants in an in vitro decapping assay (Lykke-Andersen, 2002). To this end, I expressed 
GFP-tagged wild-type or mutant DCP1a in human HEK293 cells and immunoprecipitated the 
respective DCP1a protein and copurifying interaction partners. I incubated the 
immunoprecipitate with a capped RNA substrate. Since I labeled the cap-structure of this 
RNA substrate radioactively, I could detect by autoradiography non converted still capped 
RNA substrate and m
7
GDP, the product of the decapping reaction. After stopping the in vitro 
decapping reaction with EDTA, I spotted an aliquot on a polyethylenimine-modified cellulose 
plate and separated the reaction mix by thin-layer chromatography. Decapping activity 
copurifies with wild-type DCP1a and DCP1a-ΔMI, but not with DCP1a-ΔTD. The absence of 
in vitro decapping activity in DCP1a-ΔTD immunoprecipitate could be either due to an 
impaired ability of DCP1a-ΔTD to stimulate DCP2 activity or DCP1a-ΔTD could no longer 
be incorporated into active decapping complexes. 
To discriminate between these two possibilities and to answer the question why the 
trimerization domain is essential for DCP1a to immunoprecipate decapping activity, I tested 
wild-type DCP1a, DCP1a-ΔMI and DCP1a-ΔTD in coimmunoprecipitation experiments for 
interactions with decapping activators and for self-interaction. I showed that motif I is critical 
for DCP1a to interact with EDC3 and DDX6/Me31B, but not for the interaction with EDC4 
or DCP2. In contrast the trimerization domain mediates self-interaction. Furthermore, this 
domain also confers binding to DCP2 and EDC4. However it is not important for binding of 
DCP1a to EDC3 or DDX6/Me31B. 
My results suggested that DCP1a has central role in the assembly of two decapping 
complexes (DCP1a-EDC3-DDX6/Me31B and DCP1a-DCP2-EDC4). Together with the self-
interaction of DCP1a, these two decapping activator complexes could interact suggesting the 
existence of larger decapping complexes formed from these building blocks. 
To study the role of DCP1 in vivo I established a complementation assay for DCP1 in Dm S2 
cells (Figure 7). In such a complementation assay the cellular function of a certain protein – 
here DCP1 – is monitored. The cells are depleted of endogenous DCP1 by RNA interference 
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(RNAi). These knockdowns are typically achieved in Dm S2 cells by siRNAs targeting the 
open reading frame of DCP1 mRNA or long double-stranded RNAs (dsRNAs) targeting its 
untranslated regions. However using these approaches the knockdown efficiency was not 
sufficient. I therefore established a new approach in which long dsRNAs targeting the open 
reading frame of DCP1 were used. A version of DCP1, that I made resistant to the long 
dsRNAs by silent mutations in the several hundred nucleotides long targeted sequence, is then 
added back to the cells. In this way I could test whether DCP1 mutants can complement the 
loss of endogenous DCP1 as efficient as wild-type DCP1 or if the mutations affect the protein 
function. I established this complementation strategy successfully for DCP1 in Dm S2 cells 
and meanwhile this complementation strategy has been frequently used also in other studies in 
S2 cells. When I tested DCP1 lacking the trimerization domain in this complementation assay, 
I observed clearly reduced decapping activity, showing that the trimerization domain is 
important for efficient decapping in vivo. 
 
  
Figure 7: Complementation assay in Dm S2 cells. S2 cells are depleted from endogenous DCP1 by 
RNA interference (RNAi) and decapping is inhibited. An RNAi-resistant version of DCP1 wild-type 
or mutant is transfected together with a reporter to monitor decapping. This allows for testing if the 
mutant DCP1 rescues decapping in cells comparable to wild-type or if the mutation affects its function 
in cells. 
 
Summarizing this study on DCP1, I found that metazoan DCP1 – in contrast to yeast DCP1 – 
self-interacts and establishes an interaction network via motif I and the trimerization domain 
(Figure 8). This results in an unexpected connectivity and complexity of the metazoan 
decapping complex and explains the central role of DCP1 in decapping activator assembly 
and activation of decapping. 
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Figure 8: Metazoan DCP1 assembles via the trimerization domain (TD) and motif I (MI) into two 
decapping activator complexes. TD mediates DCP1 self-interaction and binding to DCP2 and EDC4 
and M1 confers binding to EDC3 and DDX6. 
 
4.1.2 Pat assembles into distinct mRNA decapping complexes. 
The work described in this chapter has been published in Braun et al., 2010. Experimental 
data and detailed description of experimental procedures are available in the attached 
manuscript. 
As mentioned above, the Pat protein plays an important role in the transition of translationally 
active mRNAs to mRNAs that are repressed and committed to degradation. However the 
molecular details of how the Pat protein serves as a scaffold in this transition was unclear, in 
particular for the human Pat protein (Coller and Parker, 2005; Scheller et al., 2007; Pilkington 
and Parker, 2008). In this study I dissected the human Pat protein and determined how it 
assembles into distinct decapping activator complexes. In human there are two paralogs of the 
Pat protein, however only PatL1 and not PatL2 is a functional ortholog of the yeast Pat1 
protein, which is why I studied the human PatL1 protein. 
 
  
Figure 9: Domain organization of Hs PatL1: PatL1 consists of a conserved N-terminal sequence (N-
term), a proline-rich region (P-rich), a conserved Middle domain (Mid) and a conserved C-terminal 
domain (Pat-C). Numbers underneath the protein schematic represent amino acid positions at the 
fragment boundaries (adopted from Braun et al., 2010). 
 
First, I examined the interaction of PatL1 with decapping activators in coimmunoprecipitation 
experiments in human HEK293 cells. I could detect interactions of PatL1 with 
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DDX6/Me31B, DCP2, EDC4 and the LSm1-7 ring. Analysis of the domain organization of 
PatL1 revealed a conserved N-terminal sequence (N-term), a proline-rich region (P-rich), a 
conserved Middle domain (Mid) and a conserved C-terminal domain (Pat-C) (Figure 9). To 
map which part of the PatL1 protein is important for these interactions, I generated a series of 
expression constructs to express fragments of PatL1. I showed that DDX6/Me31B interacts 
with the N-term of PatL1. Using deletion constructs I found Pat-C is essential for PatL1 to 
interact with DCP2, EDC4 and the LSm1-7 ring. The P-rich cooperates with Pat-C to bind 
DCP2 and EDC4, whereas Mid and Pat-C form a bipartite binding site for the LSm1-7 ring. 
Interestingly, a construct of PatL1 comprising the P-rich in addition to the Mid and the Pat-C 
interacts less efficient with the LSm1-7 ring than Mid and Pat-C alone, therefore the P-rich 
interferes with LSm1-7 ring binding. This might be due to the induction of a different 
conformation of PatL1 with lower affinity for the LSm1-7 ring in consequence of 
DCP2/EDC4-binding. Alternatively binding of an as yet unknown factor X to the P-rich could 
block the accessibility of the Mid domain to the LSm1-7 ring. 
In summary, I could describe several distinct PatL1 complexes (Figure 10). DDX6-binding to 
PatL1 is independent of the binding of DCP2, EDC4 and the LSm1-7 ring, however I could 
observe a negative correlation of DCP2/EDC4- and LSm1-7-binding to PatL1. Therefore, 
either the Mid and Pat-C domains cooperate to bind the LSm1-7 ring (Figure 10A) or the P-
rich binds together with Pat-C to DCP2 and EDC4 (Figure 10B). An additional complex with 
an as yet unknown protein (factor X) binding to the P-rich region and blocking the 
accessibility of the Mid domain to the LSm1-7 ring cannot be excluded (Figure 10C). 
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Figure 10: Hs PatL assembles into distinct mRNA decapping complexes and may adopt different 
conformations: A) one with the ability to interact with the LSm1-7 ring and the other B) interacting 
either with EDC4 and DCP2. A third complex C) with an as yet unknown protein factor (X) binding to 
the P-rich region and blocking the accessibility of the Mid domain to the LSm1-7 ring cannot be 
excluded. 
 
Since PatL1 interacts with DCP2 I asked whether decapping activity can be copurified with 
PatL1. To address this question I performed an in vitro decapping assay as described in 4.1.1 
and showed that PatL1coimmunoprecipitates decapping activity. I mapped using deletion 
constructs which part of PatL1 is important to incorporate PatL1 into active decapping 
complexes. Consistently with the interaction data described above Pat-C is essential for PatL1 
incorporation into active decapping complexes. 
In conclusion, the mapping of interactions revealed distinct complexes of PatL1 with 
potentially specific function or representing sequential steps of mRNA decay challenging the 
prevailing model of a static super-decapping complex. Further this indicates a central role for 
the Pat-C domain in PatL1, which has been described to be dispensable in the yeast Pat1 
ortholog (Pilkington and Parker, 2008). 
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4.1.3 The DEAD box helicase DDX6/Me31B interacts with EDC3, Tral and Pat to form 
distinct complexes with roles in translational repression and mRNA decapping. 
The work described in this chapter has been published in Tritschler et al., 2009a and Haas et 
al., 2010. Experimental data and detailed description of experimental procedures are available 
in the attached manuscripts. 
The DEAD box helicase DDX6/Me31B has been implicated in translational repression and 
mRNA decapping (Weston and Sommerville, 2006). Consistently, DDX6/Me31B interacts 
with the decapping factors EDC3, DCP1, DCP2, Pat and the LSm1-7 ring and with Tral and 
Cup, which are involved in translational repression. The resulting protein complexes might 
explain the functional diversity of DDX6/Me31B. Previous work from our lab identified two 
complexes in Dm, one complex contains minimally DCP1, Tral and Cup and another complex 
EDC3, DCP1 and DCP2 (Tritschler et al., 2007; Tritschler et al., 2008). Taking advantage of 
the structural information on the interaction interface of DDX6/Me31B with EDC3 (3.1.3) I 
tested a set of mutants of DDX6/Me31B and EDC3 predicted to be defective in 
DDX6/Me31B-EDC3 interaction in coimmunoprecipitation experiments in Dm S2 cells. 
I identified amino acids in DDX6/Me31B important for EDC3-binding. These mutants 
allowed me to test in coimmunoprecipitation experiments, if Tral uses a mode of interaction 
similar to EDC3 to interact with DDX6/Me31B. Indeed, Tral binds to the same protein 
surface of DDX6/Me31B as EDC3. I also generated mutants of EDC3 deficient in 
DDX6/Me31B-binding and defined the amino acids of EDC3 critical for the interaction with 
DDX6/Me31B. Sequence similarities between EDC3 and Tral suggested that a related Phe-
Asp-Phe motif (FDF) in Tral is important for binding to DDX6/Me31B. I confirmed this 
prediction in coimmunoprecipitation experiments. These interaction mutants of 
DDX6/Me31B and EDC3 also allowed me to test the functional importance of the interaction 
of DDX6/Me31B with EDC3 and Tral to repress the expression of bound mRNAs in tethering 
assays. Wild-type DDX6/Me31B or EDC3 repress translation of bound mRNAs. In contrast, 
DDX6/Me31B or EDC3 mutants that no longer interact were also unable to repress the 
expression of the mRNA target. 
Interestingly, DDX6/Me31B not only interacts with EDC3 and Tral, but also with HPat. 
Testing a mutant of DDX6/Me31B that is deficient in EDC3 and Tral binding in 
coimmunoprecipation experiments I could show that different amino acids of DDX6/Me31B 
are important for the interaction with HPat than with EDC3 and Tral. Nevertheless, the 
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binding of DDX6/Me31B to HPat and EDC3 or Tral is mutually exclusive, as I observed in 
competition experiments. 
Summarizing this data, I could provide evidence for three mutually exclusive complexes 
containing DDX6/Me31B as common factor (Figure 11). These distinct complexes containing 
translational repressors and decapping activators suggest how at the molecular level different 
function of DDX6/Me31B dependent on the respective interaction partners could be achieved. 
 
  
Figure 11: DDX6/Me31B establishes mutually exclusive interactions with EDC3, Tral and Pat. 
 
 4.2 GW182 proteins directly recruit cytoplasmic deadenylase complexes to 
miRNA targets. 
The work described in this chapter has been published in Braun et al., 2011 and Huntzinger et 
al., 2010. Experimental data and detailed description of experimental procedures are available 
in the attached manuscripts. 
miRISCs cause translational repression and/or mRNA degradation of miRNA targets. 
miRNA-mediated mRNA degradation is initiated by deadenylation. But despite strong 
evidence that miRISCs can promote deadenylation the mechanism of how they accelerate 
deadenylation has remained controversial and two models can be envisioned: 1) miRISCs 
could directly promote deadenylation of miRNA targets, 2) the observed accelerated 
deadenylation could be only an indirect consequence of miRISC activity. In the latter case the 
translational block or the interaction of GW182 proteins with PABPC could indirectly 
promote deadenylation of miRNA targets. 
To discriminate between these possibilities I systematically screened for interactions between 
the miRISC and subunits of the two cytoplasmic deadenylation complexes in human and Dm 
cells. 
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I started with a systematic screen between the AGO/GW182 proteins as the core components 
of the miRISC and the components of the two major cytoplasmic deadenylases, the CCR4-
NOT complex and the PAN2-PAN3 complex in human HEK293 cells and Dm S2 cells by 
coimmunoprecipitation experiments. I observed that human and Dm GW182 proteins interact 
with subunits of the CCR4-NOT and the PAN2-PAN3 complexes. When I compared the three 
human GW182 proteins I could not observe a significant difference in their interaction profile 
consistent with the functional data so far available on these proteins suggesting a redundant 
function in the miRNA pathway. I detected only much weaker interactions between the AGO 
proteins and the deadenylase factors, so I focused on the GW182 proteins. 
In human cells I could observe interactions between the GW182 proteins and PAN3, NOT1, 
NOT2, CCR4a, CCR4b, CAF1 and POP2. Since this screen for interactions was done with 
transiently overexpressed proteins, it was important to validate these interactions with 
endogenous proteins, what I did for PAN3 and NOT1, for which suitable antibodies were 
available. 
Since these interaction studies were done in cell lysates, the discussed interactions could be 
direct or mediated by another protein present in the cell lysate. To address this question, I 
tested the positive hits of the interaction screen as candidates for direct interactions in GST-
pulldown experiments, where I incubated GST-tagged GW182 purified from E. coli with the 
respective in vitro translated deadenylation factor. Only PAN3 and NOT1 interacted with 
GW182 under these conditions. 
However neither PAN3 nor NOT1 have deadenylase activity themselves, so to test if PAN3 
and NOT1 indeed recruit the PAN2-PAN3 and the CCR4-NOT complex to the GW182 
proteins to promote deadenylation, I performed a combination of overexpression and 
depletion experiments. These experiments provided evidence, that PAN3 can recruit PAN2 
and NOT1 can recruit the CCR4-NOT complex to miRNA targets (Figure 12).  
Further these experiments showed also that NOT1 and PAN3 mediate at least in part indirect 
binding of GW182 to PABP that I recently observed in human cells (Huntzinger et al., 2010). 
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Figure 12: GW182 is recruited by the AGO-protein to the miRNA target and interacts with PABPC. 
GW182 directly recruits the CCR4-NOT and PAN2-PAN3 complexes to promote deadenylation of the 
miRNA target. Mid1 (M1), Mid2 (M2) and the C-term (C) of the silencing domain are important for 
the direct interactions with PAN3 and NOT1 as depicted. 
 
To define which part of the GW182 proteins confers binding to the deadenylation factors, I 
tested not only full-length GW182 proteins, but also a fragment lacking the silencing domain 
or only the silencing domain alone. I found the silencing domain was necessary and sufficient 
for these interactions, which is consistent with the observation that the silencing confers the 
silencing activity. 
Thus, the silencing domain of GW182 proteins provides a binding platform for PABPC 
(Fabian et al., 2009; Zekri et al., 2009; Huntzinger et al., 2010) and deadenylase complexes to 
promote silencing. Further these results indicate that deadenylation is a direct effect of 
miRNA regulation. 
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5 Conclusions 
In the first part of my PhD thesis I studied how decapping activators assemble into distinct 
mRNA decapping complexes in metazoa to promote mRNA decapping. Studying the 
examples of DCP1, Pat and DDX6/Me31B provided detailed insights into the decapping 
activator network and revealed an unexpected complexity and connectivity. The results also 
confirmed the prediction, that studying mRNA decapping in metazoa was relevant to obtain 
new insights into principles of activation and regulation of mRNA decapping. 
The observed interactions could also provide the molecular basis for RNA granules/P body 
formation. Previous models that suggested P body formation by prion-like aggregation 
(Decker et al., 2007; Reijns et al., 2007) were questioned by an investigation of the physical 
properties of such RNA granules, which show rather the behavior of liquid droplets 
(Brangwynne et al., 2009). Detailed information about the interactions of decay factors will 
be essential to model the physical properties of such decay ensembles and compare them with 
the observed physical properties of RNA granules in cells. 
My results challenge also the prevailing model of a super-decapping activator complex, since 
distinct, and at least partially mutual exclusive, decapping activator complexes seem to be a 
common characteristic of decapping activators assemblies. In future it will be of great interest 
to determine if these distinct complexes represent different pathways or sequential events of a 
single pathway. 
Motif I of metazoan DCP1 as well as the FDF motif of EDC3 and Tral represent short linear 
motifs. Linear motifs are short protein sequences with a specific function, such as localization 
signals, phosphorylation sites or mediation of protein-protein interactions (Neduva and 
Russell, 2005; Davey et al., 2012). Due to their shortness linear motifs can evolve rapidly and 
are difficult to predict from protein sequence. Therefore, experimental identification and 
characterization of linear motifs in decapping factors was important to dissect the assembly of 
decapping complexes. It is interesting to note in this context that in later studies linear motifs 
similar to the motif I of DCP1 were identified in yeast DCP2 that interact with EDC3 in a 
similar way (Harigaya et al., 2010; Fromm et al., 2011). 
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In the second part of my PhD thesis, I studied how general mRNA decay factors can be 
recruited by specialized pathways to degrade the mRNA target. In particular, I focused on the 
miRNA pathway. Despite that several previous studies (Meister et al., 2005; Landthaler et al., 
2008; Chen et al., 2009; Zekri et al., 2009; Piao et al., 2010)  failed to detect any significant 
interaction of the miRISC with components of deadenylase complexes, I could identify two 
deadenylation factors as new direct binding partners using a systematic 
coimmunoprecipitation screening approach. This experimental approach could also be applied 
to other target specific decay pathways. 
Future challenges in the field are now to study how the intricate network of AGO proteins, 
GW182 proteins, PABPC, the PAN2-PAN3 complex and the CCR4-NOT complex cooperate 
to promote translational repression and mRNA degradation of miRNA targets. It will be of 
great interest to dissect how translational repression and mRNA degradation or miRNA 
targets are interconnected. Specific interaction mutants of the proteins mentioned above 
would greatly contribute to this task. In order to get time-resolved information about mRNA 
decay it will be also important to further develop time-course experiments in cells to study 
miRISC function, since in vitro systems currently seem to insufficiently recapitulate the full 
aspect of miRNA mediated gene silencing. 
Exciting progress in observing single events in RNA metabolism has recently been made in 
the field of splicing (Hoskins et al., 2011). Using a combination of genetic engineering, 
chemical biology, and multi-wavelength fluorescence microscopy the authors were able to 
follow the assembly of single spliceosomes in real time in yeast whole-cell extracts. The 
authors reasonably suggest that this experimental setup is expected to prove widely useful for 
mechanistic analysis of macromolecular enzymes in environments approaching the 
complexity of living cells. The application of this approach to the field of mRNA decay or 
miRNA-mediated gene silencing promises deep mechanistic insights into these fundamental 
processes of post-transcriptional gene regulation. 
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CCR4    Carbon catabolite repressor protein 4 
C-term    C-terminal 
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DCP1    decapping protein 1 
DCP2    decapping protein 2 
DCPS    scavenger decapping protein 
DDX6    DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 
DEAD box   Asp-Glu-Ala-Asp box 
DNA    deoxyribonucleic acid 
dsRNAs   double-stranded RNAs 
E. coli    Escherichia coli 
EDC3    enhancer of decapping 3 
EDC4    enhancer of decapping 4 
eIF    eukaryotic translation initiation factor 
eIF4E-BP   eIF4E binding protein 
EVH1    Ena-VASP homology 1 domain 
F-Luc    firefly luciferase 
FDF    Phe-Asp-Phe 
GDP    guanosine diphosphate 
GMP    guanosine monophosphate 
GST    glutathione-S-transferase 
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GW-repeat   Gly-Trp-repeat 
GW182   Gly-Trp repeat containing protein of 182 kDa 
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HA    hemagglutinin 
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HEK293 cells   human embryonic kidney 293 cells 
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LSm    Sm-like 
m
7
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MBP    maltose binding protein 
Me31B   maternal expression at 31B 
Mid    Middle 
miRISC   miRNA induced silencing complex 
miRNA   microRNA 
mRNA   messenger ribonucleic acid 
mRNP    messenger ribonucleoprotein 
Mut    mutant 
NMD     nonsense-mediated mRNA decay 
N-term   N-terminal 
NOT    Negative regulator of transcription homolog 
nt    nucleotide(s) 
ORF    open reading frame 
P body    mRNA processing body 
PABPC   cytoplasmic poly(A) binding protein 
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PAM2    PABPC-interacting motif 2 
PAN    poly(A) specific ribonuclease subunit homolog 
Pat-C    C-terminal domain of Pat proteins 
Pat1    protein associated with topoisomerase II 
PatL1    Pat1-like 
poly(A) tail   poly adenine tail 
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miRNAs are posttranscriptional regulators of gene
expression that associate with Argonaute and
GW182 proteins to repress translation and/or pro-
mote mRNA degradation. miRNA-mediated mRNA
degradation is initiated by deadenylation, although
it is not known whether deadenylases are recruited
to the mRNA target directly or by default, as a
consequence of a translational block. To answer
this question, we performed a screen for potential
interactions between the Argonaute and GW182
proteins and subunits of the two cytoplasmic deade-
nylase complexes. We found that human GW182
proteins recruit the PAN2-PAN3 and CCR4-CAF1-
NOT deadenylase complexes through direct interac-
tions with PAN3 and NOT1, respectively. These inter-
actions are critical for silencing and are conserved in
D. melanogaster. Our findings reveal that GW182
proteins provide a docking platform through which
deadenylase complexes gain access to the poly(A)
tail of miRNA targets to promote their deadenylation,
and they further indicate that deadenylation is adirect
effect of miRNA regulation.
INTRODUCTION
MicroRNAs (miRNAs) are key regulators of gene expression that
posttranscriptionally silence mRNA targets containing comple-
mentary sequences (Huntzinger and Izaurralde, 2011). To do
so, they associate with Argonaute and GW182 family proteins
into effector complexes known as miRNA-induced silencing
complexes (miRISCs), which repress translation and promote
target mRNA degradation. Recent studies have indicated that
target degradation is a widespread effect of miRNA-based regu-
lation that accounts for an important fraction of the repression
mediated by miRNAs (reviewed by Huntzinger and Izaurralde,
2011).
Although miRNAs can induce the degradation of fully comple-
mentary targets via endonucleolytic cleavage catalyzed by Argo-
naute proteins, they rarely do so in animal cells, in which the vast
majority of targets are partially complementary (reviewed by120 Molecular Cell 44, 120–133, October 7, 2011 ª2011 Elsevier Inc.Huntzinger and Izaurralde, 2011). In such cases, the mRNA
target is degraded by the enzymes involved in the cellular
50-to-30 mRNA decay pathway (Behm-Ansmant et al., 2006;
Chen et al., 2009; Eulalio et al., 2007, 2009; Giraldez et al.,
2006; Piao et al., 2010; Wu et al., 2006). In this pathway, after
being deadenylated, mRNAs are decapped by the decapping
enzyme DCP2. Decapped mRNAs are ultimately degraded by
the major cytoplasmic 50-to-30 exonuclease XRN1.
In eukaryotes, the mRNA poly(A) tail is removed by the
consecutive action of two cytoplasmic deadenylase complexes
(Yamashita et al., 2005). The PAN2-PAN3 complex is involved in
an early phase of deadenylation in which long poly(A) tails
are shortened to approximately 50–110 nucleotides, depending
on the organism (Yamashita et al., 2005). The PAN2-PAN3
complex is stimulated by the cytoplasmic poly(A)-binding protein
PABPC1 (Boeck et al., 1996; Brown et al., 1996; Uchida et al.,
2004). Accordingly, PAN3 interacts with PABPC1 and recruits
PAN2, the catalytic subunit, to mRNA targets (Brown et al.,
1996; Mangus et al., 2004; Siddiqui et al., 2007; Uchida et al.,
2004). The second, more rapid phase of deadenylation is cata-
lyzed by the CCR4-CAF1-NOT complex (Tucker et al., 2001;
Yamashita et al., 2005), which is sufficient for mRNA deadenyla-
tion in the absence of PAN2 (Brown et al., 1996; Tucker et al.,
2001; Yamashita et al., 2005).
Several lines of evidence support a role for the two cyto-
plasmic deadenylase complexes in miRNA-mediated gene
silencing. First, depletion of components of the CCR4-CAF1-
NOT complex partially suppresses silencing by inhibiting miRNA
target deadenylation and their subsequent decay (Behm-Ansm-
ant et al., 2006; Eulalio et al., 2007; Piao et al., 2010). Second,
transcriptome analysis of cells depleted of CCR4-CAF1-NOT
complex components showed that themajority of miRNA targets
(both predicted and validated) are upregulated, indicating that
deadenylation is indeed important for global miRNA regulation
(Eulalio et al., 2009). Third, overexpression of catalytically
inactive CCR4a, CAF1, or POP2 (a CAF1 paralog) mutants also
suppresses silencing in a dominant negative manner (Chen
et al., 2009; Piao et al., 2010). Although PAN2 depletion does
not suppress silencing (Behm-Ansmant et al., 2006; Piao et al.,
2010), overexpression of a catalytically inactive PAN2 mutant
slows down the initial phase of target deadenylation (Chen
et al., 2009), indicating that the PAN2-PAN3 complex is involved
in but is not essential for degradation of miRNA targets.
Although the role of the PAN2-PAN3 and the CCR4-CAF1-
NOT deadenylase complexes in the miRNA pathway is well
Molecular Cell
GW182 Proteins Interact with PAN3 and NOT1established, the molecular mechanism underlying their recruit-
ment has remained a controversial question, and three distinct
models have been proposed. One model suggests that miRISC
components (e.g., AGO and/or GW182 proteins) recruit (directly
or indirectly) deadenylases to miRNA targets (Behm-Ansmant
et al., 2006; Eulalio et al., 2007; 2009; Fabian et al., 2009; Hunt-
zinger et al., 2010; Huntzinger and Izaurralde, 2011; Zekri et al.,
2009). An alternative model proposes that miRISCs indirectly
increase the efficacy of deadenylation, for example, by making
the mRNA poly(A) more susceptible to deadenylases without
increasing their local concentration. The observation that
GW182 proteins contain a PAM2 motif, which confers direct
binding to PABPC1 supports this model (Fabian et al., 2009;
Huntzinger et al., 2010; Jinek et al., 2010; Kozlov et al., 2010;
Zekri et al., 2009). Indeed, GW182 proteins could facilitate
PABPC1 dissociation from the mRNA poly(A) tail, thereby
exposing it to deadenylases (Fabian et al., 2009; Huntzinger
et al., 2010; Zekri et al., 2009). A third model suggests that dead-
enylases are recruited to miRNA targets by default as an indirect
consequence of a primary inhibitory effect of miRISCs on trans-
lation (reviewed by Djuranovic et al., 2011).
To investigate whether deadenylases are recruited directly
to miRNA targets, we systematically screened for potential inter-
actions between AGO and GW182 and each subunit of the
PAN2-PAN3 and CCR4-CAF1-NOT complexes in both human
and D. melanogaster cells. We found that the three human
GW182 paralogs (known as TNRC6A-C) associate with the
PAN2-PAN3 and CCR4-CAF1-NOT complexes through direct
interactions with PAN3 and NOT1, respectively. These interac-
tions are independent of each other and are conserved in
D. melanogaster. Our findings indicate that the TNRC6 proteins
provide a binding platform for deadenylation factors to cause
rapid deadenylation of mRNA targets and further suggest that
deadenylation is a direct effect of miRNA regulation.
RESULTS
TNRC6 Proteins Interact with Subunits of Cytoplasmic
Deadenylase Complexes
To systematically screen for potential interactions between
miRISCs and components of the two major cytoplasmic deade-
nylase complexes (the PAN2-PAN3 and CCR4-CAF1-NOT
complexes), we coexpressed either GFP-tagged AGO2 or
TNRC6C with HA-tagged subunits of these complexes in human
HEK293 cells and performed coimmunoprecipitation assays
using anti-GFP antibodies.
The conserved core of the CCR4-CAF1-NOT complex in
metazoan consists of 5 subunits: NOT1, NOT2, NOT3 (also
known as NOT3/5), and two catalytically active subunits, CCR4a
or its paralog CCR4b and CAF1 or its paralog POP2 (Table S1)
(Lau et al., 2009; Temme et al., 2004). Of these, TNRC6C coim-
munoprecipitated NOT1, NOT2, CCR4a/b, CAF1, and POP2
(Figures 1B, 1C, and 1E–1H). TNRC6C showed weak but repro-
ducible interactions with NOT3 and NOT10, but no significant
interaction with the human-specific subunits TAB182 and
C2ORF29 (Figures 1D and S1) (Lau et al., 2009).
Additionally, TNRC6C interacted with PAN3, a subunit of the
dimeric PAN2-PAN3 complex, but not with PAN2, which is theMocatalytically active subunit (Figures 1I and 1J). Interactions with
deadenylation factors were observed in cell lysates treated
with either RNase A or micrococcal nuclease, suggesting that
they are not mediated by RNA. Importantly, the deadenylation
factors did not discriminate between TNRC6 paralogs because
similar binding profiles were observed for TNRC6A and TNRC6B
(see Figures 3 [below], S2, and S3).
In contrast to TNRC6s, human AGO2 exhibited weak interac-
tions with CCR4a/b and POP2, as previously reported (Fabian
et al., 2009), and it associated weakly with NOT1 and NOT2
(Figure S4). These interactions, however, are not mediated
by TNRC6s because an AGO2 mutant that no longer binds
TNRC6s (the F2V2 mutant [Eulalio et al., 2008]) interacted with
deadenylation factors as well as wild-type (Figure S4). In
summary, TNRC6s (and to a lesser extent AGO2) coimmunopre-
cipitate components of both of the major cytoplasmic deadeny-
lase complexes, suggesting that miRISCs have the ability to
recruit these complexes to mRNA targets. Here, we limit our
analysis to the more prominent interactions mediated by GW182
proteins.
The Interactions with Deadenylation Factors
Are Conserved
Next, we investigated whether the interactions observed in
human cells are conserved in Drosophila melanogaster (Dm).
We found that Dm GW182 coimmunoprecipitated NOT1,
NOT2, PAN3, and to a much lesser extent PAN2 (Figures 2A,
2B, 2G, and 2H). The interaction of GW182 with PAN2 was
strongly enhanced in cells in which PAN3 was coexpressed (Fig-
ure 2I, lane 8 versus 6), suggesting that PAN3 bridges the
GW182-PAN2 interaction. This observation prompted us to
test whether PAN3 also bridges TNRC6-PAN2 interaction in
human cells. We observed that TNRC6C did indeed coimmuno-
pecipitate PAN2 in HEK293 cells in which PAN3 was also coex-
pressed (Figure 2J, lane 8 versus 6).
Additionally, in agreement with the results obtained in human
cells, D. melanogaster GW182 exhibited weak but reproducible
interactions with CCR4, POP2, and NOT3/5 (Figures 2C, 2E,
and 2F), suggesting that these interactions may be bridged by
the other components of the CCR4-CAF1-NOT complex. Finally,
NOT4 did not associate with Dm GW182 (Figure 2D), consistent
with the observation that NOT4 is not an integral subunit of the
complex in human or D. melanogaster cells (Lau et al., 2009;
Temme et al., 2004).
Our findings indicate that the interactions of GW182 pro-
teins with components of the two major cytoplasmic dea-
denylase complexes are conserved. In particular, PAN3, NOT2,
and NOT1 coimmunoprecipitated with TNRC6s and Dm
GW182 to an extent similar to that observed with endogenous
PABPC1 (Figure 1H), which interacts with GW182 proteins
directly (Fabian et al., 2009; Huntzinger et al., 2010; Jinek
et al., 2010; Kozlov et al., 2010).
Validation of the Interaction Screen
Because the interaction screen was performed with transiently
expressed proteins, it was important to validate the newly iden-
tified TNRC6s partners using alternative approaches. First, we
confirmed the interactions with PAN3 and NOT1 in reciprocallecular Cell 44, 120–133, October 7, 2011 ª2011 Elsevier Inc. 121
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Figure 1. TNRC6C Interacts with Deadenylation Factors
(A) The domain organization of Hs TNRC6C and Dm GW182. Human TNRC6C and Dm GW182 consist of an N-terminal AGO-binding domain, which contains
multiple GW-repeats (light green), and a bipartite silencing domain (SD), which includes the middle (Mid) and C-terminal (C-term) regions. UBA: ubiquitin
associated domain; Q-rich: region rich in glutamine; PAM2: PABP-interacting motif 2; RRM: RNA recognition motif; M1 and M2: regions within the Mid region.
(B–J) Human HEK293 cells were cotransfected with plasmids expressing GFP-tagged TNRC6C and HA-tagged deadenylase subunits as indicated. GFP-tagged
maltose-binding protein (MBP) served as a negative control. Cell lysates were immunoprecipitated with a polyclonal anti-GFP antibody. Inputs and
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exchanged. We found that GFP-tagged PAN3 and NOT1 coim-
munoprecipitated HA-TNRC6C (Figures S5A and S5B). Second,
we immunoprecipitated GFP-TNRC6C and identified endoge-
nous PAN3, NOT1, and NOT2 in the immunoprecipitates using
specific antibodies (Figure S5C). Remarkably, endogenous
proteins coimmunoprecipitated with GFP-TNRC6C more effi-
ciently than the transiently expressed counterparts (compare
Input and IP ratios in Figure 1 versus Figure S5C), most likely
because the transiently expressed subunitsmay not be quantita-
tively incorporated into endogenous complexes.
Finally, we confirmed the interactions described above using
endogenous proteins. We observed that endogenous TNRC6
proteins coimmunoprecipitated endogenous PAN3 and NOT1
(Figure 3A), which are the two directly interacting subunits of
the endogenous deadenylase complexes (see below). Further-
more, we performed a similar experiment in Drosophila cells
and showed that endogenous Dm GW182 coimunoprecipitated
with endogenous NOT1 (Figure 3B). In summary, our results indi-
cate that the TNRC6 proteins associate with subunits of the two
major cytoplasmic deadenylase complexes.
The Silencing Domains of TNRC6s Confer Binding
to Deadenylation Factors
To define domains within TNRC6s that are important for their
interaction with deadenylase complex subunits, we performed
coimmunoprecipitations with a series of TNRC6B deletion
mutants. We observed that deleting the TNRC6B silencing
domain (SD, amino acids 1218–1723) abolished its interaction
with NOT1, NOT2, CCR4a/b, CAF1, POP2 and PAN3 (Fig-
ure 3C–I, lane 7). Conversely, the silencing domain was sufficient
to interact with NOT1, NOT2, CCR4a/b, CAF1 and POP2 as effi-
ciently as full-length TNRC6B (Figure 3C–3H, lanes 8 versus 6),
but was slightly impaired for PAN3 binding (Figure 3I, lane 8
versus 6). Similar results were obtained with the silencing
domains of TNRC6A and C (Figures S2 and S3). Thus, the
silencing domains are both necessary and sufficient for TNRC6s
to interact with deadenylase subunits.
Notably, although the interaction with PAN3 and NOT1 are
conserved in D. melanogaster, deletion of the GW182 SD
did not abolish NOT1 and PAN3 binding (Figures 3J and 3K,
lanes 8 versus 6), suggesting that, in contrast to the human
proteins, additional regions in Dm GW182 also contribute to
these interactions.
TNRC6 Silencing Domains Bind PAN3 and NOT1 Directly
To investigate whether the interaction of TNRC6 proteins with
deadenylation factors is direct, we performed GST (glutathione
S-transferase) pull-down assays with recombinant proteins
expressed in E. coli. In particular, we focused on the conserved
interactions with PAN3, NOT1, and NOT2. We also tested the
interaction of recombinant TNRC6s with CCR4a because
CCR4a/b were efficiently coimmunoprecipitated with TNRC6s
from human cell lysates (Figures 1E and 1F).immunoprecipitates were subjected to Western blotting using anti-GFP and ant
immunoprecipitate was loaded, whereas for the HA-tagged proteins, 1% of the inp
were treated with RNase A prior to immunoprecipitation. See also Figures S1–S4
MoThe results showed that aGST fusion of the TNRC6B-silencing
domain (GST-6B-SD) pulled down full-length PAN3 (Figure 4A,
lane 10). This interaction was specific because PAN3 did not
bind to beads coated with GST (Figure 4A, lane 7). In contrast
to PAN3, neither NOT2 nor CCR4a bound to GST-6B-SD
in vitro (Figure 4A, lanes 11 and 12), indicating that the interaction
of these proteins with TNRC6s in cell lysates is indirect.
NOT1 was expressed at low levels in E. coli (NOT1 contains
2371aminoacids), and in addition to the full-lengthproteinweob-
tained shorter polypeptides that may have arose from degrada-
tion, premature translation termination, or internal initiation due
to the length of NOT1 ORF. Nevertheless, the higher molecular
weightpolypeptideswerepulleddownwith theTNRC6Bsilencing
domain (Figure 4B, lane 4). To confirm these results, we per-
formed GST pull-down assays with in vitro translated NOT1 in
wheat germ extracts (Figures 4C and 4D). As shown in Figure 4C,
in wheat germ extracts, we also obtained full-length NOT1 and
additional shorter polypeptides. Again, the higher molecular
weight polypeptides were pulled down with GST-6B-SD (Fig-
ure 4C, lane 3). In vitro translated PAN3 and PABPC1, which
interact directly with TNRC6s and therefore served as positive
controls, were also pulled down under these conditions, as ex-
pected (Figure 4C, lane 3). In contrast, in vitro translated NOT2
and CCR4a did not interact with TNRC6B-SD above background
levels (Figure 4C), which is in agreement with the results shown in
Figure 4A using recombinant proteins expressed inE. coli. Finally,
in vitro translated POP2 also failed to interact with the silencing
domain (Figure 4C). These results suggest that we observed
only direct interactions in wheat germ extracts. Taken together,
our observations indicate that the silencing domain of the
TNRC6 proteins interact directly with PAN3 and NOT1.
NOT1 Mediates the Interaction of TNRC6s
with the CCR4-CAF1-NOT Complex
To investigate the interdependence of TNRC6 interactions with
PAN3, the CCR4-CAF1-NOT1 complex, and PABPC1, we per-
formed immunoprecipitation assays in cells in which either
PAN3 or NOT1 proteins were depleted using pooled siRNAs.
We observed that PAN3 depletion did not affect the interaction
of TNRC6C with NOT1, NOT2, or CCR4a (Figures 5A–5C, lanes
8 versus 4), although PAN3 levels were reduced down to 25%
(Figure S6A). In contrast, PAN3 depletion slightly reduced the
interaction of TNRC6 with endogenous PABPC1 (Figure 5D,
lane 8 versus 4), indicating that PAN3, although not essential,
could facilitate PABPC1 binding.
When we reduced the levels of NOT1 (by 50%), we observed
that the interaction of TNRC6C with NOT2, CCR4a, and POP2
was also strongly reduced (Figures 5E–5G and S6B). In contrast,
NOT1depletion did not affect TNRC6binding toPAN3but slightly
decreased PABPC1 binding (Figure 5G and 5H, lanes 8 versus 4).
Three conclusions can be drawn from these experiments.
First, NOT1 and PAN3 interact with TNRC6s independently of
each other. Second, NOT1 mediates the interactions between
TNRC6s and the additional subunits of the CCR4-CAF1-NOTi-HA antibodies. For the GFP-tagged proteins, 1% of the input and 5% of the
ut and 30% of the immunoprecipitate was analyzed. In each panel, cell lysates
and Table S1.
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Figure 2. The Interactions of GW182 Proteins with Deadenylation Factors Are Conserved in D. melanogaster
(A–H) Lysates from S2 cells cotransfected with plasmids expressing GFP-tagged Dm GW182 and HA-tagged deadenylase subunits were immunoprecipitated
using a polyclonal anti-GFP antibody. GFP-tagged firefly luciferase served as a negative control. Inputs and immunoprecipitates were analyzed by western
blotting as described in Figure 1, with the exception that 1% of the input and 40% of the immunoprecipitates were loaded for the HA-tagged proteins.
Molecular Cell
GW182 Proteins Interact with PAN3 and NOT1
124 Molecular Cell 44, 120–133, October 7, 2011 ª2011 Elsevier Inc.
Molecular Cell
GW182 Proteins Interact with PAN3 and NOT1complex because these interactions are abolished in NOT1-
depleted cells. Finally, PAN3 and NOT1 may facilitate TNRC6-
PABPC1 interaction, in agreement with the fact that PAN3 also
contains aPAM2motif (Mangus et al., 2004; Siddiqui et al., 2007).
PAN3 and NOT1 Bind to the Mid and C-Term Regions
of the Silencing Domains
The silencing domain of TNRC6 proteins consists of four regions:
M1, PAM2 motif, M2, and C term (Figure 1A) (Huntzinger et al.,
2010; Zekri et al., 2009; Huntzinger and Izaurralde, 2011). The
RRM domain connecting the M2 and C-term regions is not
required for silencing. To further delineate regions within the
silencing domain that contribute to interaction with PAN3 and
NOT1 we deleted each region alone or in combination and per-
formed GST pull-down assays.
We observed that GST-6B-SD mutants lacking either the M1
region or the PAM2 motif interacted with PAN3 to the same
extent as full-length GST-6B-SD (Figure 6A, lanes 11–13). In
contrast, deleting the M2 or C-term regions individually reduced
the interaction of GST-6B-SD with PAN3 (Figure 6A, lanes 14
and 15). The interaction was abolished when both regions
were deleted (Figure 6A, lane 18), suggesting that the M2 and
C-term regions contribute to PAN3 binding in an additive
manner. Accordingly, theM2 and C-term regions (with or without
the connecting RRM domain) were sufficient for binding to PAN3
in vitro (Figure S6C, lanes 11 and 12).
When the same series of GST-6B-SD deletion mutants was
tested for interactions with in vitro translated NOT1, we observed
that the M1, M2, and C-term regions all contributed to binding
because deleting each one of these regions individually slightly
reduced, but did not abolish, NOT1 binding (Figures 6B [lanes
4, 6, and 7] and S6D). Binding was strongly reduced when any
two of these three regions were deleted simultaneously (Figures
6B [lanes 8–10] and S6D). In contrast, deletion of the PAM2motif
did not affect binding to NOT1 (Figure 6B, lane 5). Additionally,
we observed that NOT1 binding to GST-6B-SD was not affected
(i.e., neither stimulated nor inhibited) in the presence of a large
excess of recombinant human PAN3 (data not shown), suggest-
ing that, although the PAN3 and NOT1-binding sites on TNRC6s
overlap, their binding is neither interdependent nor mutually
exclusive. Combined, these experiments demonstrate that the
interactions of the TNRC6 proteins with PAN3 and NOT1 are
mediated by theMid and C-term regions of the silencing domain.
These interactions are independent of each other and are also
compatible, suggesting that TNRC6s could bind PAN3 and
NOT1 simultaneously.
TNRC6 Proteins Interact with the PAN3 C-Terminal
Domain
PAN3 proteins are characterized by an N-terminal region (amino
acids 1–290) and a C-terminal domain (amino acids 291–687).(I) S2 cells were cotransfected with a mixture of two plasmids: one expressing HA-
In addition, the transfection mixtures contained a third plasmid expressing either H
immunoprecipitated and analyzed by western blotting as described above.
(J) Human HEK293 cells were co-transfected with plasmids expressing HA-PAN2
the transfection mixtures also contained a plasmid expressing HA-MBP, whereas
HA-PAN3. Cell lysates were immunoprecipitated and analyzed as described in F
MoThe N-terminal region contains a canonical PAM2 motif and
interacts with PABPC1, whereas the C-terminal domain is
required for PAN3 association with PAN2 (Mangus et al., 2004;
Siddiqui et al., 2007; Uchida et al., 2004). In GST pull-down
assays, we observed that the PAN3 C-terminal domain (PAN3
C term) was sufficient for binding to GST-6B-SD (Figure S6C,
lane 14). The PAN3 C term was also pulled down by TNRC6B
protein fragments containing the M2 and C-term regions (Fig-
ure S6C, lanes 15 and 16). We conclude that the TNRC6B M2
andC-term regions bind directly to the PAN3C-terminal domain,
which itself interacts with PAN2 but not with PABPC1, reinforc-
ing the conclusion that PAN3 interacts with GW182 indepen-
dently of PABPC1.
The M2 and C-Term Regions of TNRC6s Are Critical
for Silencing
To evaluate how the interactions between TNRC6 proteins
and deadenylase subunits contribute to silencing, we tested
whether a TNRC6 mutant lacking the M2 and C-term regions,
which cannot bind PAN3 and has reduced NOT1 binding, could
rescue silencing in cells lacking endogenous TNRC6s. In this
complementation assay, endogenous TNRC6A and TNRC6B
were depleted from HeLa cells using specific siRNAs target-
ing the corresponding mRNAs. Cells were then transfected
with plasmids expressing siRNA-resistant versions of either
wild-type or mutant TNRC6A together with a miRNA reporter.
Control cells were treated with a siRNA against b-Gal (b-Gal-
siRNA).
Codepletion of TNRC6A and TNRC6B efficiently suppresses
silencing of a Renilla luciferase reporter containing three let-7
binding sites in its 30UTR (Figure 6C, R-Luc-3xlet-7 [Huntzinger
et al., 2010]). Silencing is restored when these cells are trans-
fected with a plasmid expressing a siRNA-resistant wild-type
TNRC6A (Huntzinger et al., 2010) (Figure 6C).
Remarkably, deleting both theM2 andC-term regions strongly
impaired TNRC6A silencing activity, indicating that these regions
are critical for silencing (Figure 6C). As previously reported,
a TNRC6Amutant that does not interact with PABPC1 (i.e., lack-
ing the PAM2motif) was also largely unable to rescue silencing of
the let-7 reporter (Figure 6C) (Huntzinger et al., 2010), although
this mutant was still able to interact with deadenylation factors
(Figures 6A and 6B). TNRC6A silencing activity was abolished
when the entire silencing domain was deleted, which is consis-
tent with previously published work (Figure 6C) (Huntzinger
et al., 2010). Each protein was expressed to a similar level
(Figure 6D).
Two important conclusions can be drawn from these results.
First, there is a correlation between the deadenylation factor
binding and the silencing activity of TNRC6A. Second, a TNRC6A
mutant that does not bind PABPC1 (DPAM2) has impaired
silencing activity even though this mutant is able to interactPAN2 and one expressing either GFP-GW182 or GFP-F-Luc (negative control).
A-GST (lanes 1, 2, 5, and 6) or HA-PAN3 (lanes 3, 4, 7 and 8). Cell lysates were
and either GFP-TNRC6C or GFP-MBP (negative control). In lanes 1, 2, 5 and 6,
in lanes 3, 4, 7, and 8, the transfection mixtures contained a plasmid expressing
igure 1. The asterisk indicates cross-reactivity of the anti-HA antibody.
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Figure 3. Endogenous TNRC6 Proteins Coimmunoprecipitate Subunits of the Endogenous Deadenylase Complexes
(A) Lysates from human HEK293 cells were immunoprecipitated with a control antibody (anti-GFP antibody) or an antibody recognizing TNRC6s. Inputs and
immunoprecipitates were analyzed by western blotting using antibodies recognizing endogenous NOT1 or PAN3. An antibody to endogenous Actin served as
a control to determine the specificity of the immunoprecipitations.
(B) S2 cell lysates were immunoprecipitated with a control antibody (anti-GFP antibody) or an antibody recognizing Dm GW182. Inputs and immunoprecipitates
were analyzed by western blotting using an antibody specific for NOT1. An antibody to endogenous eIF4E served as a negative control.
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GW182 Proteins Interact with PAN3 and NOT1with deadenylation factors (Figures 6A and 6B), indicating that
the mere recruitment of deadenylases is not sufficient for full
silencing activity. Conversely, PABPC1 binding is not sufficient
for silencing. Thus, TNRC6 proteins may require interaction
with both deadenylation factors and PABPC1 for full silencing
activity. Nevertheless, because both the M2 and C-term regions
must be deleted to inhibit binding to deadenylase complexes, we
cannot rule out that these regions are also required for additional
interactions.
The CCR4-CAF1-NOT Complex Provides a Major
Contribution to miRNA-Mediated mRNA Degradation
It has been shown that knockdown of the components of the
CCR4-CAF1-NOT1 complex strongly reduces miRNA-medi-
ated mRNA deadenylation and decay both in Drosophila and
human cells (Behm-Ansmant et al., 2006; Chen et al., 2009;
Eulalio et al., 2009; Piao et al., 2010), whereas inactivation of
the PAN2-PAN3 complex slows down the initial deadenylation
rate of miRNA targets in human cells, but deadenylation and
decay still occur (Chen et al., 2009), providing one explanation
for the observation that PAN2-PAN3 complex inactivation
minimally affects miRNA target levels at steady state (Behm-
Ansmant et al., 2006; Chen et al., 2009; Piao et al., 2010).
Furthermore, these results are consistent with previous obser-
vations indicating that the CCR4-CAF1-NOT complex takes
over cytoplasmic deadenylation in the absence of the PAN2-
PAN3 complex (Tucker et al., 2001; Yamashita et al., 2005)
and that deadenylation mediated by the CCR4-CAF1-NOT
complex leads to decay of the mRNA body, whereas PAN2-
PAN3-mediated deadenylation results in an initial shortening
of the poly(A) tail without further mRNA decay (Yamashita
et al., 2005).
The data presented above indicate that both deadenylase
complexes can be recruited to miRNA targets independently of
each other and may independently contribute to miRNA target
degradation. Therefore, we re-examined the contribution of
these complexes to the degradation of miRNA targets in
Drosophila cells, in which the effect of depleting the PAN2-
PAN3 complex on miRNA target half-life has not been analyzed.
The decay rate of miRNA targets was analyzed in cells depleted
of PAN3 and NOT1 either individually or in combination. For this
assay, we used the F-Luc-Nerfin reporter that was previously
shown to be deadenylated in the presence of miR-9b in S2 cells
(Behm-Ansmant et al., 2006; Eulalio et al., 2007). We exposed
transfected cells to actinomycin D to inhibit transcription and
compared F-Luc-Nerfin mRNA levels over time with the long-
lived rp49 mRNA, which has a half-life >8 hr.
In the absence of miR-9b, the half-life of F-Luc-Nerfin mRNA
was 35 ± 4 min, whereas its half-life was 14 ± 2 min in cells ex-
pressing miR-9b (Figures 7A–7C). In PAN3-depleted cells, the
F-Luc-Nerfin reporter exhibited a half-life of 18 ± 1 min (Figures
7A and 7D), which is in agreement with previous studies showing(C–I) Lysates from human HEK293 cells coexpressing GFP-TNRC6B wild-type
cipitated and analyzed as described in Figure 1. Similar immunoprecipitation ass
(J and K) Lysates from S2 cells coexpressing GFP- tagged wild-type Dm GW182
immunoprecipitated and analyzed as described in Figure 2.
Mothat depletion of the PAN2-PAN3 complex does not significantly
prevent miRNA-mediated mRNA decay (Behm-Ansmant et al.,
2006). In contrast, NOT1 depletion brought miR-9b-mediated
decay of the F-Luc-Nerfin mRNA almost to a halt, resulting in
an mRNA half-life of 39 ± 6 min, which is similar to the mRNA
half-life in the absence of miR-9b (Figures 7A and 7E). Codeplet-
ing PAN3 and NOT1 resulted in only a slight increase in the
mRNA half-life relative to the single NOT1 knockdown (Figures
7A and 7F). These results confirm previous studies showing
that the CCR4-CAF1-NOT complex provides the major contribu-
tion to miRNA target degradation (Behm-Ansmant et al., 2006;
Chen et al., 2009; Eulalio et al., 2009; Piao et al., 2010). Impor-
tantly, firefly luciferase activity was not fully restored in NOT1-
depleted cells even though mRNA degradation was prevented,
suggesting that the F-Luc-Nerfin mRNA was still translationally
repressed (Figure 7G), as previously reported (Behm-Ansmant
et al., 2006). Similar results were obtained with a F-Luc-Par-6
reporter, which is silenced by miR-1 (Figures S7A and S7B),
except that for this reporter, the increase on mRNA abundance
correlated with a corresponding increase in firefly luciferase
activity, indicating that this reporter is silenced predominantly
at the mRNA level.
To further confirm these results, we analyzed the decay rate of
endogenous Vha-68 mRNA, which is a validated target of
miR-9b (Behm-Ansmant et al., 2006). In control cells, this mRNA
is rapidly degraded through the miRNA pathway (Behm-Ansm-
ant et al., 2006) and exhibits a half-life of 28 ± 1 min (Figures
7H and S7C–S7F). In PAN3-depleted cells, the transcript was
slightly stabilized and exhibited a half-life of 38 ± 3 min (Fig-
ure 7H). Again, NOT1 depletion strongly stabilized the mRNA,
resulting in a half-life >360 min (Figure 7H). The half-life was
slightly increased both PAN3 and NOT1 were codepleted (Fig-
ures 7H and S7F).
The role of the PAN2-PAN3 complex in silencing was also
analyzed by determining the effects of PAN3 and NOT1 deple-
tion on silencing that was mediated directly by tethering the
GW182 protein. In this assay, GW182 was fused to a peptide
derived from the N protein of the bacteriophage l (lN tag) to
enable tethering to a firefly luciferase (F-Luc) reporter containing
five Box B hairpins (5BoxB) inserted in the 30UTR. It has been
shown that tethered GW182 promotes deadenylation of the
mRNA reporter, which is followed by decay of the mRNA body
(Behm-Ansmant et al., 2006; Eulalio et al., 2007). Codepleting
PAN3 and NOT1 suppressed silencing of the R-Luc-5BoxB
reporter slightly more efficiently than the depletion of NOT1
alone, whereas PAN3 depletion had only a minor effect (Fig-
ure 7I). As observed for the F-Luc-Par-6 reporter, the increase
in F-Luc-5BoxBmRNAabundancecorrelatedwith acorrespond-
ing increase in F-Luc activity.
These results together with previous studies indicate that the
CCR4-CAF1-NOT complex is a major contributor to miRNA
target decay, with the PAN2-PAN3 complex playing only aor mutants together with HA-tagged deadenylation factors were immunopre-
ays were performed with TNRC6A and TNRC6C (Figures S2 and S3).
or the indicated mutants together with HA-tagged deadenylation factors were
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Figure 4. The Silencing Domain of TNRC6B Directly Binds PAN3 and
NOT1
(A) Interaction of recombinant MBP-tagged PAN3, NOT2, or CCR4a with GST-
tagged TNRC6B-SD (GST-6B-SD). GST served as a negative control. Inputs
(1%) and bound fractions (10%) were analyzed by 10% SDS-PAGE (note that
NOT2 and CCR4a have similar molecular weights). GST-6B-SD shows
multiple degradation fragments (indicate in brackets). See also Figure S6C.
(B) Recombinant 6xHis-tagged NOT1 was pulled down using GST or GST-6B-
SD coated beads. NOT1 shows multiple degradation fragments.
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complexmay be important for the silencing of a subset of miRNA
targets.
Deadenylases Are Also Required for Silencing
Unadenylated Targets
Thus far, our data indicate that GW182 proteins recruit deade-
nylase complexes to miRNA targets via direct protein-protein
interactions, suggesting that deadenylases could also be re-
cruited to mRNAs lacking a poly(A) tail and could eventually
promote silencing in the absence of deadenylation. This possi-
bility has been suggested by a recent report showing that a
catalytically inactive CAF1 mutant can repress the translation
of an mRNA reporter to which it is tethered without promoting
deadenylation (Cooke et al., 2010). To investigate this possi-
bility, we used a F-Luc-5BoxB reporter whose 30 end is gener-
ated by a self-cleaving hammerhead ribozyme (F-Luc-5BoxB-
HhR) and thus lacks a poly(A) tail. In agreement with previous
studies, expression of lN-GW182 reduced luciferase activity
without affecting mRNA abundance (Figure 7J) (Eulalio et al.,
2008). Remarkably, for this reporter, codepleting PAN3 and
NOT1 also suppressed silencing slightly more efficiently than
depletion of NOT1 alone, suggesting that the two deadenylase
complexes cooperate to repress the expression of the unadeny-
lated reporter.
DISCUSSION
Emerging evidence suggests that mRNA deadenylation is part
of the mechanism used by miRNAs to silence gene expression.
Indeed, deadenylation of miRNA targets has now been
reported in zebrafish and C. elegans embryos, human and
D. melanogaster cells, and in various cell-free extracts that reca-
pitulate silencing (reviewed by Huntzinger and Izaurralde, 2011).
However, whether miRISCs directly recruit deadenylases to
miRNA targets has remained unclear.
This study provides compelling evidence that the silencing
domains (SDs) of TNRC6 proteins contain binding sites for
PAN3 and NOT1, which are subunits of each of the two major
cytoplasmic deadenylase complexes. These findings provide
strong support for the hypothesis that GW182 proteins enhance
poly(A) tail removal by directly recruiting deadenylases to asso-
ciated mRNA targets. More broadly, our results have implica-
tions for the understanding of miRNA-based regulation because
they show that target deadenylation is notmerely a consequence
of a translational block.
GW182 Proteins Interact with Two Cytoplasmic
Deadenylase Complexes
Previous studies have reported conflicting evidence regarding
the interaction of deadenylation factors with the two major(C and D) GST-tagged TNRC6B-SD (GST-6B-SD) or GST was used to pull
down [35S]-methionine-labeled in vitro translated PABPC1 or the indicated
deadenylation factors. Inputs (1%) and bound fractions (16%) were analyzed
by 10% SDS-PAGE followed by fluorography (C). The corresponding
Coomassie-stained gel is shown in (D).
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Figure 5. NOT1 and PAN3 Interact with
TNRC6 Independently of Each Other
(A–D) Human HEK293 cells were treated with
a control siRNA (targeting b-Gal) or a siRNA pool
targeting PAN3. In panels A–C, cells were then
co-transfected with plasmids expressing GFP-
TNRC6C or GFP-MBP (negative control) and HA-
tagged deadenylase subunits, as indicated. Cell
lysates were immunoprecipitated and analyzed as
described in Figure 1. The presence of endoge-
nous PABPC1 in the immunoprecipitates was
determined in (D). The efficiency of PAN3 deple-
tion is shown in Figure S6A.
(E–H) A similar experiment was performed in
HEK293 cells treated with control siRNA or a
siRNA pool targeting NOT1. The presence of
endogenous PABPC1 in the immunoprecipitates
was analyzed in (G). The efficiency of NOT1
depletion is shown in Figure S6B.
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Figure 6. The M2 and C-term Regions of the Silencing
Domains Interact with PAN3 and NOT1 and Are Required
for Silencing
(A) Interaction of recombinant MBP-PAN3 with either wild-type or
mutant GST-6B-SD.
(B) GST pull-down assays were performed with [35S]-methionine
labeled full-length NOT1 and either wild-type or mutant GST-6B-
SD. GST served as a negative control. Samples were analyzed as
described in Figure 4C. The corresponding Coomassie-stained
gel is shown in Figure S6D.
(C and D) HeLa cells were transfected with a control b-Gal siRNA
or a mixture of siRNAs targeting TNRC6A and TNRC6B. Two days
later, the cells were retransfected with the same siRNAs and
a mixture of three plasmids: R-Luc-3xlet-7 or a corresponding
reporter lacking the let-7-binding sites (R-Luc-Mut), a plasmid
expressing F-Luc as a transfection control, and a plasmid ex-
pressing either MBP or siRNA-resistant HA-TNRC6A (wild-type or
mutant). Renilla luciferase activity was measured and normalized
to that of F-Luc, setting the value to 100 in cells expressing the
reporter lacking the let-7-binding sites for each condition (gray
bars). The mean values ± standard deviations from three inde-
pendent experiments are shown. (D) shows protein expression
level.
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GW182 Proteins Interact with PAN3 and NOT1components of miRISCs (AGO and GW182). Indeed, several
studies failed to detect a significant interaction between human
AGO or TNRC6 proteins and components of deadenylase
complexes, including POP2, CAF1, CCR4a, CCR4b, and
PAN2 (Chen et al., 2009; Landthaler et al., 2008; Meister et al.,
2005; Piao et al., 2010; Zekri et al., 2009). In contrast, Fabian
et al. (2009) observed an interaction of miRISCs with CAF1
and CCR4.
Using coimunoprecipitation and in vitro pull-down assays, we
determined that PAN3 and NOT1 interact directly with TNRC6-
SDs, whereas the interaction with PAN2 and the additional
components of the CCR4-CAF1-NOT complex is indirect and130 Molecular Cell 44, 120–133, October 7, 2011 ª2011 Elsevier Inc.bridged by PAN3 and NOT1, respectively. These
observations provide one explanation for the negative
results reported in previous studies (Chen et al., 2009;
Piao et al., 2010; Zekri et al., 2009). Indeed, these
studies focused on the interaction of AGO and
GW182 with subunits of the deadenylase complexes
that interact indirectly (e.g., the catalytic subunits
and NOT3). These indirect interactions are likely to
be affected by the efficiency of the immunoprecipita-
tion and the expression of the tagged proteins relative
to the expression of the endogenous bridging factors.
In agreement with this interpretation, we showed that
human TNRC6C did not coimmunoprecipitate PAN2,
as reported by Chen et al. (2009) and Piao et al.
(2010); nevertheless, an interaction with PAN2 was
observedwhen PAN3 (the bridging factor) was overex-
pressed (Figure 2J).
A Network of Protein-Protein Interactions
Recruits PABPC1 and Deadenylation Factors
to the TNRC6-Silencing Domains
Previous studies have shown that the silencing domain
of GW182 proteins contains two binding sites forPABPC1: one in the PAM2 motif and one in the M2 and
C-terminal regions (Figure 1A) (reviewed by Huntzinger and
Izaurralde, 2011). The PAM2 motif interacts directly with the
C-terminal MLLE domain of PABPC1 (Fabian et al., 2009;
Huntzinger et al., 2010; Jinek et al., 2010; Kozlov et al., 2010).
The M2 and C-terminal regions mediate indirect binding to
PABPC1, which is only observed in cell lysates (Huntzinger
et al., 2010). Here, we show that the TNRC6 M2 and C-term
regions mediate direct binding to PAN3. PAN3, in turn, binds
to PABPC1 and PAN2 and may act as a bridging factor. We
also show that the M1, M2, and C-term regions of the silencing
domain confer direct binding to NOT1, which, in turn, mediates
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Figure 7. The CCR4-CAF1-NOT Complex Provides a Major Contri-
bution to miRNA-Mediated Target Degradation
(A–G) Control S2 cells or cells depleted PAN3, NOT1, or PAN3 and NOT1 were
transfected with a mixture of three plasmids: one expressing the F-Luc-Nerfin
reporter, one expressing miR-9b primary transcripts or the corresponding
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Mointeraction with the additional subunits of the CCR4-CAF1-NOT
complex.
Figure S8 represents amodel that summarizes the interactions
uncovered in our work as well as those from previous studies.
TNRC6 proteins are recruited to miRNA targets through their
interaction with AGOs, and they contact PABPC1 directly
through their PAM2 motifs (Figures S8A and S8B) (Fabian
et al., 2009; Huntzinger et al., 2010; Jinek et al., 2010; Kozlov
et al., 2010). TNRC6 proteins also bind PAN3 and NOT1 via their
Mid and C-term regions, as shown in our study. These interac-
tions may occur consecutively, simultaneously, or alternatively
(for clarity in Figure S8, they are shown as alternative). PAN3
interacts with the catalytic subunit PAN2 (Mangus et al., 2004).
Additionally, PAN3 contains anN-terminal PAM2motif that could
bind to theMLLE domain of a second PABPC1molecule (Figures
S8C and S8D) (Siddiqui et al., 2007). Finally, NOT1 recruits the
additional subunits of the CCR4-CAF1-NOT complex (Fig-
ure S8E). Although the detailed molecular interactions between
the deadenylases, PABPC1 and TNRC6s need to be further
elucidated, an important conclusion emerging from our studies
is that TNRC6 proteins engage in multiple interactions with
deadenylases and PABPC1 to promote target mRNA degrada-
tion. Moreover, the observation that depletion of PAN3 and
NOT1 suppresses silencing of an unadenylated reporter,
suggests that deadenylase complexes could also contribute to
translational repression in addition to promoting deadenylation
and decay. Thus, it is possible that translational repression and
deadenylation are two distinct outcomes triggered by the recruit-
ment of deadenylase complexes to the 30UTR of miRNA targets.
Further studies will determine how deadenylase complexes
interact with TNRC6 proteins at the molecular level, and the
role they may play in translational repression.empty vector (), and a plasmid expressing Renilla luciferase (R-Luc). The
decay of F-Luc-Nerfin mRNA was monitored following inhibition of transcrip-
tion by actinomycin D. F-Luc-Nerfin mRNA levels were normalized to rp49
mRNA and plotted against time. mRNA half-lives (t1/2) ± standard deviations
calculated from the decay curves are indicated on the right of (A). In (G),
samples were collected before actinomycin D treatment, and firefly luciferase
activity wasmeasured and normalized to that of theRenilla luciferase. For each
knockdown, normalized F-Luc values were set to 100 in cells transfected with
the empty vector (i.e., in the absence of miR-9b, black bar shown only for
control cells). The mean values ± standard deviations from three independent
experiments are shown. KD, knockdown. Similar results were obtained for the
F-Luc-Par6 reporter (Figures S7A and S7B).
(H) The decay of the endogenous Vha-68 mRNA was monitored in control and
knockdown cells as described in (A). Northern blots corresponding to the
decay curves are shown in Figures S7C–S7F.
(I) S2 cells treated with dsRNAs targeting GFP, PAN2 or NOT1 or a mixture of
PAN2 and NOT1 dsRNAs. These cells were transfected with a mixture of three
plasmids: one expressing the F-Luc-5BoxB reporter, one expressing Renilla
luciferase (R-Luc) as a transfection control and a plasmid expressing lN or
lN-GW82, as indicated. For each knockdown, firefly luciferase activity and
mRNA levels were normalized to those of Renilla luciferase and set to 100 in
cells expressing lN. The mean values ± standard deviations from three
independent experiments are shown.
(J) An experiment similar to that described above was performed using an
F-Luc-5BoxB reporter in which the cleavage and polyadenylation signal
had been substituted with a self-cleaving hammerhead ribozyme (F-Luc-
5BoxB-HhR).
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Coimmunoprecipitation Assays and Western Blot Analysis
Subunits of the deadenylase complexes were cloned as indicated in Table S1.
Plasmids for the expression of GFP-GW182, full-length AGO2 or the corre-
sponding F2V2 mutant were described by Eulalio et al. (2008). Plasmids for
the expression of full-length TNRC6A-C or the corresponding silencing
domains were generated by inserting the corresponding cDNAs into the
pEGFP-C1 vector (Clontech) using the following restriction sites: XhoI-PstI
(TNRC6A), HindIII-BamHI (TNRC6B) and XhoI-SalI (TNRC6C). Coimmunopre-
cipiation assays in human HEK293 and Drosophila S2 cells were performed as
described by Huntzinger et al. (2010). Detailed protocols for the immunopre-
cipitations, Western blotting, and knockdowns in human cells are given in
the Supplemental Experimental Procedures.
GST Pull-Down Assays
To express the silencing domain of TNRC6B (amino acids 1218–1723) in
E. coli, the corresponding cDNA was cloned into the pGEX6P1 vector (GE
Healthcare), resulting in an N-terminal GST fusion protein. Deletions andmuta-
tions were introduced using the QuikChangeMutagenesis Kit (Stratagene) and
appropriate oligos. Human PAN3, NOT2, and CCR4a cDNAs were cloned into
the pETM41 vector, resulting in N-terminal MBP fusion proteins. Human NOT1
cDNA was cloned into the pET-Duet vector, resulting in N-terminal 6xHistidine
fusion protein. GST pull-down assays were performed as described by
Huntzinger et al. (2010). See additional information in the Supplemental
Experimental Procedures.
Complementation Assay in Human Cells and Knockdowns
in S2 Cells
Complementation assays in human HeLa cells and RNA interference in S2
cells were performed as described by Huntzinger et al. (2010). Knockdowns
in S2 cells and plasmids expressing miRNA primary transcripts, F-Luc mRNA
reporters, and lN-HA-tagged proteins have been described by Behm-
Ansmant et al. (2006). siRNA sequences and detailed protocols are given in
the Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.molcel.2011.09.007.
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Figure S1. TNRC6C interacts with deadenylation factors. 
 (A–C) Human HEK293 cells were transfected with a plasmid expressing GFP-tagged 
TNRC6C together with plasmids expressing HA-tagged deadenylase subunits as 
indicated. GFP-tagged Maltose Binding Protein (MBP) served as a negative control. 
Two days after transfection, the cells were lysed and proteins were 
immunoprecipitated as described in Figure 1. Related to main Figure 1. 
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Figure S2. The silencing domain of TNRC6A is sufficient for binding to 
deadenylation factors. 
(A–G) Human HEK293 cells expressing GFP-tagged TNRC6A or the TNRC6A 
silencing domain together with HA-tagged deadenylation factors were lysed two days 
after transfection. Proteins were immunoprecipitated from the cell lysates using a 
polyclonal anti-GFP antibody and analyzed by Western blotting as described in 
Figure 1. TNRC6A is subject to extensive proteolytic degradation in cell lysates even 
in the presence of protease inhibitors. Related to main Figures 1 and 3. 
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Figure S3. The silencing domain of TNRC6C is sufficient for binding to 
deadenylation factors. 
(A–G) Human HEK293 cells expressing GFP-tagged TNRC6C or the TNRC6C 
silencing domain together with HA-tagged deadenylation factors were lysed two days 
after transfection. The cell lysates were immunoprecipitated with a polyclonal anti-
GFP antibody and analyzed by Western blotting as described in Figure 1. Related to 
main Figures 1 and 3. 
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Figure S4. AGO2 interacts with subunits of the CCR4-CAF1-NOT complex. 
(A–G) Human HEK293 cells were transfected with plasmids expressing GFP-AGO2 
(either wild-type or F2V2 mutant) together with HA-tagged deadenylase subunits as 
indicated. GFP-tagged Maltose Binding Protein (MBP) served as a negative control. 
Two days after transfection, the cells were lysed and proteins were 
immunoprecipitated with a polyclonal anti-GFP antibody. Inputs and 
immunoprecipitates were subjected to Western blotting using anti-GFP and anti-HA 
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antibodies. In all panels, the cell lysates were treated with RNase A prior to 
immunoprecipitation.  
(H) Coimmunoprecipitation of V5-tagged PABPC1 with wild-type GFP-AGO2 or  
the F2V2 mutant. 
(I) Interaction of AGO2 or the AGO2 F2V2 mutant with HA-TNRC6C.Related to 
main Figure 1. 
 
Figure S5. Validation of the interaction screen. 
(A, B) Human HEK293 cells were co-transfected with a plasmid expressing HA-
TNRC6C and plasmids expressing either GFP-PAN3 or GFP-NOT1. GFP-MBP 
served as a negative control. Cell lysates were immunoprecipitated using a polyclonal 
anti-GFP antibody and were analyzed as described in Figure 1. Related to main Figure 
3. 
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 (C) Human HEK293 cells were transfected with a plasmid expressing GFP-
TNRC6C or GFP-MBP (negative control). Cell lysates were immunoprecipitated 
using a polyclonal anti-GFP antibody. Inputs and immunoprecipitates were analyzed 
by western blotting using anti-GFP antibodies or antibodies recognizing endogenous 
NOT1, PAN3, or NOT2, as indicated. An antibody to endogenous actin served as a 
control to determine the specificity of the immunoprecipitations. For endogenous 
proteins, 1% of the input and 30% of the immunoprecipitates were loaded. 
 
Figure S6. TNRC6B interacts with the PAN3 C-terminal domain. 
(A, B) The efficiency of PAN3 and NOT1 depletion was determined by western blot 
analysis using specific antibodies. Actin served as a loading control. In lanes 2–4, 
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dilutions of lysates from control cells were loaded to estimate the efficacy of the 
depletion. 
(C) The interaction of GST-6B-SD deletion mutants with recombinant MBP-tagged 
PAN3 (filled circle) or the PAN3 C-terminal domain (asterisk) was analyzed as 
describe in Figure 5A. The GST-6B-SD ΔM1 mutant was used instead of GST-6B-SD 
because the later co-migrates with MBP-PAN3 C-term.  
(D) Coomassie stained gel corresponding to the GST pull down shown in Figure 6B. 
Related to main Figures 5 and 6. 
 
 
Figure S7. The CCR4-CAF1-NOT complex provides a major contribution to 
miRNA-mediated target degradation. 
(A,B) Control S2 cells or cells depleted PAN3, NOT1 or PAN3 and NOT1 were 
transfected with a mixture of three plasmids: one expressing the F-Luc-Par-6 reporter, 
one expressing miR-1 primary transcripts or the corresponding empty vector (-) and a 
plasmid expressing Renilla luciferase (R-Luc). For each knockdown, firefly luciferase 
activity and mRNA levels were normalized to those of the Renilla luciferase 
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transfection control and set to 100 in cells transfected with the empty vector (i.e. in 
the absence of miR-1, shown only for control cells).  
(C–F) The decay of the endogenous Vha-68 mRNA was monitored in control and 
knockdown cells following inhibition of transcription by actinomycin D and analyzed 
by northern blot. The corresponding decay curves are shown in Figure 7H. mRNA 
half-lives (t1/2) ± standard deviations calculated from the decay curves are indicated 
on the right. Related to main Figure 7. 
 
 
Figure S8. A model for the recruitment of deadenylases to miRNA targets. 
(A) The TNRC6 domains are as described in Figure 1A. PABPC1 consist of an N-
terminal domain (containing four RRMs), a linker region and a C-terminal domain 
termed MLLE. PAN3 consist of N-terminal and C-terminal domain. The N-terminal 
domain contains a PAM2 motif and directly interacts with the PABPC1 MLLE 
domain (Siddiqui et al., 2007). The C-terminal domain interacts simultaneously with 
PAN2 and the M2 and C-term regions of the TNRC6-SD (Mangus et al., 2004; this 
study).  
(B) Animal miRNAs in complex with AGO and TNRC6 proteins recognize their 
mRNA targets by base-pairing to partially complementary binding sites 
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predominantly located in the 3' UTR. TNRC6 proteins interact directly with PABPC 
through their PAM2 motifs.  
(C, D) PAN3 directly binds to the M2 and C-term regions of TNRC6 and recruits 
PAN2. PAN3 can also contact a second PABPC1 protein through its PAM2 motif 
(note that one PABPC1 protein cannot interact with the PAM2 motifs of PAN3 and 
TNRC6 simultaneously).  
(E) Consecutively (or simultaneously) the M1, M2 and C-term regions of the TNRC6 
silencing domain interact with the CCR4-CAF1-NOT complex trough NOT1. It is 
important to note that it is not clear whether the interactions between TNRC6 proteins 
interactions and PAN3 or NOT1 occur simultaneously or consecutively.  
 Braun et al. 
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 Table S1. Subunits of the CCR4-CAF1-NOT and PAN2-PAN3 deadenylase 
complexes 
 
Human (alternative names) /ORF length 
in amino acids / accession and cloning sites 
D. melanogaster (alternative names) / ORF 
length in amino acids / accession and 
cloning sites 
Human CAF1-CCR4-NOT complex Dm CAF1-CCR4-NOT complex 
CAF1 (CNOT7) *1 / 285 / NM_013354.5 / 
cloned XhoI–NotI into pCIneo-λN-HA 
 
POP2 (CNOT8) *1 / 292 / NM_004779.4 / 
cloned SacII–BamHI into pλN-HA-C1
POP2 (CG5684) / 297 / NM_140281.2 / 
cloned EcoRV–NotI into pAc5.1B-λN-HA 
CCR4a (CNOT6) / 557 / NM_015455.3 / 
cloned XhoI–KpnI into pλN-HA-C1 
CCR4 (CG31137, Twin) / 552 / 
NM_170129.2 / cloned EcoRI–NotI into 
pAc5.1B-λN-HA 
CCR4b (CNOT6L) / 555 / NM_144571.2 / 
cloned Xho–EcoRI into pλN-HA-C1 
 
CNOT1 / 2371 / EF553522.1 / 
cloned XhoI–SacII into pλN-HA-C1 
NOT1 (CG34407) / 2505 /  
NM_001103772.2 / cloned PacI–XbaI into 
pAc5.1B-λN-HA 
CNOT2 / 540 / NM_014515.4 / 
cloned HindIII–SacII into pλN-HA-C1 
NOT2 (CG2161, Rga) / 585 / NM_169080.1 / 
cloned HindIII–XbaI into pAc5.1B-λN-HA 
CNOT3 / 753 / NM_014516.2 / 
 cloned SacII–BamHI into pλN-HA-C1 
NOT3/5 *2 (CG8426) / 844 / NM_136332.2 / 
cloned HindIII–NotI into pAc5.1B-λN-HA 
CNOT4  NOT4 (CG31716) /1048 / NM_164919.1 / 
cloned XhoI–BstBI into pAc5.1B-λN-HA 
CNOT9 (RQCD1, RCD-1)  CAF40 (CG14213)  
CNOT10 / 744 / NM_015442.1 / 
cloned XhoI–BamHI into pλN-HA-C1 
CG18616  
C2ORF29 (C40) / 510 / NM_017546.4 
cloned KpnI–BamHI into pλN-HA-C1 
CG13567 
TAB182 (TNKS1BP1) / 1729 / 
NM_033396.2  cloned SalI–XbaI into pλN-
HA-C1 
 
  
Human PAN2-PAN3 complex Dm PAN2-PAN3 complex 
PAN2 / 1202 / BC094885.1 / 
cloned XhoI–EcoRI into pλN-HA-C1 
PAN2 (CG8232) / 1241 / LP04771 / 
cloned EcoRV–SacII into pAc5.1B-λN-HA 
PAN3 / 687 / BC128180.1 / 
cloned XhoI–KpnI into pλN-HA-C1
PAN3 (CG11486) / 790 / LD14901 /  
cloned EcoRI–NotI into pAc5.1B-λN-HA 
 
Subunits in blue are considered core components of the CCR4-CAF1-NOT complex. 
NOT4 and CAF40 are not integral core components (Temme et al., 2004; 2010; Lau et al; 
2009) and it is unclear whether the D. melanogaster homologs of CNOT10, C2ORF29 and 
TAB182 are part of the complex in D. melanogaster. 
 
*1 CAF1 and POP2 are related proteins. 
 
 
*2 In yeast there are two similar proteins NOT3 and NOT5, but humans and D. melanogaster 
contain only one orthologous protein termed NOT3 or NOT3/5. 
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Co-immunoprecipitation assays and western blot analysis of human cells 
For co-immunoprecipitation assays, HEK293 cells were grown in 10-cm dishes and 
transfected using Lipofectamine 2000 (Invitrogen). The transfection mixtures 
contained 8 µg of plasmid expressing GFP-tagged AGO2, TNRC6A–C or the 
corresponding mutants and 7 µg of HA-tagged deadenylation factor. In reciprocal 
immunoprecipitations in which bait and prey proteins were exchanged, transfection 
mixtures contained 8 µg of plasmid expressing GFP-tagged deadenylation subunits, 
and 7 µg of HA-tagged TNRC6C. Knockdowns in human HeLa and HEK293 cells 
were performed as described by Huntzinger et al. (2010) using β-Gal siRNA as a 
negative control  (5'-CUACACAAAUCAGCGAUUUUU-3'; Dharmacon) and PAN3 
or NOT1 SMARTpool siRNA (Dharmacon). 
Cells were harvested two days after transfection and lysed for 15 min on ice in NET 
buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, and 0.1% Triton X-100) 
supplemented with protease inhibitors and 10% glycerol (1 ml NET buffer/ plate). 
Cell lysates were treated with RNase A for 30 min and spun at 18,000 g for 15 min at 
4°C. Alternatively, cell lysates were supplemented with 2.5 mM CaCl2 and treated 
with micrococcal nuclease for 30 min. Immunoprecipitation was performed as 
described by Huntzinger et al. (2010). Endogenous proteins were detected with the 
following antibodies: TNRC6A (Bethyl Laboratories A302-329A; 1:10,000), 
PABPC1 (Abcam ab21060; 1:10,000), PAN3 (Abcam ab96325; 1:1,000), and NOT2 
(Abcam ab90703; 1:1,000). An anti-NOT1 antibody was kindly provided by Elmar 
Wahle. β-Actin was detected using a monoclonal antibody (SIGMA, A5441, clone 
AC-15). HA-tagged and GFP-tagged proteins were detected using HRP-conjugated 
monoclonal anti-HA (Roche 3F10; 1:5,000) and anti-GFP antibodies (Roche 
11814460001; 1:2,000), respectively. V5-tagged proteins were detected with anti-V5 
antibodies (Invitrogen, 1:5,000). All western blots were developed with the ECL 
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western blotting detection system (GE Healthcare) as recommended by the 
manufacturer. 
 
Co-immunoprecipitation assays and western blot analysis of D. melanogaster S2 
cells 
For co-immunoprecipitation assays, S2 cells (10–12 x 106 cells) were collected 3 days 
after transfection, washed with PBS, and lysed in 0.5 ml of NET buffer supplemented 
with protease inhibitors. Cell lysates were treated with RNase A for 30 min and spun 
at 18,000 g for 15 min at 4°C. Immunoprecipitations were performed as described by 
Huntzinger et al. (2010). NOT1 and tagged proteins were detected as described above. 
Endogenous GW182 and eIF4E were detected with polyclonal antibodies raised in 
rabbits against the N-terminal domain of GW182 (amino acids 1–539) and full-length 
eIF4E. 
 
GST pull-down assays 
In vitro transcription/translation reactions were performed using the TNT T7-coupled 
Wheat Germ Extract System (Promega, L4140) and [35S]-methionine (EasyTag, 
Perkin Elmer, NEG709A) according to the manufacturer's instructions. 
For the GST pull-down assays shown in Figure 4A, 12 µg of purified GST or GST-
TNRC6B silencing domain was mixed with purified MBP-tagged PAN3, NOT2 or 
CCR4a in 1 ml of binding buffer (10 mM Hepes (pH 7.5), 150 mM NaCl, 1 mM DTT 
and 1% [v/v] Triton X-100). The samples were incubated with 20 μL of Protino 
Glutathione Agarose 4B beads (Macherey Nagel) for 1 hr at 4°C. The beads were 
washed three times with 1 ml of binding buffer. The proteins were then eluted with 40 
μL of SDS-PAGE loading buffer and analyzed by 10% SDS-PAGE.  
For all other GST pull down assays, lysate from E. coli cells expressing GST, GST-
TNRC6B-SD, or the indicated deletion mutant were incubated with 20 μL of Protino 
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Glutathione Agarose 4B beads in lysis buffer (10 mM Hepes (pH 7.5), 300 mM 
NaCl, 5 mM MgCl2 and 1 mM DTT) for 1 hr at 4°C. The beads were washed three 
times with 1 ml of lysis buffer. The pre-coated beads were then incubated with 
approximately 25 µg of recombinant MBP-PAN3, MBP-PAN3-C-term or 6xHis-
NOT1 in 1 ml of binding buffer for 1 hr at 4°C. Alternatively, pre-coated beads were 
incubated with in vitro translated proteins in 150 µl of NET buffer (see above) 
supplemented with 1mM DTT and 0.1 g/l BSA. The beads were washed four times 
with 1 ml of binding buffer and eluted as indicated above. The proteins were eluted 
with 40 μL of SDS-PAGE loading buffer and analyzed by 10% SDS-PAGE. [35S]-
methionine-labeled proteins were detected by fluorography using Amplify 
(NAMP100, GE Healthcare) according to the instructions of the manufacturer. 
 
Complementation assay in human cells 
The Renilla and firefly luciferase reporters have been described before (Huntzinger et 
al., 2010; Pillai et al., 2005). Complementation assays in human HeLa cells were 
performed as described by Huntzinger et al. (2010). The following siRNAs were used: 
TNRC6A 5'-GCCUAAUCUCCGUGCUCAATT-3', TNRC6B 5'-
GGCCUUGUAUUGCCAGCAATT-3', and β-Gal 5'-
CUACACAAAUCAGCGAUUUUU-3'; Dharmacon). R-Luc and F-Luc activities 
were measured using the Dual-Luciferase Reporter Assay System (Promega).  
 
Knockdowns in S2 cells, RNA analysis and luciferase assays 
Transfection of S2 cells was performed in 6-well or 24-well dishes using Effectene 
transfection reagent (Qiagen). For the λN-tethering assay, the following plasmids 
were cotransfected: 0.1μg reporter plasmid (F-Luc-5BoxB), 0.4μg pAc5.1-R-Luc as 
transfection control and 10ng of pAc5.1λN-HA construct for the expression of λN-
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HA-fusion proteins. For the miRNA reporter experiments, the following plasmids 
were cotransfected: 0.1μg of F-Luc-Nerfin (or F-Luc-Par-6) reporter plasmid, 0.4μg 
pAc5.1-R-Luc (as transfection control), and 0.1μg of pAc5.1 plasmid without insert 
(empty vector) or expressing miRNA primary transcripts.  
For the measurement of mRNA half-life, transfected cells were treated with 
actinomycin D (5µg/ml final concentration) 3 days after transfection and harvested at 
the indicated time points. Firefly and Renilla luciferase activity was measured using 
the Dual-Luciferase reporter assay system (Promega), and total RNA was isolated 
using TriFast (peqlab biotechnologies). RNA samples were analyzed as described by 
Behm-Ansmant et al. (2006).  
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miRNA-mediated gene silencing requires the GW182
proteins, which are characterized by an N-terminal
domain that interacts with Argonaute proteins (AGOs),
and a C-terminal silencing domain (SD). In Drosophila
melanogaster (Dm) GW182 and a human (Hs) orthologue,
TNRC6C, the SD was previously shown to interact with the
cytoplasmic poly(A)-binding protein (PABPC1). Here, we
show that two regions of GW182 proteins interact with
PABPC1: the first contains a PABP-interacting motif 2
(PAM2; as shown before for TNRC6C) and the second
contains the M2 and C-terminal sequences in the SD.
The latter mediates indirect binding to the PABPC1
N-terminal domain. In D. melanogaster cells, the second
binding site dominates; however, in HsTNRC6A–C the
PAM2 motif is essential for binding to both Hs and
DmPABPC1. Accordingly, a single amino acid substitution
in the TNRC6A–C PAM2 motif abolishes the interaction
with PABPC1. This mutation also impairs TNRC6s silen-
cing activity. Our findings reveal that despite species-
specific differences in the relative strength of the
PABPC1-binding sites, the interaction between GW182
proteins and PABPC1 is critical for miRNA-mediated
silencing in animal cells.
The EMBO Journal (2010) 29, 4146–4160. doi:10.1038/
emboj.2010.274; Published online 9 November 2010
Subject Categories: RNA
Keywords: argonaute; miRNAs; mRNA decay; silencing;
TNRC6
Introduction
GW182-family proteins are essential in animal cells for
miRNA-mediated silencing (reviewed by Ding and Han,
2007; Eulalio et al, 2009a). Analysis of GW182 domains in
Drosophila melanogaster (Dm) and human cells identified
two domains that are required for silencing. The first is the
N-terminal domain, which contains multiple glycine-trypto-
phan repeats (GW repeats) and confers binding to Argonaute
proteins (AGOs; Behm-Ansmant et al, 2006; Till et al, 2007;
Eulalio et al, 2008; Lazzaretti et al, 2009; Takimoto et al,
2009). The second is a bipartite silencing domain (SD),
consisting of the Mid and C-terminal regions, which elicits
translational repression and degradation of miRNA targets
(Figure 1A; Eulalio et al, 2009b; Lazzaretti et al, 2009;
Zipprich et al, 2009).
Exactly how the bipartite SD of GW182 proteins interferes
with translation and accelerates mRNA degradation is not
completely understood, but recent studies provide important
insight by showing that these domains interact with the
cytoplasmic poly(A)-binding protein PABPC1, both in
D. melanogaster and human cells (Fabian et al, 2009; Zekri
et al, 2009).
PABPC1 is a highly conserved eukaryotic protein that binds
the poly(A) tail of mRNAs and stimulates translation through
multiple interactions with translation factors (reviewed by
Kahvejian et al, 2001; Derry et al, 2006). PABPC1 contains
four N-terminal RNA recognition motifs (RRM1–4), a proline-
rich unstructured linker and a C-terminal domain (termed
PABC or MLLE, because of a conserved KITGMLLE signature
motif in this domain; Figure 1A; Kozlov et al, 2010a). The
MLLE domain recognizes a conserved motif termed PABP-
interacting motif 2 (PAM2), which was first identified in the
translational regulators Paip1 and Paip2 (PABP-interacting
proteins 1 and 2) and is also present in multiple proteins
involved in translation or mRNA decay (Khaleghpour et al,
2001; Roy et al, 2002; Albrecht and Lengauer, 2004; Kozlov
et al, 2004, 2010a).
Interestingly, the SD of TNRC6C contains a PAM2 motif
(previously termed conserved motif III or DUF; Figure 1A).
This PAM2 motif in TNRC6C interacts directly with the
PABPC1 MLLE domain in a way similar of those found in
Paip1 and Paip2 (Fabian et al, 2009; Jı´nek et al, 2010; Kozlov
et al, 2010b). In particular, when both TNRC6C and Paip2
bind to the MLLE domain, the invariant glutamate, phenyl-
alanine and proline residues of the PAM2 motifs occupy
structurally equivalent positions (Jı´nek et al, 2010; Kozlov
et al, 2010b). Moreover, when the phenylalanine residue is
substituted with alanine, the interaction of TNRC6C with the
MLLE domain is abolished as shown before for Paip2 (Kozlov
et al, 2004, 2010a, b).
The PAM2 motif is also conserved in DmGW182.
Surprisingly, however, our previous studies showed that
this motif is dispensable for PABPC1 binding in cell lysates
(Zekri et al, 2009). DmGW182 instead binds PABPC1 via
sequences downstream of the PAM2 motif (termed M2), plus
sequences in the very C-terminal (C-term) region (Figure 1A).
Nevertheless, the affinity of these regions for PABPC1 in-
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creases when the PAM2 motif is included (Zekri et al, 2009);
however, deleting the PAM2 motif does not affect the
DmGW182 silencing activity in vivo (Eulalio et al, 2009b).
The M2 and C-term regions of DmGW182 do not interact with
the MLLE domain of DmPABPC1 but rather interact with the
N-terminal PABPC1 RRM domains (Zekri et al, 2009). These
observations raise a key question: Do the differences in
human TNRC6C and DmGW182 reflect differences in the
mechanisms of silencing between these distant species?
Another important question that remains open is to what
extent the interaction between GW182 proteins and PABPC1
contributes to silencing in vivo. Currently, two lines of evi-
dence support a role for PABPC1 in silencing. First, over-
expressing PABPC1 in both D. melanogaster and human cells
suppresses silencing (Zekri et al, 2009; Walters et al, 2010).
Second, depleting PABPC1 from cell-free extracts abolishes
miRNA-mediated deadenylation (Fabian et al, 2009). It has
been difficult to obtain more direct evidence of a role for
PABPC1 in the miRNA pathway (i.e. using RNAi knockdowns)
because depleting PABPC1 causes rapid cell death and general
mRNA destabilization (Behm-Ansmant et al, 2007).
In this study, we investigate further the interaction of
DmGW182 and human TNRC6A–C proteins with PABPC1.
We show that PABPC1 provides two binding sites for GW182
proteins: one on the MLLE domain and another on the RRM
domains. Conversely, GW182 proteins contain two PABPC1-
binding sites: the PAM2 motif, which confers direct binding to
the MLLE domain (as shown before for TNRC6C; Fabian et al,
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Figure 1 PABPC1 provides two binding sites for GW182 proteins. (A) Domain organization of HsPABPC1, HsTNRC6B isoform 1 and
DmGW182. PABPC consists of four N-terminal RRM domains, a proline-rich unstructured linker, and a conserved C-terminal domain, termed
MLLE. HsTNRC6B and DmGW182 consist of an N-terminal AGO-binding domain, which contains multiple GW-repeats (yellow); and a bipartite
silencing domain (SD) which includes the Mid (M) and C-terminal regions but not the RRM. UBA, ubiquitin-associated domain;
Q-rich, region rich in glutamine; PAM2, PABP-interacting motif 2; RRM, RNA recognition motif; M1 and M2, regions within the Mid (M)
domain; C-term, C-terminal region. (B) S2 cells were transfected with a plasmid expressing V5-tagged DmPABPC1 together with plasmids for
expression of GFP-tagged proteins (DmGW182, human TNRC6A–C, or firefly luciferase (F-Luc, which served as a negative control)). Three
days after transfection, cells were lysed and proteins were immunoprecipitated using a polyclonal anti-GFP antibody. Inputs and
immunoprecipitates were analysed by western blotting using anti-GFP and anti-V5 antibodies. The presence of endogenous AGO1 in the
immunoprecipitates was analysed using a specific anti-AGO1 antibody. (C–E) The interaction of GFP-TNRC6B or GFP-GW182 with full-length
DmPABPC1-V5 or the indicated PABPC1 deletion mutants (V5 tagged) was analysed as described in panel (B). Note that in panel (E), cell
lysates were treated with micrococcal nuclease prior to immunoprecipitation.
GW182–PABPC1 interaction is required for silencing
E Huntzinger et al
&2010 European Molecular Biology Organization The EMBO Journal VOL 29 | NO 24 | 2010 4147
2009; Jı´nek et al, 2010; Kozlov et al, 2010b), and a less-
defined sequence comprising the M2 and C-term regions,
which interacts indirectly with the PABPC1 RRMs (as shown
before for DmGW182; Zekri et al, 2009). Both sites contribute
to PABPC1-binding in vivo, but for the human proteins, the
dominant interaction is between PABPC1 MLLE and PAM2,
whereas for DmGW182, the critical interaction is with
PABPC1 RRMs. These results reconcile the apparent discre-
pancy between earlier studies in human and D. melanogaster
cells (Fabian et al, 2009; Zekri et al, 2009).
We also show that in D. melanogaster cells depleted of
endogenous GW182, human TNRC6B can rescue silencing.
Remarkably, this ability to restore silencing is abrogated by a
single amino acid substitution in the PAM2 motif of TNRC6B.
This mutation also abolishes TNRC6s binding to both Dm and
HsPABPC1. Moreover, a chimeric DmGW182 construct con-
taining the PAM2 motif, plus the M2 and C-term regions of
human TNRC6B, requires the PAM2 motif to interact with
PABPC1. Importantly, a phenylalanine to alanine substitution
within the PAM2 motif abrogated both PABPC1 binding and
the silencing activity of the chimeric protein. Finally, we
show that a TNRC6A protein lacking the PAM2 motif or
carrying a single amino acid substitution in this motif does
not interact with HsPABPC1 and is strongly impaired in
restoring silencing in human cells depleted of endogenous
TNRC6A and TNRC6B. Together, our results definitively
establish a crucial role for GW182–PABPC1 interaction in
the miRNA pathway.
Results
PABPC1 provides two binding sites for GW182 proteins
Previous studies reported that DmGW182 and TNRC6C
interact with different PABPC1 domains (see Introduction).
Therefore, we wished to determine whether, the species-
specific binding differences reside in the GW182 proteins,
in PABPC1 or both. To do this, we examined the interaction of
human TNRC6s with DmPABPC1 in D. melanogaster
Schneider-2 cells (S2 cells). In S2 cells, the expression level
of TNRC6B was comparable to that of DmGW182, whereas
human TNRC6A and TNRC6C were expressed at lower levels
(Figure 1B, lanes 2–5). Nevertheless, considering the amount
of proteins detected in the immunoprecipitates, the three
human proteins coimmunoprecipitated DmPABPC1 and
endogenous DmAGO1 more efficiently than DmGW182
(Figure 1B, lanes 7–10).
To define the domains in DmPABPC1 that are important for
the interaction with either DmGW182 or human TNRC6B, we
tested each with a series of DmPABPC1 deletion mutants.
PABPC1 contains four RRMs connected to the C-terminal
MLLE domain by a flexible linker (Figure 1A; Derry et al,
2006). Deleting RRM1 reduced the PABPC1 interaction with
both DmGW182 and TNRC6B (Figure 1C and D, lane 18
versus lane 16). In contrast, deleting the MLLE domain
inhibited PABPC1 from binding to TNRC6B but not to
DmGW182 (Figure 1C and D, lane 28). Deleting RRM2,
RRM3, RRM4 or the linker region had no effect in any of
these interactions (Figure 1C and D, lanes 19–26). Together,
these results indicate that PABPC1 has two binding sites for
GW182 proteins: one that is contributed by the RRM1 domain
and another by the MLLE domain.
We next asked whether PABPC1 RRMs or the MLLE
domain were sufficient for binding to DmGW182 and
TNRC6B, respectively. We observed that TNRC6B interacted
with PABPC1 fragments comprising either the RRMs or the
MLLE domain (Figure 1E, lanes 15 and 18). However, these
interactions were less efficient than those observed with full-
length PABPC1 (Figure 1E, lane 12), suggesting that the RRM
and the MLLE domains contribute (additively or synergisti-
cally) to the interaction with TNRC6B. Furthermore, we
confirmed that, in cell lysates, DmGW182 interacts with the
PABPC1 RRMs but not the MLLE domain as shown before
(Figure 1E, lanes 14 and 17; Zekri et al, 2009). Importantly,
the interactions shown in Figure 1E were observed in cell
lysates treated with micrococcal nuclease, suggesting that
they are not mediated by RNA.
GW182 proteins interact with PABPC1 through two
distinct binding sites
We next tested how the various sequences within the SDs of
DmGW182 and TNRC6B contribute to PABPC1 binding. Both
SDs consist of four segments: M1, PAM2 motif, M2 and
C-term (Figures 1A and 2A). Deleting the TNRC6B PAM2
motif abolished the interaction with PABPC1, whereas no
effect was observed when the M2 and C-term regions were
deleted individually (Figure 2B, lanes 10–12). When, how-
ever, the M2 and C-term regions were both deleted, then
PABPC1 binding was reduced, suggesting that these regions
work in concert to bind PABPC1 (Figure 2B, lane 13). Thus,
for TNRC6B, although the PAM2 motif is the high-affinity
PABPC1-binding site, the M2 and C-term regions also
contribute.
In the case of DmGW182, we previously reported that the
same three regions (PAM2 motif and the M2 and C-term
regions) contribute to PABPC1 binding (Zekri et al, 2009).
However, the contribution of the PAM2 motif and the M2
region was apparent only when binding to PABPC1 was
impaired, for example by deleting the C-term region (Zekri
et al, 2009). The results shown in Figure 2C confirm and
extend these previous observations. Indeed, we confirmed
that the interaction of GW182 with PABPC1 is not affected
when the M2 region or the PAM2 motif are deleted individu-
ally (Figure 2C, lanes 13 and 14; Zekri et al, 2009). In
contrast, deleting the C-term region reduced PABPC1 binding
(Figure 2C, lane 15). PABPC1 binding was further decreased
when the C-term region was deleted in combination with the
M2 region or the PAM2 motif (Figure 2C, lanes 16 and 17;
Zekri et al, 2009). PABPC1 binding was abolished when all
three regions were deleted (i.e. PAM2, M2 and C-term;
Figure 2C, lane 19; Zekri et al, 2009). Similar results were
obtained when cell lysates were treated with micrococcal
nuclease (Supplementary Figure S1).
An important implication of the results shown in Figure 2C
is that the GW182 C-term region provides a major PABPC1-
binding sites in cell lysates, however, the M2 region and the
PAM2 motif also contribute, although on their own they are
not sufficient. This conclusion is further supported by experi-
ments aimed at defining the minimal PABPC1-binding do-
main in DmGW182. We observed that a protein fragment
containing the PAM2 motif and the M2 and C-ter regions was
sufficient for PABPC1 binding (Supplementary Figure S2A,
lane 17 versus lane 13; Zekri et al, 2009), whereas fragments
containing one or two of these sequences exhibited reduced
GW182–PABPC1 interaction is required for silencing
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or no affinity for PABPC1 in cell lysates (Supplementary
Figure S2A, lanes 15, 16 and 18–22). These results remained
unchanged in the presence of micrococcal nuclease
(Supplementary Figure S2B).
The results described above, together with the observation
that DmGW182 interacts with the RRM domains as efficiently
with full-length PABPC1, suggest that the role of the M2
and C-term regions is to confer binding to PABPC1 RRMs.
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Figure 2 GW182 proteins contain two PABPC1-binding sites. (A) Sequence alignment of PAM2 motifs of human TNRC6A–C, Paip2 and
DmGW182. Invariant residues are shown in red. The asterisk indicates the phenylalanine residue that is substituted with alanine in our
mutants (Mut). Dots indicate the residues in the PAM2 motif of GW182 that were substituted in the experiment shown in Figure 3B. (B, C) S2
cells expressing GFP-TNRC6B, GFP-DmGW182 or the corresponding protein mutants together with DmPABPC1-V5 were lysed 3 days after
transfection. Proteins were immunoprecipitated from cell lysates using a polyclonal anti-GFP antibody and analysed by western blotting as
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Therefore, we constructed a PABPC1 mutant containing only
the RRM1–4 domains and tested how well it interacts with
various GW182 deletion mutants. We observed that deleting
the M2 and C-term regions inhibited DmGW182 from inter-
acting with the PABPC1 RRMs as efficiently as deleting the
entire SD (which includes the PAM2 motif); in contrast,
deleting the PAM2 motif alone had no effect (Figure 2D,
lanes 8–10). Collectively, these results clearly demonstrate
that the M2 and C-term regions interact with DmPABPC1
RRM domains in cell lysates.
A single amino acid substitution in the PAM2 motif
of human TNRC6s abolishes binding to DmPABPC1
The PAM2 motifs from diverse proteins contain three invar-
iant residues EF(X)P that occupy equivalent structural posi-
tions when bound to an MLLE domain (Figure 2A; Jı´nek et al,
2010; Kozlov et al, 2010a, b). In particular, the invariant
phenylalanine residue is critical for this interaction: if this
phenylalanine is substituted with alanine then the Paip2 and
TNRC6C PAM2 motifs cannot bind PABPC1 (Kozlov et al,
2004, 2010a, b). Similarly, this substitution abolishes the
TNRC6B interaction with DmPABPC1 as efficiently as deleting
the entire PAM2 motif (Figure 2B, lane 14; Figure 3A, lane
16). The critical role of the invariant phenylalanine residue in
the interaction with DmPABPC1 was confirmed for TNRC6A
and TNRC6C SDs (Figure 3A, lanes 14 and 18). The equiva-
lent substitution in the PAM2 motif of DmGW182 had only a
minor effect on DmPABPC1 binding, as expected (Figure 3A,
lane 12).
The coimmunoprecipitation assays suggest that the
D. melanogaster PAM2 motif has a relatively lower affinity
for the DmPABPC1 MLLE domain. This might be because the
motif lies in a suboptimal sequence context. However, we
consider this possibility unlikely because the human PAM2
motif is functional in the context of DmGW182 (i.e. it
enhances DmGW182 binding to PABPC1; see below
Figure 8A). An alternative explanation is that the affinity
may be lower because a negatively charged residue sits at the
core of the PAM2 motif (between the invariant phenylalanine
and proline residues, Figure 2A). Indeed, negatively charged
residues are extremely rare at the equivalent position in
PAM2 motifs from diverse proteins and are absent in all
PAM2 motifs validated experimentally (Albrecht and
Lengauer, 2004; Kozlov et al, 2010a). Additionally, in the
human TNRC6A–C, the invariant residues of the PAM2 motifs
are preceded by proline residues that establish hydrophobic
interactions with the MLLE domain (Kozlov et al, 2010b),
these residues are substituted with valine and glutamine in
DmGW182 (Figure 2A).
We therefore tested whether substituting residues in the
PAM2 motif of GW182 with the residues present in the
human proteins could enhance PABPC1 binding.
Substituting the GW182 PAM2-motif amino acids V958 and
Q959 with prolines enhanced GW182 binding to DmPABPC1
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(B) S2 cells transiently expressing DmPABPC1-V5 together with GFP-GW182 wild type or the indicated GW182 mutants were lysed 3 days after
transfection. Proteins were immunoprecipitated from cell lysates using anti-GFP antibodies and analysed as described in Figure 1B. GW182
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(Figure 3B, lane 8 versus lane 7). Similar results were
obtained when the negatively charged residue E962 was
substituted with glutamine as in TNRC6B (Figure 3B, lane
9). The two GW182 mutants interacted with DmPABPC1 as
efficiently as TNRC6B (Figure 3B, lane 10). Thus, the differ-
ences in the amino acid sequences of these PAM2 motifs can
account for the different affinities for the DmPABPC1 MLLE
domain.
The PAM2 motifs of human TNRC6s are essential
for binding to HsPABPC1
We next analysed whether the human proteins interact in a
similar way with HsPABPC1. We transfected human HEK-293
cells with plasmids expressing either wild-type TNRC6A–C
SDs or the corresponding mutants carrying the phenylalanine
to alanine substitution in the PAM2 motifs. We observed that
the single amino acid substitution in the PAM2 motifs was
sufficient to abolish the interaction with endogenous PABPC1
(Figure 4A–C). Thus, the PAM2 motifs of TNRC6A–C are
essential in mediating binding to both Hs and DmPABPC1.
We also tested whether the M2 and C-term regions of
human TNRC6s contribute to PABPC1 binding in human
cell lysates. Remarkably, deleting either the M2 or C-terminal
regions in the TNRC6C SD reduced the interaction with
PABPC1, whereas deleting the RRM from TNRC6C had no
effect (Figure 4D, lanes 12–14). As a control, we confirmed
that deleting the PAM2 motif (or the entire Mid domain)
abrogated PABPC1 binding (Figure 4D, lanes 10 and 11).
Similar results were obtained when cell lysates were treated
with micrococcal nuclease (data not shown). These findings
demonstrate that TNRC6s contain two PABPC1-binding sites:
the PAM2 motif and the M2 plus C-term regions.
To investigate whether the interaction mediated by the
M2 and C-term regions of GW182 proteins is direct, we
performed glutathione S-transferase (GST) pull-down assays
with recombinant proteins expressed in Escherichia coli.
These experiments revealed the following observations:
First, we observed that a GST-tagged C-terminal fragment
of TNRC6B containing the PAM2 motif and the downstream
protein sequences (i.e. M2, RRM and C-term) interacted with
both human and DmPABPC1, but did not interact with the
corresponding PABPC1 mutants lacking the MLLE domain
(Figure 4E, lanes 11 versus 14, and 27 versus 30, respec-
tively). Second, deleting the PAM2 motif abolished the inter-
action of TNRC6B SD with both Hs and DmPABPC1
(Figure 4E, lanes 12 and 28, respectively; Figure 5A, lane
10), in agreement with the coimmunoprecipitation assays. In
contrast, deleting the M2 and C-terminal regions did not
affect PABPC1-binding in vitro (Figure 5A, lane 13).
Surprisingly, in vitro, the interaction of DmGW182 SD with
DmPABPC1 was mediated by the PAM2 motif (Figure 5B, lane
10 versus lane 9). Accordingly, a GW182 SD mutant lacking
the M2 and C-terminal regions pulled down DmPABPC1
(Figure 5B, lane 13). Together, these results indicate that
the PAM2 motifs of GW182 proteins mediate direct binding
to PABPC1, whereas the M2 and C-term regions interact with
PABPC1 indirectly, most likely through additional proteins
present in cell lysates. Alternatively, the interaction of the
M2 and C-term regions with PABPC1 may require post-
translational modifications that do not occur in bacteria.
Importantly, the observation that the DmGW182 PAM2
motif directly interacts with DmPABPC1 in vitro, but is
neither sufficient nor necessary for binding to DmPABPC1
in cell lysates, suggest that the DmPAM2 motif might not be
able to efficiently compete with additional PAM2-containing
proteins for binding to PABPC1 in D. melanogaster cells.
GW182 silencing activity correlates with PABPC1
binding
To evaluate how the interaction between GW182 and PABPC1
contributes to silencing, we tested whether DmGW182 mu-
tants that are impaired in PABPC1 binding in cell lysates
could complement silencing in cells lacking endogenous
GW182. To this end, we used a complementation assay
described before (Eulalio et al, 2009b). In this assay, endo-
genous GW182 is depleted using a dsRNA that targets the
coding sequence of the GW182 mRNA. This depletion inhi-
bits miRNA-mediated silencing (Figure 6A–G). GW182 mu-
tants were then tested for the ability to restore silencing in
GW182-depleted cells. Transcripts encoding the recombinant
proteins were made resistant to the dsRNA by introducing
mutations that disrupt basepair interactions with the dsRNA
without altering the protein sequence.
We monitored miRNA activity using two different repor-
ters: the F-Luc-Par-6 reporter which is degraded in the pre-
sence of miR-1 and the F-Luc-Nerfin reporter which is
silenced by miR-9b or miR-279 mainly at the translational
level (Behm-Ansmant et al, 2006; Eulalio et al, 2007). We
observed that, independently of the reporter, a DmGW182
mutant lacking the PAM2 motif fully rescued silencing
(Figure 6A–F). Deleting the M2 region had a slight inhibitory
effect (particularly for the F-Luc-Par-6 reporter), whereas
deleting the C-term region impaired silencing for all reporters
as shown before (Figure 6A–F; Eulalio et al, 2009b). When in
addition to the C-term region, the PAM2 motif and the M2
region were deleted, the silencing activity of the protein
decreased further and was comparable to that of the protein
lacking the entire SD (Figure 6A–F). Note that these deletion
mutants did not rescue silencing even though they were
expressed at higher levels than the wild type (Figure 6H).
Moreover, the activity of wild-type GW182 and mutants
remained unchanged when the amounts of transfect plasmid
were increased up to 10-fold (Supplementary Figure S3). We
conclude that the silencing activity of GW182 mutants
strongly correlates with the ability to bind to PABPC1.
Nevertheless, because several regions of DmGW182 must
be deleted to abolish PABPC1-binding in vivo, we cannot
rule out that these regions are also required for additional
functions.
Human TNRC6s complement silencing in
D. melanogaster cells
Next, we investigated whether the human proteins could
restore silencing in S2 cells depleted of endogenous
DmGW182. As shown above, depleting endogenous GW182
suppresses silencing of the F-Luc-Par-6 reporter, leading to a
five- to nine-fold increase in firefly luciferase expression
(Figure 6A and B; Supplementary Figure S4). Expressing a
dsRNA-resistant form of GW182 fully restored silencing, over
a broad range of transfected expression plasmid (from 10 to
200 ng; Supplementary Figures S3 and S4). Similarly, expres-
sing TNRC6B restored silencing almost as efficiently as
GW182 (Supplementary Figure S4). In contrast, TNRC6A
and TNRC6C rescued silencing significantly only when the
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Figure 4 The PAM2 motifs of TNRC6A–C are essential for binding to HsPABPC1. (A–C) Human HEK-293 cells transiently expressing HA-tagged
silencing domains of TNRC6A–C or the indicated mutants were lysed 2 days after transfection. Proteins were immunoprecipitated from
RNaseA-treated cell lysates using anti-HA antibodies. HA-tagged maltose-binding protein (MBP) served as a negative control. Inputs and
immunoprecipitates were analysed by western blotting using anti-HA antibodies. The presence of endogenous PABPC1 in the immunopre-
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highest amount of expression plasmid was transfected
(Supplementary Figure S4). The differences in silencing
activity between TNRC6s could be due to differences in
protein expression levels (see Figure 1B) and not to incom-
patibility with the D. melanogaster silencing machinery, as all
three human proteins interact with DmAGO1 and PABPC1
(Figure 1B). However, it is possible that TNRC6A and
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Figure 6 DmGW182 silencing activity correlates with the ability to bind
PABPC1 in cell lysates. (A–F) S2 cells were treated with dsRNA targeting
the coding sequence of GW182 mRNA. Control cells were treated with
GST dsRNA. These cells were subsequently transfected with a mixture
of three plasmids: one expressing the indicated F–Luc miRNA reporters;
another expressing miRNA primary transcripts or the corresponding
empty vector (); and a third expressing Renilla luciferase (R–Luc).
Plasmids (10ng) encoding wild-type GFP-GW182 or various deletion
mutants were included in the transfection mixtures, as indicated. Firefly
luciferase activities were normalized to those of the Renilla luciferase
transfection control and set to 100 in cells transfected with the empty
vector (i.e. in the absence of miRNAs). (A, C, E) Normalized firefly
luciferase activities in the absence or presence of miRNAs in control
cells (i.e. cells treated with GST dsRNA and expressing GFP). (B, D, F)
The relative fold derepression for each condition. Mean values±s.d.
from three independent experiments are shown. (G) The effectiveness
of the GW182 depletion was analysed by western blotting using anti-
GW182 antibodies. In lanes 1–4, dilutions of untreated cells (control)
are loaded. Blots were probed with anti-tubulin antibodies to test for
equal loading. (H) Expression levels of full-length GW182 and mutants.
F-Luc-GFP served as a transfection control.
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TNRC6C are impaired for interaction with other factors
required for silencing.
The TNRC6s–PABPC1 interaction is required
for silencing
As TNRC6B can complement silencing in S2 cells and a single
point mutation in TNRC6B is sufficient to prevent binding to
PABPC1 both in vivo and in vitro, we had the opportunity to
test whether the TNRC6B–PABPC1 interaction is relevant for
silencing in a cellular context. In complementation assays in
S2 cells, we observed that a TNRC6B mutant lacking the
PAM2 motif was strongly impaired (Figure 7A–F). More
importantly, a protein carrying the phenylalanine to alanine
substitution in the PAM2 motif (Mut, F1370A) also failed to
rescue silencing (Figure 7A–F). The equivalent mutation in
GW182 (Mut, F961A) had no effect (Figure 7A–F). Deleting
the TNRC6B M2 and C-term regions also affected silencing
(Figure 7A–F); however, whether this effect reflects that these
regions indirectly contribute to PABPC1 binding or that they
have additional functions in silencing is unknown.
For the F-Luc-Par-6 reporter that is directed to degradation
by miR-1, we analysed transcript levels by Northern blotting.
In control cells expressing miR-1, F-Luc-Par-6 mRNA levels
were strongly reduced (Figure 7G, lane 2 versus lane 1).
Depleting GW182 inhibited miR-1-mediated mRNA degrada-
tion as reported before (Figure 7G, lane 4; Eulalio et al, 2008).
Transfecting GW182-depleted cells with a plasmid expressing
either wild-type GW182 or TNRC6B, restored mRNA degra-
dation (Figure 7G, lanes 6 and 12). The GW182 mutant
lacking the PAM2 motif also mediated mRNA degradation
(Figure 7G, lane 8). In contrast, the TNRC6B mutant lacking
the PAM2 motif could not trigger reporter degradation
(Figure 7G, lane 14). The control, a GW182 lacking the M2
and C-term regions, failed to restore mRNA degradation
(Figure 7G, lane 10). The mutant proteins were expressed
at comparable or slightly higher levels than wild type
(Figure 7H). We conclude that the TNRC6B–PABPC1 interac-
tion is required for silencing of miRNA targets, regardless of
whether the target is degraded (F-Luc-Par-6) or translation-
ally repressed (F-Luc-Nerfin).
A chimeric GW182 protein requires the interaction with
PABPC1 to elicit silencing
To further investigate how the GW182–PABPC1 interaction is
relevant in silencing, we sought to engineer a DmGW182
protein that requires the PAM2 motif to bind to PABPC1.
Initially, we generated a DmGW182 variant in which the
PAM2 motif was substituted with the TNRC6B PAM2 motif
(GW182-PAM26B). This chimeric protein interacted with Dm
PABPC1 more efficiently than wild-type GW182 (Figure 8A,
lane 13 versus lane 11); however, if the F1370A substitution
in the PAM2 motif was introduced, binding to PABPC1 was
comparable to that of wild-type GW182 (Figure 8A, lane 14
versus lane 11). Accordingly, in cells depleted of endogenous
GW182, the chimeric protein complemented silencing regard-
less of the F1370A substitution (Figures 8B–G). These results
further support the conclusion that in the context of
DmGW182, the PAM2 motif is dispensable for both PABPC1
binding and silencing.
Next, in addition to the PAM2 motif, we substituted the
M2, RRM and C-term sequences of DmGW182 with those
from TNRC6B (GW182-SD6B). This chimeric protein behaved
like TNRC6B with respect to PABPC1 binding (Figure 8A).
Indeed, relative to wild-type GW182, the PABPC1-binding
efficiency increased (Figure 8A, lane 15 versus lane 11).
More importantly, the F1370A substitution strongly reduced
the interaction with PABPC1 (Figure 8A, lane 16 versus lane
15). Thus, as for TNRC6B, the chimeric protein relies mainly
on the PAM2 motif to interact with PABPC1. In complementa-
tion assays, the chimeric protein carrying the F1370A sub-
stitution was impaired (Figure 8B–G), indicating that the
interaction of GW182 proteins with PABPC1 is critical for
silencing of miRNA targets.
The interaction of TNRC6A with PABPC1 is critical
for silencing in human cells
So far, we demonstrated that the interaction between TNRC6s
and PABPC1 has a critical function in silencing in D. mela-
nogaster S2 cells. To determine whether this is also true in
human cells, we examined whether overexpressing TNRC6C
in HeLa cells stimulated silencing of an R-Luc reporter con-
taining three let-7-binding sites in the 30 UTR (Pillai et al,
2005). We found that TNRC6C enhanced silencing, decreas-
ing luciferase activity an additional two-fold relative to con-
trol cells (Figure 9A and B). In contrast, the TNRC6C mutant
carrying the F1389A substitution failed to stimulate silencing
(Figure 9A and B).
Next, we depleted TNRC6 proteins using specific siRNAs
and tested whether siRNA-resistant forms of the TNRC6s
could complement silencing in depleted cells. We observed
that siRNAs targeting TNRC6A and TNRC6B efficiently sup-
pressed silencing of the let-7 reporter in HeLa cells (Figure 9C
and D; other combinations of siRNAs and protein expression
were less effective, data not shown). In cells codepleted of
TNRC6A and TNRC6B, the expression of wild-type TNRC6A
partially restored silencing, while the TNRC6A mutant
either lacking the PAM2 motif or carrying the F1359A sub-
stitution were impaired in restoring silencing, although they
were expressed at comparable levels as the wild type (Figure
9C–E). A TNRC6A mutant lacking the entire SD was inactive
in the complementation assay, although this mutant was
expressed at higher levels (Figure 9C–E). Altogether, these
data support the idea that the interaction of TNRC6s
with PABPC1 is also critical for silencing miRNA targets in
human cells.
Discussion
Proteins of the GW182 family have an essential function in
the miRNA pathway in diverse organisms (reviewed by Ding
and Han, 2007; Eulalio et al, 2009a). The GW182 N-terminal
and C-terminal domains interact with AGOs and PABPC1,
respectively (reviewed by Tritschler et al, 2010). Here, we
show that the GW182–PABPC1 interaction plays a crucial role
in miRNA-mediated gene silencing.
GW182 proteins are PABP-interacting proteins (Paips)
We found GW182 proteins are similar to Paip1 and Paip2 in
that they contain two binding sites for PABPC1: one in the
PAM2 motif and another in the M2 and C-terminal regions
(Figure 9F). In human TNRC6A–C and DmGW182, the PAM2
motif interacts directly with the C-terminal MLLE domain of
PABPC1. Previous structural and functional studies indicated
that the PAM2 motifs in TNRC6C, Paip1 and Paip2 are
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Figure 7 miRNA-mediated gene silencing requires TNRC6B interaction with PABPC1. (A–F) Complementation assays were performed with
wild-type TNRC6B and various TNRC6B mutants (10 ng) and the indicated miRNA reporters, as described in Figure 6. Wild-type GW182 and
the corresponding F961A mutant served as controls. (G) Northern blot analysis of representative RNA samples are shown in panels (A, B).
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Figure 8 Generation of a chimeric GW182 protein that depends on the PAM2 motif for PABPC1 binding. (A) Two DmGW182-TNRC6B chimeric
proteins were generated. The protein GW182-PAM26B consist of DmGW182 protein sequences in which the PAM2 motif was replaced with the
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functionally equivalent (Fabian et al, 2009; Jı´nek et al, 2010;
Kozlov et al, 2010b). Our findings extend this conclusion to
the PAM2 motifs of TNRC6A and TNRC6B. Indeed, substitut-
ing alanine for the invariant phenyalanine in the PAM2 motif
abolished binding to Hs or DmPABPC1 for all three human
TNRC6 proteins (Figures 2B, 3A and 4). Nevertheless, the M2
and C-term regions also contribute to PABPC1 binding in cell
lysates (Figures 2B and 4D). In DmGW182, the M2 and
C-terminal site mediates binding to the RRM domains at the
PABPC1 N-terminus (Figure 2D); this binding is most likely
mediated by additional proteins and not by RNA because
it is also observed in cell lysates treated with micrococcal
nuclease.
For human TNRC6A–C, PABPC1 binding is mediated pre-
dominantly by the PAM2 motifs (Figure 9F). In D. melano-
gaster cell lysates, in contrast, the GW182 PAM2 motif is
dispensable for PABPC1 binding. Nevertheless, the D. mela-
nogaster PAM2 motif contributes to PABPC1 binding, because
when it is deleted from a protein lacking the C-term region,
PABPC1-binding efficiency decreases further (Figure 2C).
Thus, although the human and D. melanogaster PAM2 motifs
and M2 and C-term regions differ in their contribution to
PABPC1-binding in vivo (Figure 9F), it is likely that TNRC6s
and GW182 form complexes with PABPC1 that are function-
ally equivalent. Accordingly, human TNRC6CA–C can com-
plement silencing in S2 cells depleted of endogenous
DmGW182 (Figure 7; Supplementary Figure S4), indicating
that silencing mechanisms are conserved between these
organisms.
How does the GW182–PABPC1 interaction contribute
to silencing?
Although both Paip1 and Paip2 contain PAM2 motifs, and
interact with PABPC1 in a similar manner, they affect transla-
tion in opposite ways: Paip1 stimulates translation whereas
Paip2 inhibits translation (Kahvejian et al, 2001; Khaleghpour
et al, 2001; Derry et al, 2006). Clearly, GW182 proteins are
likely to act like Paip2 and interfere with PABPC1 function in
translation and/or mRNA stabilization. So, how do GW182
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Figure 9 The interaction of TNRC6s with PABPC1 contributes to
silencing in human cells. (A, B) Human HeLa cells were transfected
with a mixture of three plasmids: the R-Luc-3xlet-7 or the corre-
sponding reporter lacking let-7-binding sites (R-Luc-Mut), a plasmid
expressing firefly luciferase as a transfection control, and plasmids
expressing GFP or the indicated GFP-tagged proteins. Renilla luci-
ferase activity was normalized to that of the firefly luciferase and set
to 100 in cells expressing the reporter lacking the let-7-binding sites
for each condition. (A) Normalized Renilla luciferase activities
in control cells (i.e. cells expressing GFP). (B) Relative silencing
activity for each condition. Mean values±s.d. are shown. (C–E)
HeLa cells were transfected with a control b-Gal siRNA or a mixture
of siRNAs targeting TNRC6A and TNRC6B. Two days later, cells
were re-transfected with the same siRNAs and a mixture of three
plasmids: the R-Luc-3xlet-7 or the corresponding reporter lacking
let-7-binding sites (R-Luc-Mut), a plasmid expressing F-Luc as a
transfection control, and plasmids expressing MBP or siRNA-resis-
tant versions of HA-TNRC6A wild type or mutants. Cells were
harvested 48 h after the second transfection. Renilla luciferase
activity was measured and normalized to that of the F-Luc and
set to 100 in cells expressing the reporter lacking the let-7-binding
sites for each condition. (C) Normalized Renilla luciferase activities
in control cells (i.e. cells treated with b-Gal siRNA and expressing
MBP). (D) The relative fold derepression for each condition.
Mean values±s.d. are shown. (E) Protein expression levels.
(F) Schematic diagram showing the interaction of HsTNRC6B and
DmGW182 silencing domains with the N- and C-terminal domains
of PABPC1. Protein domains are as described in Figure 1A. Red lines
indicate the dominant interactions observed in cell lysates. Dashed
lines indicate interactions observed only in cell lysates but not with
recombinant proteins expressed in E. coli.
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proteins affect PABPC1 function? One possible mechanism is
that GW182 proteins prevent mRNA circularization as de-
scribed previously with Paip2 (Karim et al, 2006). This idea is
based on the observation that the SD of DmGW182 competes
with eukaryotic initiation factor 4G (eIF4G) for binding to
PABPC1 in cell lysates (Zekri et al, 2009). eIF4G interacts with
the N-terminal RRMs of PABPC1; this interaction stimulates
translation by enabling the mRNA to adopt a closed-loop
conformation (reviewed by Kahvejian et al, 2001).
Consequently, by interfering with PABPC1–eIF4G interaction,
GW182 proteins could inhibit translation. Moreover, when an
mRNA is in the open conformation, the 50 cap and poly(A)
tail could be more accessible to the mRNA decay enzymes
leading to mRNA degradation.
Another mechanism by which the PABPC1–GW182 inter-
action could contribute to silencing is by reducing PABPC1
affinity for the poly(A) tail as described for Paip2
(Khaleghpour et al, 2001). This could render the poly(A)
tail more accessible to deadenylases and thus indirectly
interfere with mRNA circularization.
Finally, it is notable that not all proteins containing a PAM2
motif act directly on PABPC1, as shown for Paip1 and Paip2.
Other proteins such as human TOB for example, just use
PABPC1 as a binding platform that allows them to hook onto
mRNAs using a PAM2 motif. TOB also interacts with the
CAF1–CCR4–NOT mRNA deadenylase complex, and thus
through its interaction with PABPC1, it can promote dead-
enylation of mRNAs (Ezzeddine et al, 2007). Analogously, it
is possible that a GW182–PABPC1 complex might provide a
binding platform for additional interactions required in silen-
cing; these could include interactions with the CAF1–CCR4–
NOT1 deadenylase complex. Indeed, Fabian et al (2009)
showed that PABPC1 is required for the accelerated dead-
enylation of miRNA targets observed in vitro. Here we show
that the role of GW182–PABPC1 interaction is not restricted
to promoting deadenylation but rather this interaction is
required for silencing independently of whether or not the
target is degraded. Thus GW182–PABPC1 interaction may
contribute to silencing through multiple mechanisms.
Independently of the precise molecular mechanism, our
findings indicate that PABPC1 has a crucial function in
miRNA-mediated gene silencing in animal cells.
Materials and methods
DNA constructs
Luciferase reporters and plasmids for expression of miRNAs and
epitope-tagged proteins were described before (Zekri et al, 2009;
Eulalio et al, 2007, 2008, 2009b). cDNAs encoding human TNRC6A
and C were cloned into the HindIII and XhoI site of plasmid pAc5.1-
EGFP. Human TNRC6B cDNA was cloned into the HindIII and XbaI
sites of plasmid pAc5.1-EGFP. Mutations in DmGW182, DmPABPC1
and human TNRC6A–C were generated by site-directed mutagen-
esis using the Quick Change mutagenesis kit from Stratagene. The
protein GW182-PAM26B consist of DmGW182 protein sequences in
which the PAM2 motif (residues T952–Q971) were replaced with
the PAM2 motif of human TNRC6B (residues S1361–Q1380), the
corresponding PAM2-motif sequences are shown in Figure 2A). In
GW182-SD6B protein sequences downstream of DmGW182 residue
N937 were replaced with TNRC6B sequences downstream of
residue S1361, which contain the PAM2 motif, the M2 and C-term
regions and the RRM.
Complementation and luciferase assays in S2 cells
Complementation assays were performed as described before
(Eulalio et al, 2008, 2009b). Transfections of S2 cells were
performed in 24-well plates, using Effectene transfection reagent
(Qiagen). For miRNA-mediated silencing assays, the transfection
mixtures contained 0.02mg of firefly luciferase reporter plasmid,
0.08mg of the Renilla transfection control and 0.04mg of plasmids
expressing miRNA primary transcripts or the corresponding vector
without insert. When indicated, 10–200 ng of plasmids expressing
recombinant proteins were cotransfected. Firefly and Renilla
luciferase activities were measured 3 days after transfection using
the Dual-Luciferase Reporter Assay System (Promega). Total RNA
was isolated using TriFast (Peqlab Biotechnologies) and analysed as
described before (Eulalio et al, 2007).
Coimmunoprecipitations and western blots in S2 cells
For coimmunoprecipitation assays, S2 cells (10–12106 cells) were
collected 3 days after transfection, washed with PBS and lysed in
0.5 ml of NET buffer (50 mM Tris at pH 7.4, 150 mM NaCl, 1 mM
EDTA, 0.1% Triton) supplemented with protease inhibitors.
Immunoprecipitations were performed as described by Zekri et al
(2009). When indicated, cell lysates were supplemented with
2.5 mM CaCl2, treated with micrococcal nuclease (NEB, M0247S)
for 30 min and spun at 18 000 g for 15 min at 41C prior to
immunoprecipitation. Antibodies to AGO1 (dilution 1:1000) were
purchased from Abcam (catalogue number ab5070). Endogenous
GW182 and GFP-tagged proteins were detected with polyclonal
antibodies raised in rabbits. V5-tagged proteins were detected with
anti-V5 antibodies (Invitrogen, dilution 1:5000). All western blot
experiments were developed with the ECL Western blotting
detection system (GE Healthcare) as recommended by the
manufacturer.
Coimmunoprecipitations and western blots in human cells
Plasmids driving the expression of full-length TNRC6A–C or the
corresponding SDs in human cells were described by Lazzaretti et al
(2009). For coimmunoprecipitation assays, HEK-293 cells were
grown in 10 cm dishes and transfected using the calcium phosphate
method. The transfection mixtures contained 25mg of plasmid for
expression of HA-tagged TNRC6A–C SDs. Two days after transfec-
tion, cells were washed with PBS and lysed for 15 min on ice in NET
buffer supplemented with protease inhibitors and 10% glycerol
(1 ml NET buffer/plate). Cell lysates were treated with RNase A for
30 min and spun at 18 000 g for 15 min at 41C. Alternatively, cell
lysates were supplemented with 2.5 mM CaCl2 and treated with
micrococcal nuclease for 30 min. Monoclonal anti-HA antibodies
(Covance) were added to the supernatants (dilution 1:200).
Samples were incubated for 1 h at 41C. Then, 25ml of GammaBind
G Sepharose (GE Healthcare) were added and the mixtures were
rotated for an additional hour at 41C. Beads were washed three
times with NET buffer. Bound proteins were eluted with 100 ml of
protein sample buffer and analysed by western blotting. Endogen-
ous PABP was detected with a polyclonal anti-PABPC1 antibody
(Abcam ab21060; dilution 1:3000).
Luciferase assays in human cells
Renilla and firefly luciferase reporters were described before (Pillai
et al, 2005; Lazzaretti et al, 2009). For overexpression assays,
human HeLa cells were seeded in six-well plates and transfected
using the calcium phosphate method. The transfection mixtures
contained 0.05 mg of R-Luc-3xlet-7 reporter plasmid or the corre-
sponding reporter carrying mutations in the let-7-binding sites (R-
Luc-Mut), 0.5mg of the pEGFP-N3-F-Luc transfection control and
3mg of plasmids expressing GFP or GFP-protein fusions. R-Luc and
F-Luc activities were measured 48 h after transfection using the
Dual-Luciferase Reporter Assay System (Promega).
For complementation assays, human HeLa cells (0.25106) were
seeded in six-well plates in DMEM media without antibiotics (day
0). On day 1, cells were transfected with a mixture of two siRNAs
targeting TNRC6A and TNRC6B, respectively (75 pmol of each)
using Lipofectamine 2000 transfection reagent. Alternatively, cells
were transfected with a control siRNA targeting b-Gal. On day 2,
cells are reseeded in 12-well plates at 0.25106 cells per well in
DMEM without antibiotics. On day 3, cells are retransfected with
the same mixture of siRNAs and three plasmids: one expressing
the R-Luc-3xlet-7 reporter (20 ng) or the corresponding reporter
carrying mutations in the let-7-binding sites (R-Luc-Mut), one
expressing the transfection control (120 ng, pEGFP-N3-F-Luc); and a
third plasmid (165 ng) expressing HA-tagged TNRC6A wild type or
mutants or MBP. Cells were harvested 48 h after the second
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transfection. The following siRNAs were used: TNRC6A 50-GCCUAA
UCUCCGUGCUCAATT-30; TNRC6B 50-GGCCUUGUAUUGCCAGCAA
TT-30; b-Gal 50-CUACACAAAUCAGCGAUUUUU-30; Dharmacon).
GST pull-down assays
To express the SDs of TNRC6B (amino acids 1361–1723) or
DmGW182 (amino acids 937–1384) in E. coli, the corresponding
cDNAs were cloned into the pGEX6P1 vector (GE healthcare),
resulting in N-terminal GST fusions. Deletions and mutations were
introduced using the QuikChange mutagenesis kit (Stratagene) and
the appropriate oligos. For the MBP-tagged HsPABPC1 or
DmPABPC1 constructs, the corresponding cDNAs were cloned into
the pETM41 vector, resulting in N-terminal fusions with MBP.
For the GST pull-down assays shown in Figure 4E, 12 g of
purified GST, GST-TNRC6B SD or the corresponding DPAM2 mutant
were added to lysates from E. coli cells expressing MBP-tagged
HsPABPC1, MBP-DmPABPC1 or the corresponding mutants lacking
the MLLE domain in a total volume of 1 ml of binding buffer (10 mM
Hepes (pH 7.5), 150 mM NaCl, 2 mM MgCl2, 1 mM EDTA and 1%
[v/v] Triton-X100). Samples were incubated with 40 ml GST beads
(50% slurry) for 1 h at 41C. The beads were washed three times
with 1 ml of binding buffer. The proteins were eluted with 40ml of
sample buffer (50 mM Tris–HCl (pH 6.8), 2% SDS, 10% (v/v)
gylcerol, 100 mM DTT and 0.05% bromophenol blue) and analysed
on a 10% SDS–PAGE.
For the GST pull-down assays shown in Figure 5, lysates from
E. coli cells expressing GST, GST-TNRC6B-SD, GST-DmGW182-SD or
the indicated deletion mutants, were incubated with 40ml GST
beads (50% slurry) in lysis buffer (10 mM Hepes (pH 7.5), 300 mM
NaCl, 5 mM MgCl2 and 1 mM DTT) for 1 h at 41C. The beads were
washed three times with 1 ml of lysis buffer. The pre-coated beads
were then incubated with B25mg of recombinant MBP-HsPABPC1
or MBP-DmPABPC1 in a total volume of 1 ml of binding buffer (see
above) for 1 h at 41C. The beads were washed three times with 1 ml
of binding buffer. Proteins were eluted with 40ml of sample buffer
and separated on a 10% SDS–PAGE.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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Two PABPC1-binding sites in GW182 proteins promote miRNA-mediated gene silencing
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Supplementary Figure S1 GW182-PABPC1 interaction in cell lysates treated with 
micrococcal nuclease. S2 cells expressing GFP-DmGW182 or the indicated protein 
mutants together with DmPABPC1-V5 were lysed three days after transfection. Proteins 
were immunoprecipitated from micrococcal nuclease-treated cell lysates using a poly-
clonal anti-GFP antibody and analyzed by Western blotting as described in Figure 1. 
PABPC1-V5
Input
1 2 3 4 5 6 7 8 9 10 11
F-L
uc
 
M+
RR
M+
C
M+
C
M2
+R
RM
+C
M2
+C
PA
M2
+M
2+
C
PA
M2
+C
PA
M2
+R
RM
M2
+R
RM
RR
M
C F-L
uc
M+
RR
M+
C
M+
C
M2
+R
RM
+C
M2
+C
PA
M2
+M
2+
C
PA
M2
+C
PA
M2
+R
RM
M2
+R
RM
RR
M
C
IP (anti-GFP)
12 13 14 15 16 17 18 19 20 21 22
66
158
97
97
116
66
55
42
34
Huntzinger et al. Figure S2 
Supplementary Figure 2 The PAM2 motif of DmGW182 together with the M2 and C-term 
regions are sufficient for DmPABPC1 binding in cell lysates. (A,B) S2 cells expressing  the 
indicated GFP-GW182 fragments together with DmPABPC1-V5 were lysed three days 
after transfection. Proteins were immunoprecipitated from cell lysates using a polyclonal 
anti-GFP antibody and analyzed by Western blotting as described in Figure 1. In panel 
(B), the interaction of DmGW182 fragments with DmPABPC1-V5 was analyzed in the 
absence or presence of micrococcal nuclease as indicated. 
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Supplementary Figure 3 Complementation assay in S2 cells. (A–C) S2 cells were treated with 
dsRNA targeting the coding sequence of GW182 mRNA. Control cells were treated with GST 
dsRNA. These cells were subsequently transfected with a mixture of three plasmids: one expressing 
the indicated miRNA reporters; another expressing miRNA primary transcripts or the corresponding 
empty vector (-); and a third expressing Renilla luciferase (R Luc). Plasmids (10–100 ng) encoding 
wild-type GFP-GW182 or GFP-GW182ΔSD were included in the transfection mixtures, as indicated. 
GFP served as a negative control. Firefly luciferase activities were normalized to those of the Renilla 
luciferase and set to 100 in cells transfected with the empty vector (i.e. in the absence of miRNA). 
Mean values ± standard deviations from three independent experiments are shown. 
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Supplementary Figure 4 Human TNRC6A–C complement silencing in S2 cells. 
A complementation assay as described in Figure 6 was performed using plasmids 
encoding wild-type GFP-GW182, GFP-TNRC6A–C or GFP and the F-Luc-Par-6 
reporter. In panels (A) and (B) 10 ng of plasmids were transfected; in panels (C) and 
(D) 200 ng. Firefly luciferase activity was analyzed as described in Figure 6. Mean 
values ± standard deviations from three independent experiments are shown. 
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Pat proteins regulate the transition of mRNAs from a state
that is translationally active to one that is repressed,
committing targeted mRNAs to degradation. Pat proteins
contain a conserved N-terminal sequence, a proline-rich
region, a Mid domain and a C-terminal domain (Pat-C). We
show that Pat-C is essential for the interaction with mRNA
decapping factors (i.e. DCP2, EDC4 and LSm1–7), whereas
the P-rich region and Mid domain have distinct functions
in modulating these interactions. DCP2 and EDC4 binding
is enhanced by the P-rich region and does not require
LSm1–7. LSm1–7 binding is assisted by the Mid domain
and is reduced by the P-rich region. Structural analysis
revealed that Pat-C folds into an a–a superhelix, exposing
conserved and basic residues on one side of the domain.
This conserved and basic surface is required for RNA,
DCP2, EDC4 and LSm1–7 binding. The multiplicity of
interactions mediated by Pat-C suggests that certain of
these interactions are mutually exclusive and, therefore,
that Pat proteins switch decapping partners allowing
transitions between sequential steps in the mRNA decap-
ping pathway.
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Introduction
Decapping of bulk mRNA in eukaryotes occurs after they
have been deadenylated. This order of events (deadenylation
first, then decapping) ensures that functional, fully polyade-
nylated mRNAs are not decapped and degraded prematurely
(Bail and Kiledjian, 2006; Simon et al, 2006; Franks and
Lykke-Andersen, 2008). How decapping and deadenylation
are coordinated is, however, poorly understood. The yeast
protein Pat1 and its orthologs in Drosophila melanogaster
(HPat) and humans (PatL1) are conserved decapping activa-
tors that likely mediate this coordination by interacting both
with components of the CAF1-CCR4-NOT1 deadenylase com-
plex and with decapping factors (e.g. the DEAD-box protein
Me31B, the decapping enzyme DCP2 and the LSm1–7 ring;
Hatfield et al, 1996; Bonnerot et al, 2000; Bouveret et al,
2000; Tharun et al, 2000; He and Parker, 2001; Tharun and
Parker, 2001; Chowdhury et al, 2007; Chowdhury and
Tharun, 2008, 2009; Tharun, 2009; Haas et al, 2010).
Pat proteins are characterized by a conserved N-terminal
sequence of about 50 residues (N-term) followed by a
proline-rich region (P-rich), a middle (Mid) domain, and
a C-terminal domain termed Pat-C (Figure 1A). Studies
in D. melanogaster showed that the HPat N-term sequence
confers binding to the DEAD-box protein Me31B
(Saccharomyces cerevisiae Dhh1 and human DDX6/RCK),
whereas the Mid domain is necessary and sufficient for
LSm1–7 binding (Haas et al, 2010). Despite conservation,
the N-term sequence is not required to restore decapping in
cells depleted of endogenous HPat (Haas et al, 2010). In
contrast, the P-rich region together with the Mid domain
and Pat-C are all required to restore decapping in comple-
mentation assays (Haas et al, 2010). A somewhat different
picture has emerged from studies in S. cerevisiae where only
the Mid domain was shown to be essential for Pat1 function
in vivo (Pilkington and Parker, 2008). These differences raise
important and unresolved questions: what are the functions
of the Pat protein domains in decapping and to what extent
are these functions conserved?
In this study, we characterized PatL1, the human ortholog
of the Pat protein family. We found that PatL1 interacts with
DDX6/RCK, DCP2, EDC4 and the LSm1–7 ring. With the
exception of DDX6, these interactions require Pat-C.
Moreover, Pat-C is also critical for PatL1 to accumulate in
P-bodies and to be incorporated into active decapping com-
plexes. To shed light on the molecular basis for Pat-C func-
tions, we determined the Pat-C three-dimensional structure at
3.1 A˚ resolution. Pat-C adopts an a–a superhelical fold related
to armadillo- and huntigton-elongation-A-subunit-TOR
(HEAT)-repeat proteins. Using structure-based mutagenesis,
we show that both a basic surface patch and a partially
overlapping surface composed of highly conserved residues
have a critical function in the interaction with DCP2, EDC4
and the LSm1–7 ring. We further show that the conserved
surface of Pat-C is also essential for LSm1–7 binding in D.
melanogaster. Accordingly, a D. melanogaster HPat protein
carrying mutations in the conserved Pat-C surface cannot
rescue decapping in cells depleted of endogenous HPat. Our
results provide structural insight into Pat proteins and show
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that Pat-C has an unprecedented and essential function in
mRNA decapping.
Results
PatL1 interacts with DDX6/RCK, DCP2, EDC4
and the LSm1–7 ring
To investigate the function of PatL1 in decapping, we first
examined its association with decapping activators in human
embryonic kidney 293 cells (HEK293 cells). We observed that
epitope-tagged PatL1 coimmunoprecipitated DDX6/RCK,
DCP2, LSm1 and EDC4. These interactions were all insensi-
tive to RNase A treatment (Figure 1B–E). Together with
earlier studies, these results indicate that Pat proteins estab-
lish conserved interactions with DDX6/RCK, DCP2 and
the LSm1–7 ring, as these interactions are observed for the
orthologous proteins in human, D. melanogaster, and
S. cerevisiae cells (Figure 1B–D; Bonnerot et al, 2000;
Bouveret et al, 2000; Fromont-Racine et al, 2000; Tharun
et al, 2000; Coller et al, 2001; Tharun and Parker, 2001;
Fischer and Weis, 2002; Haas et al, 2010). In contrast, an
interaction between Pat proteins and EDC4 has not been
reported earlier. This interaction may only occur in metazoa,
because there is no EDC4 ortholog in yeast.
Pat-C is the only structured domain in Pat proteins
Pat proteins contain a conserved N-term sequence, the P-rich
region, the Mid domain and Pat-C (Figure 1A). Secondary
structure predictions suggest that PatL1 residues 1–398 (span-
ning the N-term sequence and the P-rich region) do not
contain a folded protein domain, consistent with the very
high content of proline residues (16.4%) and the low level of
sequence conservation in the P-rich region.
The two remaining domains (Mid: residues 399–516, and
Pat-C: residues 517–770) are well conserved and predicted to
be mainly a-helical (Supplementary Figure S1). Using multi-
angle static laser-light scattering coupled with size-exclusion
chromatography, we found that purified recombinant Pat-C is
monomeric in solution (Supplementary Table S1) and elutes
as expected for a well behaved, globular protein domain of
the respective mass (29 kDa; Supplementary Table S1).
A protein fragment containing the Mid domain and Pat-C
(residues 399–770) was also monomeric in solution, but
eluted much earlier than expected for a globular protein
(apparent molecular mass of 75 kDa as opposed to the
expected value of 42 kDa (Supplementary Table S1)). These
results suggest the Mid domain is unstructured in this con-
text. Accordingly, even if the Mid domain was N-terminally
extended to include a conserved motif between residues 353
and 370 (Figure 1A, red box), it did not assume any second-
ary structure in solution, as determined by NMR analysis
(Supplementary Figure S2). Although these results do not
rule out the possibility that the Mid domain adopts the
predicted secondary structure only when bound to a protein
partner, they clearly indicate that Pat-C is the only domain in
PatL1 that folds independently as ultimately shown through
crystal structure analysis (see below).
PatL1 N-terminal sequence confers binding
to DDX6/RCK
In earlier studies, we showed that the N-term sequence of
D. melanogaster HPat confers binding to Me31B (Haas et al,
2010). Accordingly, for human PatL1 the conserved N-term
sequence was necessary and sufficient for the interaction
with DDX6/RCK (Figure 1F). Two observations support this
conclusion: (1) deleting the N-term sequence abolished PatL1
interaction with DDX6/RCK (Figure 1F, lane 8) and (2) when
fused to GFP, the N-term sequence alone coimmunoprecipi-
tated DDX6/RCK as efficiently as full-length PatL1 (Figure 1F,
lane 7). Thus for PatL1, the ability to bind DDX6/RCK is
solely embedded in the conserved N-term sequence.
Pat-C is required for binding to DCP2, EDC4 and the
LSm1–7 ring
Next, we investigated which domains of PatL1 are required for
the interaction with DCP2, EDC4 and the LSm1–7 ring. We
observed that PatL1 interaction with LSm1 required both the
Mid domain and Pat-C (Figure 1G). Indeed, deleting these
domains either individually or in combination abolished
LSm1 binding (Figure 1G, lanes 8–10). In contrast, only Pat-
C, but not the Mid domain, was required for PatL1 to interact
with DCP2 and EDC4 (Figure 1H and I, lanes 9 and 10). An
important implication from these results is that DCP2 and EDC4
interact with PatL1 independently of the LSm1–7 ring. Indeed, a
PatL1 mutant lacking the Mid domain (DMid) no longer inter-
acts with the LSm1–7 ring but retains the ability to associate
with DCP2 and EDC4 (Figure 1G–I, lane 9). Furthermore, PatL1
interaction with LSm1, DCP2 or EDC4 was not affected by
deleting the N-term sequence (Supplementary Figure S3A–C),
indicating that these proteins associate with PatL1 indepen-
dently of DDX6/RCK. Of note, DCP2 and EDC4 interact with
each other (Fenger-Gr^n et al, 2005; Jı´nek et al, 2008), and may
associate with PatL1 as a complex.
The Pat-C and P-rich regions cooperate to bind DCP2
and EDC4
To gain a precise understanding of the sequences in PatL1
important for DCP2 and EDC4 binding, we performed coim-
munoprecipitation assays with several PatL1 fragments. As
mentioned above, a PatL1 fragment containing the P-rich
region, the Mid domain and Pat-C (PatL1-DN-term) behaved
similar to wild type in binding DCP2 and EDC4
(Supplementary Figure S3A and B). In contrast, without the
P-rich region, the Mid domain and Pat-C showed lower
affinity to EDC4 and did not bind DCP2 (Figure 2A and B,
lane 10). Thus, in addition to Pat-C, the P-rich region is also
required for binding EDC4 and DCP2. Accordingly, a protein
fragment containing the P-rich region and Pat-C was suffi-
cient for binding to EDC4 and DCP2 (Figure 2A and B, lane
9). These results provide further evidence that EDC4 and
DCP2 binding does not require the Mid domain; and thus,
this interaction occurs independently of the LSm1–7 ring.
The Mid domain and Pat-C form a bipartite
LSm1-binding site
As shown in Figure 1G, deleting Pat-C abrogates LSm1
binding. This result contrasts with earlier studies showing
that the Mid domain is sufficient for LSm1 binding both in
S. cerevisiae and D. melanogaster cells (Pilkington and Parker,
2008; Haas et al, 2010). Therefore, we investigated further, for
the human protein, the contribution of the Mid domain and
Pat-C in LSm1 binding. This analysis revealed two unex-
pected findings: (1) Pat-C, but not the Mid domain, was
sufficient for LSm1 binding; although binding was reduced
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relative to the wild type (Figure 2C, lane 16 versus 10) and (2)
in several independent experiments, a fragment containing the
Mid domain and Pat-C coimmunoprecipitated LSm1 more
efficiently than wild-type PatL1 or PatL1-DN-term (Figure 2C,
lane 14; Supplementary Figure S3C); these findings suggest that
Pat-C and the Mid region cooperate to provide a high-affinity
binding site for LSm1. Furthermore, PatL1 must contain se-
quences that interfere with LSm1 binding because the wild-type
protein binds LSm1 less efficiently than a fragment containing
the Mid domain and Pat-C. These interfering sequences are
located in the P-rich region, because a PatL1 mutant lacking the
N-term sequence also showed reduced LSm1 binding
(Figure 2C, lane 11). We conclude that the Mid domain and
Pat-C provide a bipartite binding site for LSm1–7, and that the
P-rich region interferes with this binding.
The P-rich region interferes with LSm1 binding
in D. melanogaster
The observations described above prompted us to re-investi-
gate the interaction between HPat and LSm1 in D. melano-
gaster, where we previously showed that the Mid domain was
sufficient for LSm1 binding (Haas et al, 2010). As reported
before (Haas et al, 2010), we confirmed that the Mid domain
alone, but not Pat-C, was sufficient for LSm1 binding
(Figure 2D, lane 13 versus 14). When the Mid domain was
fused to Pat-C, the affinity for LSm1 increased slightly,
suggesting that Pat-C contributes to the interaction
(Figure 2D, lane 12). In contrast, in mutants lacking Pat-C,
but containing the Mid domain and the P-rich region, the
interaction with LSm1 was abolished (DC and PþMid;
Figure 2D, lanes 10 and 11). We conclude that in D. melano-
gaster HPat, the Mid region confers binding to the LSm1–7
ring. This binding is enhanced by Pat-C and inhibited by the
P-rich region. The interfering effect of the P-rich region is
only observed in the absence of Pat-C, suggesting that Pat-C
counteracts the negative effect of the P-rich region. As
described above, the negative effect of the P-rich region is
less pronounced for human PatL1, most likely because the
major LSm1–7-binding site is provided by Pat-C and not by
the Mid domain.
Pat-C is required for PatL1 incorporation into active
decapping complexes
To investigate which domains of PatL1 are required for the
assembly of active decapping complexes, we performed
decapping assays in vitro. To this end, we immunoprecipi-
tated GFP-PatL1 (wild-type or deletion mutants) from
HEK293 cells and, using an m7G-capped RNA substrate,
tested for decapping activity. Immunoprecipitated GFP-
PatL1 exhibited decapping activity (Figure 3A, lane 4),
whereas a PatL1 mutant lacking the Mid and Pat-C domains
did not copurify with decapping activity (Figure 3A, lane 5).
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Thus, the Mid domain and Pat-C enable PatL1 incorporation
into active decapping complexes.
The decapping activity coimmunoprecipitating with PatL1
likely comes from the associated DCP2 (as a positive control,
compare an immunoprecipitation of GFP-DCP2; Figure 3A,
lane 3). Two observations support this conclusion: (1) if we
added nucleotide diphosphate kinase to the decapping reac-
tions containing either PatL1 or DCP2, then the m7GDP
product was converted to m7GTP (Figure 3A, lanes 8 and 9;
van Dijk et al, 2002; Fenger-Gr^n et al, 2005) and (2) a PatL1
mutant lacking Pat-C, which does not interact with DCP2, did
not copurify with decapping activity (Figure 3A, lane 7). In
contrast, a mutant carrying a deletion of the Mid domain,
which interacts with DCP2 but not with the LSm1–7 ring, was
impaired but could still coimmunoprecipitate decapping ac-
tivity (Figure 3A, lane 6). The amounts of PatL1 mutants in
the decapping assay were comparable to those of wild type
(Figure 3B). Thus, Pat-C is required for PatL1 association with
active decapping complexes.
Pat-C is required for P-body localization
S. cerevisiae Pat1 and its orthologs in metazoa localize to
P-bodies and are required for P-body integrity (Scheller et al,
2007; Eulalio et al, 2007a; Pilkington and Parker, 2008). To
define which domains are critical for human PatL1 to localize
to P-bodies, we examined the subcellular localization of
PatL1 fragments in human cells. GFP-PatL1 localized to
endogenous P-bodies (Figure 4A) as judged by the staining
with antibodies recognizing EDC4 (Kedersha and Anderson,
2007). A fragment of PatL1 comprising the N-term sequence
and P-rich region dispersed throughout the cytoplasm in 96%
of cells (Figure 4B). Moreover, 31% of the cells expressing
this fragment showed no detectable P-bodies, indicating this
protein fragment affects P-body integrity in a dominant-
negative manner. In contrast, a protein fragment comprising
the Mid domain and Pat-C retained the ability to localize to
P-bodies (16% of cells), although much less efficiently than
full-length PatL1 (Figure 4C versus 4A).
We next investigated whether the Mid domain or Pat-C are
required for PatL1 to localize to P-bodies. A PatL1 mutant
lacking the Mid domain was detected in P-bodies in 49% of
cells (Figure 4D), suggesting the Mid domain contributes, but
is not required for P-body localization. In contrast, a mutant
lacking Pat-C spread throughout the cytoplasm in 96% of
cells, although EDC4-contaning foci were detectable in 47%
of cells (Figure 4E). Together, these results indicate that
Pat-C has a critical function in promoting PatL1 accumulation
in P-bodies.
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Crystal structures of the human Pat-C domain
So far, our data indicate that Pat-C is required for binding to
DCP2, EDC4 and LSm1–7 and also enables PatL1 to localize
to P-bodies and be incorporated into active decapping com-
plexes. To gain a more detailed understanding of these
functions, we determined the crystal structure of Pat-C.
We obtained well-diffracting crystals of Pat-C (residues
517–767) and of Pat-C-Dloop (residues 517–767), where a
putative loop (residues 664–673) was replaced by a Gly-Ser
linker (Supplementary Figure S1B). Initially, the structure
was solved using single anomalous dispersion data (2.2 A˚
resolution) collected at the absorption peak of a seleno-
methionine-substituted protein crystal of Pat-C-Dloop. The
structure was automatically built starting from an excellent
multiple anomalous dispersion electron density map, and
was manually refined to an Rwork of 19.9% (Rfree¼ 23.2%),
with two molecules per asymmetric unit (crystal form I;
Supplementary Table S2; Supplementary Figure S4A).
Subsequently, this model was used in molecular replace-
ment to solve the structure of Pat-C at 3.1 A˚ resolution, with
four molecules per asymmetric unit in a different packing
environment (Rwork¼ 24.8%, Rfree¼ 28.1%, crystal form II;
Supplementary Table S2 and Supplementary Figure S4A).
Finally, we obtained an unrelated crystal form of Pat-C-
Dloop at 2.95 A˚ resolution (Rwork¼ 24.8%, Rfree¼ 29.2%,
crystal form III; Supplementary Table S2). In this crystal
form, two of the three molecules in the asymmetric unit
apparently contain a specifically bound sulphate ion from the
crystallization condition, coordinated by two arginines
(Arg591 and Arg595; Supplementary Figure S4B). Sulphate
ions can mimic the phosphate groups of the nucleic acid
backbone and therefore indicate potential nucleic acid-bind-
ing sites (see below).
Pat-C folds into an a–a superhelix
Pat-C is composed of 13 a-helices, stacked into a superhelix
with a right-handed twist. The first two helices are signifi-
cantly longer than the others and form a hairpin that pro-
trudesB20 A˚ from the cylindrical core of the domain, giving
Pat-C an overall L-shape (Figure 5A–C).
According to the structural classification of proteins
(SCOP; Murzin et al, 1995), the a–a superhelix fold (SCOP
classification 48370) is a feature of 420 protein superfami-
lies. Among those, the structure of Pat-C clusters with mem-
bers of the ARM-repeat superfamily, as revealed by a search
using the Dali server (Holm and Sander, 1995). The ARM-
repeat superfamily includes families such as the armadillo-,
HEAT- and Pumilio-repeat families. The best-scoring structur-
al relatives of Pat-C thus include yeast Cse1 (Matsuura and
Stewart, 2004), human Pumilio1 (Wang et al, 2002) and
interestingly, the C-terminal domain of EDC4 (Jı´nek et al,
2008).
Compared with canonical armadillo-, HEAT- or Pumilio-
repeat domains, however, the helical arrangement of Pat-C is
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Figure 4 Pat-C is required for PatL1 accumulation in P-bodies.
(A–H) Representative confocal fluorescent micrographs of fixed
human HeLa cells expressing wild-type GFP-PatL1 or the mutants
indicated on the left. Cells were stained with antibodies cross-
reacting with EDC4 and a nuclear human antigen (Kedersha and
Anderson, 2007). The merged images show the GFP signal in green
and the EDC4 signal in red. The fraction of cells exhibiting a
staining identical to that shown in the representative panel was
determined by scoring at least 100 cells in each of the three
independent transfections performed per protein. Scale bar: 10mm.
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quite irregular and structural alignments of 4100 residues
consistently yielded Ca root mean square deviations (r.m.s.d.)
higher than 2.9 A˚. Only the first nine helices (a1–a9) may be
classified as ARM-like repeats of three helices each.
Furthermore, Pat-C contains three large, partially ordered or
disordered loops that cluster on one face of the molecule.
These loops are located between helices a2 and a3
(L(a2–a3)), a8 and a9 (L(a8–a9)) and a10 and a11
(L(a10–a11); Figure 5A, back view; and Supplementary
Figure S4A).
Aligning the Pat-C sequence across different species shows
that key surface and structural residues are highly conserved.
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www.pymol.org). (B) Surface representation, coloured by sequence conservation, comparing six species (Supplementary Figure S2B). Colour
ramp by identity: orange (100%) to white (0%). Highly conserved solvent exposed residues are labelled. (C) Electrostatic potentials are
mapped onto the molecular surface of Pat-C and contoured from 10 kT/e (red) to 10 kT/e (blue). Residues contributing to the positively
charged surface patch are labelled. (D) Ribbon representation of six Pat-C molecules resulting from the three independent crystal forms. Green
(Form I, chain A), dark blue (Form II, chain A), light blue (Form II, chain B), orange (Form III, chain A), red (Form III, chain B), yellow (Form
III, chain C). (E) Close-up view (401 rotated along a horizontal axis) on the helical protrusion of the six structurally most divergent Pat-C
molecules. Colours are as in (D). (F) Close-up on Form I, chain A, showing two water molecules buried in the helical protrusion. Residues
adjacent to the buried water molecules are labelled and shown as sticks with carbons in green, nitrogens in blue and oxygens in red. Hydrogen
bonds are shown as dashed lines.
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This suggests that Pat-C adopts very similar fold with related
functions in all members of the Pat protein family
(Supplementary Figure S1B).
The helical protrusion of Pat-C exhibits structural
flexibility
The three crystal forms of Pat-C provide nine independent
structures, in distinct molecular packing environments.
These nine structures superimpose well over the cylindrical
core of the domain with an r.m.s.d. of 0.58 A˚ (excluding loops
(L(a2–a3), L(a8–a9) and L(a10–a11); Figure 5D). The helical
protrusion, however, displays significant structural variabil-
ity, especially near the tip of the hairpin (residues 539–557;
Figure 5D). The most extreme deviations are found in the
structures of crystal form III, with the distal parts of helix a2
(residues 550–558) being melted into an ordered loop
(Figure 5E, orange chain), or into an ordered loop with a
short b-strand (yellow), or into an entirely disordered loop
(red). One reason for this structural variability is likely the
hydrophilic nature of residues D535, R542 and D557.
Although being exposed to solvent in crystal form III, they
are also able to mediate close helix packing in crystal form I,
through two deeply buried water molecules (Figure 5F).
The structural variability of the helical protrusion
suggests a significant flexibility, which might be of functional
importance.
A basic surface on Pat-C confers binding to RNA
Proteins with an a–a superhelical fold frequently provide
scaffolds for protein or nucleic acid interactions (Huber et al,
1997; Edwards et al, 2001). In addition to be required for
protein–protein interactions, the Pat-C domain of yeast Pat1
shows affinity for RNA (Pilkington and Parker, 2008). We
therefore looked for patches of conserved and/or basic
residues on the surface of Pat-C that might mediate the
observed interactions with decapping factors and/or with
RNA. The most highly conserved surface patch on Pat-C is
located near the N-terminal end of helix a1, close to the
connection to the Mid domain. It shares contributions from
Leu523, Glu527, Tyr530 and Leu534 on helix a1 as well as
contributions from Lys592 and Arg599 on helix a4
(Figure 5B).
The conserved patch partially overlaps with a region of
high positive surface potential (Figure 5C), which coordinates
the sulphate ion in crystal form III (Supplementary Figure
S4B) and results from a high concentration of positively
charged residues (Lys518, Arg519, Arg520, Lys521 on helix
a1, Arg591, Lys592, Arg595, Arg599 on helix a4 and Lys625,
Lys626 on helix a6). We therefore tested whether Pat-C could
bind RNA and found that it directly binds to an U30 RNA
oligomer in size exclusion chromatography experiments
(Supplementary Figure S5A).
In further experiments, we established that Pat-C exhibits
RNA-binding properties similar to those reported for the
purified yeast Pat1-LSm1–7 complex (Chowdhury et al,
2007). For instance, Pat-C interacted with oligo(rU)30 but
not with oligo(rA)30 (Supplementary Figure S5A and F).
Similarly, Chowdhury et al (2007) showed that yeast Pat1-
LSm1–7 complex interacts with oligo(rU) but not with any
other homo-oligoribonucleotide. Furthermore, Pat-C inter-
acted with a 30-nucleotide long homo(rU)-oligomer, but
failed to interact with oligomers containing 20 and 15 nucleo-
tides (Supplementary Figure S5A–C). Similarly, a require-
ment that RNA be a minimum length for detectable binding
was reported for the purified yeast Pat1-LSm1–7 complex
(Chowdhury et al, 2007), suggesting that some of the RNA-
binding properties of the complex can be attributed to Pat-C.
Finally, Pat-C discriminated between ribo- and deoxy-oligor-
ibonucleotides, as it did not interact with 20-deoxy-oligo(U)30
(Supplementary Figure S5F).
To investigate how much the Pat-C conserved and basic
patches contribute to RNA and protein binding, we generated
three mutants. In mutant 1 (Mut-1), six basic residues in the
positively charged patch were substituted with alanines
(R519, R520, R591, R595, K625 and K626; Supplementary
Figure S1B). In mutant 2 (Mut-2), four residues form the
conserved patch were changed into serine or alanine (L523S,
E527A, Y530A and L534S; Supplementary Figure S1B).
Finally, in mutant 3 (Mut-3), residues 539 to 557 were
substituted with a GSGSGSG linker (Supplementary Figure
S1B), thus excising the helical protrusion. When expressed,
purified and analysed by size exclusion chromatography, all
three Pat-C mutants showed the expected elution volumes for
folded monomeric proteins of the respective size
(Supplementary Table S1), indicating that the mutations do
not disrupt the Pat-C fold. Importantly, Mut-1 lost the ability
to bind U30 RNA, whereas Mut-2 was comparable to the wild-
type protein (Supplementary Figure S5D and E). Together,
these results indicate that the basic surface on the Pat-C
domain confers the ability to bind RNA.
The conserved and basic surfaces on Pat-C are required
for binding to DCP2/EDC4 and LSm1–7
We also investigated how the Pat-C conserved and basic
patches contribute to the interactions with decapping factors.
To this end, we introduced the mutations described above in
the context of full-length PatL1 and examined the effect on
DCP2, LSm1–7, and EDC4 binding, as well as on decapping
and P-body localization. We found that mutations in the basic
and conserved patches (Mut-1 and Mut-2) prevented
PatL1 from interacting with DCP2, EDC4 and the LSm1–7
ring as efficiently as deleting the Mid and Pat-C domains
(Figure 6A–C, lanes 9–11). In contrast, the mutations did not
affect the interaction with DDX6/RCK, as expected
(Figure 6D). Removing the helical protrusion (Mut-3) did
not affect the PatL1 interaction with DCP2 and decapping
activators (Figure 6A–C, lane 12).
To assess how the mutations affect PatL1 association with
decapping complexes, we tested the activity of the mutants in
decapping assays in vitro. In accordance with the results of
the coimmunoprecipitation assay, Mut-1 and Mut-2 failed to
copurify with decapping activity, whereas Mut-3 associated
with decapping activity (Figure 3C and D). Taken together,
these results show that the Pat-C conserved and basic patches
are crucial for the interaction with DCP2, EDC4 and the
LSm1–7 ring.
We next tested the ability of PatL1 mutants to localize to
P-bodies. We observed that Mut-1 and Mut-2 were dispersed
throughout the cytoplasm in about 90% of cells (Figure 4F
and G), whereas Mut-3 accumulates in foci (Figure 4H).
Furthermore, in about 60% of cells expressing Mut-1 or
Mut-2, endogenous P-bodies were dispersed (Figure 4F and
G), indicating that these mutants inhibit P-body formation in
a dominant-negative manner.
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The Pat-C conserved surface is required for mRNA
decapping in vivo
To investigate how the Pat-C conserved surface influences
decapping in vivo, we took advantage of a complementation
assay established in D. melanogaster S2 cells (Haas et al,
2010). First, we mutated conserved residues in D. melano-
gaster HPat corresponding to Mut-2 in human PatL1
(Supplementary Figure S1B) and examined whether the
protein could coimmunoprecipitate LSm1 in S2 cells.
Similar to results obtained with human PatL1, we found
that mutating the conserved residues abrogates the interac-
tion with LSm1 as efficiently as deleting Pat-C entirely
(Figure 7A). Thus, the conserved surface on Pat-C is also
required for the interaction of D. melanogaster HPat with
LSm1–7.
Next, we investigated whether HPat Mut-2 could restore
decapping and mRNA degradation in cells depleted of en-
dogenous HPat (Haas et al, 2010). To monitor decapping, we
used the F-Luc-5BoxB reporter, which is rapidly degraded
when coexpressed with a lN fusion of the GW182 protein.
Indeed, lN-GW182 triggers deadenylation of the F-Luc-
5BoxB reporter, after which the mRNA is decapped and
then subjected to exonucleolytic digestion (Eulalio et al,
2007b). Inhibiting decapping prevents GW182-mediated
mRNA degradation and leads to the accumulation of
deadenylated mRNA decay intermediates, which exhibit a
characteristically higher electrophoretic mobility than poly-
adenylated transcripts (Figure 7B, lane 4 versus 2; Eulalio
et al, 2007b). Therefore, monitoring the accumulation
of the deadenylated F-Luc-5BoxB mRNA can track a block
in decapping.
S2 cells were transiently transfected with three plasmids:
the F-Luc-5BoxB reporter; a plasmid expressing lN-GW182
or the lN-peptide; and a transfection control plasmid, encod-
ing Renilla luciferase (R-Luc). In the presence of lN-GW182
we observed that, relative to cells expressing the lN-peptide
alone, the levels of the F-Luc-5BoxB mRNA were reduced
five-fold (Figure 7B, lane 2 versus 1 and Figure 7C). In
contrast, codepleting HPat and Me31B inhibited decapping
and allowed the deadenylated F-Luc-5BoxB mRNA to accu-
mulate (Figure 7B, lane 4 and Figure 7C).
Expressing HPat wild type in depleted cells restored de-
capping and degradation of F-Luc-5BoxB mRNA (Figure 7B,
lane 6 and Figure 7C). As reported before, the HPat mutant
lacking Pat-C was defective in promoting mRNA degradation,
indicating that Pat-C is required for decapping in vivo
(Figure 7B, lane 8; Haas et al, 2010). Importantly, HPat
Mut-2 was completely defective in restoring decapping and
therefore the deadenylated mRNA was still detectable
(Figure 7B, lane 10 and Figure 7C). All proteins were ex-
pressed at comparable levels (Figure 7D). We conclude that
the conserved surface on Pat-C is essential for HPat to
promote mRNA decapping in vivo.
Discussion
In this study, we determined the structure of PatL1 C-terminal
domain (Pat-C), the only domain in Pat proteins that folds
independently. Pat-C folds into an a–a superhelix, exposing
basic and conserved residues on one side of this domain. Our
functional and structural analysis of Pat-C identified several
critical and distinct functions for this protein domain: (1) it
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mediates RNA binding through a conserved basic surface; (2)
it cooperates with the P-rich region to provide a binding
surface for DCP2 and EDC4; (3) it cooperates with the
Mid domain to provide a high-affinity interaction with the
LSm1–7 ring; (4) it is required for PatL1 to accumulate in
P-bodies and (5) it is essential for mRNA decapping in vivo.
The multiplicity of interactions mediated by Pat-C suggests
that these interactions might be synergistic or antagonistic
and thus may have a regulatory function as discussed below.
PatL1 interacts with DCP2 and multiple decapping
activators
In this article, we show the PatL1 N-term sequence confers
binding to DDX6/RCK. This interaction is conserved in
D. melanogaster where we showed that the HPat N-term
sequence also interacts with Me31B (Haas et al, 2010). We
further show the P-rich region and Pat-C both contribute to
the interaction with DCP2 and EDC4, whereas LSm1–7 bind-
ing requires the Mid domain and Pat-C (Figures 2 and 8).
From our studies, we cannot conclude whether PatL1 inter-
acts with decapping activators and DCP2 directly.
Nevertheless, our results allow us to draw several conclu-
sions. First, DCP2, EDC4 and the LSm1–7 ring interact with
PatL1 independently of the conserved N-term sequence, and
thus independently of DDX6/RCK. Second, EDC4 and DCP2
interact with PatL1 independently of the LSm1–7 ring, be-
cause deleting the Mid domain abolishes LSm1–7 binding but
not DCP2 or EDC4 binding. Third, LSm1–7 binding anti-
correlates with the binding of EDC4/DCP2, because, if the
P-rich region is fused to a protein fragment containing the
X
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Mid domain plus Pat-C, then the affinity for LSm1–7 de-
creases, but binding to DCP2 and EDC4 is stimulated. Finally,
binding to DCP2, EDC4 and LSm1–7 is unlikely to be entirely
mediated by RNA because mutations in conserved Pat-C
surface residues do not affect RNA binding but abolish the
interaction with decapping factors. On the other hand, muta-
tions in the positive Pat-C surface abolish the interaction both
with RNA and with decapping factors, suggesting that RNA
may contribute to the affinity of PatL1 for decapping factors.
The function of Pat-C in mRNA decapping
In this study, we show that Pat-C is required for D. melano-
gaster and human Pat proteins to interact with the LSm1–7
ring. Whether this is also true for yeast has not been directly
investigated; however, indirect evidence suggests that Pat-C
might also be important for LSm1 binding in yeast. Indeed,
Pilkington and Parker (2008) reported that the accumulation
of LSm1 in P-bodies depends on Pat1, and that LSm1 interacts
with the Pat1 Mid domain. Accordingly, it is intriguing that
Pat-C is necessary and sufficient to promote LSm1 accumula-
tion in P-bodies (Pilkington and Parker, 2008). Our results
provide an explanation for this, in that although the isolated
Mid domain is sufficient for LSm1 binding, Pat-C is also
required in the context of full-length Pat proteins and may
provide a low-affinity LSm1-binding site.
Nevertheless, studies in S. cerevisiae indicated that for Pat1
function in vivo Pat-C is dispensable; whereas our studies
suggest, in D. melanogaster and human cells, this domain is
essential (Pilkington and Parker, 2008; Haas et al, 2010). One
possible explanation for resolving the discrepancy between
S. cerevisiae and metazoa lies in the realization that the
precise composition and stoichiometry of decapping
complexes differs significantly between these organisms as
for example, yeast lacks an EDC4 ortholog. Thus, it is possible
that for metazoa, Pat-C is essential in decapping because it
interacts with EDC4 and DCP2. Yeast Pat1 interacts with DCP2
but this interaction is mediated by RNA (Tharun and Parker,
2001). The essential function of Pat-C may therefore reflect
additional functions this domain acquired in metazoa.
Does Pat switch decapping partners?
An unexpected observation from our studies is that Pat-C, but
not the Mid domain is sufficient for LSm1 binding in human
cells, whereas in yeast and D. melanogaster cells, the Mid
domain but not Pat-C is sufficient (Pilkington and Parker,
2008; Haas et al, 2010). Our hypothesis to explain these
results is that Pat proteins contain two distinct LSm1-binding
sites: one in the Mid domain and one in Pat-C. Human PatL1
interacts with LSm1 predominantly through Pat-C; whereas
in D. melanogaster and S. cerevisiae, the interaction through
the Mid domain dominates. However, for LSm1 binding, even
when the interaction with the Mid domain dominates, there is
a general requirement for Pat-C in the context of full-length
Pat. Indeed, in addition to enhance LSm1 binding by the Mid
domain, Pat-C is required to counteract a negative effect of
the P-rich region. Of note, the N-terminal boundary of the
Mid domain is difficult to define and this may contribute to
the differences observed between species.
The requirement of Pat-C for LSm1–7 binding raises
the question of whether the LSm1–7 ring competes with
DCP2/EDC4 for binding to Pat-C. Two lines of evidence
support this scenario: (1) as mentioned above, we observed
that DCP2/EDC4- and LSm1 binding anti-correlate and (2) it
is unlikely that the small conserved patch on Pat-C can bind
to DCP2/EDC4 and the LSm1–7 ring simultaneously.
Competition between DCP2/EDC4 and LSm1–7 for Pat
binding would also help to explain the negative effects of
the P-rich region on the interaction with LSm1–7, because the
P-rich region enhances the affinity of DCP2/EDC4 for PatL1.
Furthermore, there may be some residual affinity of DCP2/
EDC4 for the P-rich region even in the absence of Pat-C. In
this case, DCP2/EDC4 could sterically mask the access of the
LSm1–7 ring to the Mid domain.
Alternatively, the negative effect of the P-rich region on
LSm1–7 binding could be a direct one, for example by
occluding the LSm1–7 binding site on the Mid domain.
However, it is difficult to conceive how two unstructured
protein regions could interact with each other specifically.
Consistently, we could not detect an interaction in trans
between the P-rich region and the Mid domain. A third
explanation could be that additional interacting partners
bind to the P-rich region and regulate the accessibility of
the Mid domain (Figure 8, factor X). Although proteins
binding to the P-rich region have not yet been identified, it
is likely that this region interacts with additional components
of the decay machinery, because in D. melanogaster the
P-rich region was sufficient to trigger degradation of
mRNAs in tethering assays (Haas et al, 2010).
Regardless of precisely how the P-rich region inhibits the
Mid domain from binding LSm1, our results suggest this
binding could be regulated, and that Pat proteins might
adopt two different conformations one with and the other
without affinity for LSm1–7 (Figure 8). It remains to be
established whether these conformations represent distinct
complexes with specific functions or sequential steps in the
assembly of active decapping complexes on target mRNAs.
More generally, our findings challenge the notion that Pat
proteins act as simple scaffolds for the simultaneous assem-
bly of decapping factors and rather suggest that certain
of the interactions between decapping factors may occur
sequentially allowing decapping complexes to assemble in a
stepwise manner.
Materials and methods
Protein expression, purification and crystallization
Human PatL1 proteins were expressed with an N-terminal His6-tag
in the Escherichia coli strain BL21 (DE3) or BL21 Star (DE3;
Invitrogen) at 251C overnight. After purification by an Ni2þ -affinity
step (HiTrap Chelating HP column, GE Healthcare), the His6-tag was
cleaved with PreScission protease. The proteins were further
purified by ion exchange chromatography and gel filtration (HiTrap
SP HP and HiLoad 26/60 Superdex 75 columns, GE Healthcare).
A detailed description of the crystallization procedures is provided
in the Supplementary data.
Structure determination and refinement
Diffraction data were collected on beamline X10SA of the Swiss
Light Source, Villigen, Switzerland. The structure of the human
PatL1 fragment, Pat-C-Dloop (Form I), was determined from
multiple-wavelength anomalous dispersion data, collected on a
crystal of selenomethionine-substituted protein. For Pat-C (Form II)
and Pat-C-Dloop with bound sulphate (Form III), the structures
were solved by molecular replacement using Pat-C-Dloop (Form I)
as search model. Additional information is provided in the
Supplementary data.
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DNA constructs
Plasmids for expressing DCP2, DDX6/RCK and EDC4 in human cells
were described before (Tritschler et al, 2009a, b). Plasmids for
expressing PatL1 were generated by cloning the corresponding
cDNA into the pEGFP-C1 vector (Clontech) or the plN-HA-C1
vector (Tritschler et al, 2009a, b). Human LSm1 was cloned between
the XhoI and EcoR1 sites of the plN-HA-C1 vector. PatL1 mutants
were generated by site-directed mutagenesis using the QuickChange
mutagenesis kit from Stratagene and the appropriate oligonucleo-
tide sequences.
Coimmunoprecipitation assays, western blotting
and fluorescence microscopy
For coimmunoprecipitation assays, HEK-293 cells were grown in
10 cm plates and transfected using Lipofectamine 2000 (Invitrogen).
The transfection mixtures contained 7mg of the GFP and HA
constructs. For fluorescence microscopy, human HeLa cells were
grown on coverslips in 24-well plates and transfected using
Lipofectamine 2000 (Invitrogen). The transfection mixtures con-
tained 0.3 mg of plasmids expressing GFP-protein fusions. Cells were
collected 2 days after transfection. Coimmunoprecipitations, wes-
tern blotting and fluorescence microscopy were performed as
described earlier (Tritschler et al, 2009b). Additional information is
provided in the Supplementary data.
Decapping assays
Decapping assays were performed as described earlier (Lykke-
Andersen, 2002; Tritschler et al, 2009b), using an in vitro
synthesized RNA (127 nucleotides). The RNA probe was labelled
with [a-32P]GTP using the ScriptCap m7G Capping System and the
ScriptCap 20-O-Methyltransferase kit (EPICENTRE Biotechnologies).
Reactions were stopped by adding up to 50 mM EDTA and analysed
on PEI cellulose thin-layer chromatography plates (Merck) in
0.75 M LiCl (1ml/sample). Unlabelled GDP, m7GMP, m7GDP and
m7GTP were used as markers.
Immunoprecipitations, RNA interference and
complementation assay in D. melanogaster S2 cells
Protein coimmunoprecipitations and complementation in S2 cells
were performed as described earlier (Haas et al, 2010). Mutants of
D. melanogaster HPat were generated by site-directed mutagenesis
using the plasmid pAc5.1B-HA-HPat (dsRNA resistant) as template,
and the QuickChange mutagenesis kit from Stratagene. Transfec-
tions of S2 cells were performed in six-well plates, using Effectene
transfection reagent (Qiagen). Firefly and Renilla luciferase
activities were measured 3 days after transfection using the Dual-
Luciferase Reporter Assay System (Promega). Total RNA was
isolated using TriFast (Peqlab Biotechnologies) and analysed as
described earlier (Haas et al, 2010).
Coordinate deposition
Coordinates of the human PatL1 C-terminal domain constructs Pat-
C-Dloop (Form I), Pat-C (Form II) and Pat-C-Dloop with bound
sulphate (Form III) have been deposited in the Protein Data Bank
under accession numbers 2xes, 2xeq and 2xer, respectively.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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Supplementary Methods 
Protein expression, purification and crystallization  
cDNA sequences encoding the C-terminal domain of human PatL1 (Q86TB9; 
Asp517 to Arg770) were amplified from oligo(dT)15-primed cDNA libraries 
obtained from human HeLa cells. The amplified cDNA fragments were inserted 
into a modified pRSFDuet-1 vector (Novagen) downstream of the His6–tag open 
reading frame. Constructs for expression of the crystallized proteins Pat-C (517-
767) and Pat-C-Δloop (517-767, residues 664-673 replaced by a Gly-Ser linker) 
were obtained by site directed mutagenesis of the aforementioned expression 
vector as described in the Materials and Methods. Human PatL1 proteins were 
expressed with an N-terminal His6-tag in the E. coli strain BL21 (DE3) or BL21 
Star (DE3, Invitrogen) at 25°C overnight. The proteins were purified from 
cleared cell lysates by a Ni2+-affinity step (HiTrap Chelating HP column, GE 
Healthcare), the His6-tag was cleaved with PreScission protease and the proteins 
were purified to homogeneity by ion exchange chromatography and gel filtration 
(HiTrap SP HP and HiLoad 26/60 Superdex 75 columns, GE Healthcare). 
Diffraction quality crystals were grown by hanging drop vapor diffusion. 
Highly facetted crystal clusters of Pat-C (Form II, residues 517-767) grew at 19 
°C after mixing 1 µl protein solution (16 mg/ml in 10 mM Na-HEPES pH 7.0, 
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100 mM NaCl and 3 mM DTT) and 1 µl reservoir solution (100 mM Bis-tris 
propane, pH 7.5, 20% PEG 3350 and 200 mM Na3-Citrate). Hair-seeding 
combined with the use of an additive screen (Hampton Research, HR2-428) 
was necessary to obtain single crystal plates of sufficient size for X-ray 
diffraction experiments. Briefly, 0.8 µl reservoir solution (100 mM Bis-tris 
propane, pH 7.8, 10% PEG 3350, 200 mM Na3-Citrate and 2% glycerol) was 
mixed with 0.2 µl of a 100 mM urea solution after which 1 µl protein solution 
(14 mg/ml in 10 mM Na-HEPES pH 7.0, 100 mM NaCl and 3 mM DTT) was 
added. After one day at 4°C, hair-seeding was done from the supernatant 
(centrifugation at 2,000 g for 1 min) of crushed crystal clusters. Within ca. one 
week we obtained diffraction quality crystal plates of ~ 100 x 100 x 10 µm³. 
Crystals were cryoprotected in 100 mM Bis-tris propane, pH 7.8, 10% PEG 
3350, 200 mM Na3-Citrate and 15% glycerol before flash-cooling in liquid 
nitrogen. 
To obtain crystals of Pat-C-Δloop (Form I), 1 µl protein solution (9 mg/ml 
in 10 mM Na-HEPES pH 7.0, 100 mM NaCl, 3 mM DTT) was added to 1 µl 
reservoir solution (12% PEG 3350, 0.2 M KSCN, 5% glycerol) and hair-
seeding was done from crushed crystals grown under similar crystallization 
conditions. Drops were then equilibrated at 4°C over 500 µl of reservoir. 
Crystal rods grew to a size of 150 x 70 x 70 µm³ within two days. Flash-cooling 
was done in liquid nitrogen after cryoprotection in 12% PEG 3350, 0.2 M 
KSCN and 20% glycerol. 
Crystals of Pat-C-Δloop with bound sulfate ions (Form III) were obtained 
in an attempt to co-crystallize Pat-C-Δloop with U8-RNA. 240 nmol protein 
was mixed with 360 nmol U8-RNA in a volume of 400 µl buffer (10 mM Na-
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HEPES pH 7.0, 100 mM NaCl, 3 mM DTT), the resulting precipitate was 
removed by centrifugation and 0.5 µl of the supernatant was added to 0.7 µl 
reservoir solution (100 mM Tris, pH 8.5, 1.15 M NH4(SO4)2, 150 mM Li2SO4, 
8% glycerol). Drops were incubated at 19°C over 500 µl reservoir solution. 
Crystal plates were obtained after several days and grew to their full size (ca. 
80 x 80 x 20 µm³) within one month. Flash-cooling was done in liquid nitrogen 
after cryoprotection with 100 mM Tris, pH 8.5, 1.15 M NH4(SO4)2, 150 mM 
Li2 SO4 and 20% glycerol. 
 
Structure determination and refinement  
Diffraction data were collected on beamline X10SA of the Swiss Light Source 
(SLS), Villigen, Switzerland. Data processing and integration was done with 
XDS (Kabsch 1993). Selenomethionine substituted Pat-C protein crystals 
diffracted not well enough to obtain suitable phase information. Hence, we first 
determined the crystal structure of PatL1-C-Δloop using multiple-wavelength 
anomalous dispersion. Diffraction images of selenomethionine-substituted Pat-
C-Δloop protein (Form I, 8 selenomethionines per molecule, 2 molecules per 
asymmetric unit, Table S2) were collected at the selenium absorption peak and 
the inflection point and processed with XDS to 2.2 Å resolution. AutoSHARP 
(Vonrhein at al, 2007) was used to identify (SHELX D) and refine (SHARP) 16 
selenium sites. After density modification with PIRATE, as part of the CCP4 
suite (Cowtan, 2002) the resulting excellent electron density map was used to 
automatically build (flex-wARP; Cohen et al, 2008) most of the two Pat-C-
Δloop molecules in the asymmetric unit. The model was completed manually 
with iterative cycles of model building (COOT; Emsley and Cowtan, 2004) and 
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refinement (PHENIX; Adams et al, 2010) at 2.1 Å against the dataset collected 
at the selenium absorption peak. 
The resulting structure served as search model for molecular replacement 
(PHASER, McCoy et al, 2007) to solve the structures of Form II using a dataset 
at 3.1 Å resolution of Pat-C selenomethionine crystals collected at the selenium 
absorption peak and of Form III using a 2.95 Å native dataset. 
Manual model building was done in COOT and refinement was done 
with PHENIX. Stereochemical properties were analyzed with MOLPROBITY 
(Davis et al, 2007) and WHATCHECK (Hooft et al, 1996). 
 
Analytical size exclusion chromatography and static light scattering 
Proteins were prepared as described for crystallization and analyzed in 
chromatography buffer (10 mM HEPES pH 7.0, 100 mM NaCl, 3 mM DTT). 
Proteins or mixtures of protein with RNA or DNA were injected onto a 
Superdex 75 10/300 GL analytical gel filtration column (GE Healthcare, 12°C, 
equilibrated in chromatography buffer) as part of an ÄKTA Purifier-10 at a 
flow rate of 0.5 ml/min. UV absorption was monitored simultaneously at 230 
nm, 260 nm and 280 nm. Protein and nucleic acid concentrations were 
estimated from the theoretical molar extinction coefficients at 280 nm and 260 
nm respectively. The relative contributions of protein and nucleic acid to the 
total absorption at each wavelength were calculated assuming constant ratios of 
the extinction coefficient at 230 nm to the extinction coefficient at 280 nm for 
each substance (Müller at al, 2006). Multiangle static laser light scattering was 
done online with analytical gel filtration chromatography using miniDAWN 
TREOS and Optilab rEX instruments (Wyatt Technologies) and the associated 
Braun et al. 5 
software (AstraV) for molecular weight determination. 
 
NMR measurements   
1H-NOESY spectra of the extended Mid domain of human PatL1 (353-516) 
were acquired at 291 K on a Bruker AV III-800 spectrometer, processed and 
analyzed using the Topspin software (Topspin V. 2.1.3, Bruker, Karlsruhe). 
The spectrum was recorded with 768 (t2) × 128 (t1) complex points using 16 
scans per increment, a relaxation delay of 1 s and an NOE mixing time of 70 
ms. 
 
Co-immunoprecipitation assays and Western blotting  
For co-immunoprecipitation assays, HEK-293 cells were grown in 10 cm plates 
and transfected using Lipofectamine 2000 (Invitrogen). The transfection 
mixtures contained 7 µg of the GFP- and HA-constructs. Two days after 
transfection, cells were washed with PBS and lysed for 15 min on ice, in NET 
buffer (50 mM Tris at pH 7.5, 150 mM NaCl, 1mM EDTA, 0.1% Triton X-100, 
10% glycerol), supplemented with protease inhibitors (1 ml NET buffer/ plate). 
Cell lysates were spun at 18,000 g for 15 min at 4°C. Polyclonal anti-GFP 
(dilution 1:1000) or monoclonal anti-HA antibodies (Covance, 1:2000) were 
added to the supernatants. Samples were incubated for 1h at 4°C. Then, 25 µl of 
Protein G-agarose were added and the mixtures were rotated for an additional 
hour at 4°C. Beads were washed three times with NET buffer and once with 
NET buffer without Triton X-100. Bound proteins were eluted with 100 µl of 
protein sample buffer and analyzed by Western blotting as described before 
(Tritschler et al, 2009b) 
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Fluorescence microscopy 
For fluorescence microscopy, human HeLa cells were grown on coverslips in 
24-well plates and transfected using Lipofectamine 2000 (Invitrogen). The 
transfection mixtures contained 0.3 µg of plasmids expressing GFP-protein 
fusions. Two days after transfection, cells were fixed with 4% 
paraformaldehyde in PBS for 10 min at room temperature, and permeabilized 
for 10 min with PBS containing 0.5% Triton-X100. Endogenous P-bodies were 
detected using a monoclonal antibody (sc-8418, Santa Cruz Biotechnology), 
which cross-reacts with EDC4 at a 1:1,000 dilution in PBS containing 0.1% 
Tween-20, and 10% fetal bovine serum (FBS). Alexa Fluor 594-coupled goat-
anti-mouse secondary antibody (Molecular probes) was used at a 1:1,000 
dilution. Cells were mounted using Fluoromount-G (Southern Biotechnology 
Associates, Inc.). Images were captured using a confocal fluorescent 
microscope (TCS SP2, Leica) with a Plan Apo 100x NA 1.40 oil immersion 
objective equipped with a series of three Hammamatsu Photonics 
Photomultipliers and Leica confocal software (version 2.61). Images were 
prepared using Photoshop (Adobe). 
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Supplementary Figure legends 
 
Figure 1 Conservation of the Mid domain and Pat-C. (A) Sequence alignment 
of the extended Mid domain of Pat orthologs from H. sapiens (PatL1), D. rerio 
(Pat1 homolog 1), G. gallus (PatL1), X. laevis (PatL1), D. melanogaster 
(HPat), C. elegans (Patr-1), S. cerevisiae (Pat1) and an A. thaliana hypothetical 
protein. Conserved residues are shaded gray (hydrophobic), red (acidic) and 
blue (basic). Invariant residues are marked with an asterisk. The black box 
indicates invariant residues in the Mid extension of vertebrate species. (B) 
Structure-based sequence alignment of Pat-C. Conserved and invariant residues 
are indicated as in panel A. Triangles indicate residues mutated in this study 
(red triangles: Mut1; blue triangles: Mut-2). Residues deleted in Mut-3 are 
indicated by a green bracket. Residues replaced by a Gly-Ser linker in Pat-C-
Δloop are indicated by a black bracket. Secondary structure assignment and 
numbering correspond to human PatL1, Form II, chain A. 
 
Figure 2 1H-NOESY spectra of the extended PatL1 Mid domain (residues 353–
516, unlabelled). As expected for an unfolded protein domain, a negligible 
chemical shift dispersion is observed in the region of the amide protons 
(dispersion from 7.75 to 8.35 ppm), thus excluding the possibility for the 
domain to contain β-strands. Examination of the spectra also shows that the 
domain does not harbor α-helices, due to the lack of strong sequential HN – HN 
contacts (red, dashed box). Moreover the protein is monomeric at a 
concentration of 0.1 mM in 300 mM NaCl at pH 7.0, as reflected by a diffusion 
coefficient of 0.85 (± 0.05) x  10–10 m2/s measured at 291 K. 
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Figure 3 DCP2, EDC4 and LSm1–7 interact with PatL1 independently of 
DDX6/RCK. (A–C) GFP- and HA-tagged proteins were co-expressed in human 
cells as indicated. Cell lysates were immunoprecipitated using anti-GFP or anti-
HA antibodies and analyzed as described in Figure 1. 
 
Figure 4 Comparison of Pat-C and Pat-C-Δloop structures. (A) Structure of 
Pat-C-Δloop. The crystal form I (Pat-C-Δloop, chain A, green) is superimposed 
onto the crystal form II (Pat-C, chain A, dark blue) and is shown in two 
orientations (back view and front view, related by a 180° rotation along a 
vertical axis, see Figure 5A). Disordered portions of the polypeptide chains are 
indicated with dashed lines. The loop L(α8- α9), which is replaced by a 
GlySer-linker in Pat-C-Δ-loop, is shown in magenta. (B) Sulfate ion in crystal 
Form III. Electrostatic potentials were mapped onto the molecular surface of 
Pat-C (Form III, chain B) and contoured from -10 kT/e- (red) to 10 kT/e- (blue), 
showing a positively charged surface patch. Residues contributing to this 
surface patch are labeled. A sulfate ion located near residues R591 and R595 is 
shown as sticks. 
 
Figure 5 Nucleic acid-binding of human Pat-C. Proteins were analyzed by size 
exclusion chromatography either in the absence (dashed blue lines) or presence 
(solid blue lines) of nucleic acid substrates (solid red lines). Nucleic acid 
substrates analyzed in the absence of protein are shown as dashed red lines. 
Concentrations were calculated from the relative absorption properties of the 
components. 
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Table S1. Elution volumes and molecular weights of wild-type human Pat-C and corresponding 
mutants as determined by analytical gel filtration and MALS. 
 Gel filtration MALS Expected MW for monomer 
 Elution volume [ml] Apparent 
MW[kDa] 
MW [kDa] [kDa] 
Pat-C 11.92 33 30 29.5 
Pat-C Δ loop 11.83 35 31 28.0 
Pat-C Mut-1 11.75 36 30 29.0 
Pat-C Mut-2 12.09 31 32 29.2 
Pat-C Mut-3 12.40 26 31 27.6 
Mid-Pat-C 10.38 73 47 43.2 
 
Braun et al.  
 
Table S2. Data collection, phasing and refinement statistics 
 
 
Crystallographic 
statistics 
Form I (Δ  loop) Form II Form III (Δ  loop) 
Construct SeMeth 517-767 Δ664-673 
SeMeth 517 – 767 Native 517 – 767  
Δ664-673 
Structure determination MAD MR MR 
Data set  peak infl. point   
Data Statistics    
Space group P212121 P212121 P21212 
Unit cell (a / b / c), (Å) 56.7, 70.8, 134.0 102.2, 108.6, 108.8 61.0, 100.1, 141.6 
Unit cell (α / β / γ), (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Wavelength (Å) 0.97880 0.97880 0.97922 0.97940 1.00000 
Rsym, (%) a 9.9 (66.4) 9.3 (62.2) c 10.0 (70.1) c 13.1 (88.0) 11.9 (59.4) 
Completeness, (%) a 99.3 (99.6) 100.0 (100.0) c 100.0 (100.0) c 99.4 (99.9) 98.8 (98.1) 
I/σ(I) a 9.1 (2.2) 16.8 (3.7) c 10.8 (2.3) c 9.1 (1.9) 11.1 (2.2) 
Unique reflections 32006 52824 c 51658 c 22432 18701 
Multiplicity a 4.0 (4.0) 7.7 (7.7) c 4.2 (4.1) c 4.7 (4.8) 3.3 (3.1) 
Resolution range, (Å) a 67.0 - 2.1 (2.15 - 2.1) 
67.0 - 2.2 
(2.26 - 2.2) 
67.0 - 2.2 
(2.26 -2.2) 
43.9 - 3.1 
(3.18 – 3.1) 
47.2 - 2.95 
(3.03 - 2.95) 
Phasing Statistics     
Phasing power (anom.) 1.738 0.871 
Rcullis (anom.) 0.661 0.871 
Mean FOM 
 
0.515 
 
Refinement Statistics     
Rcryst/ Rfree  (%) 19.9 / 23.2 24.8 / 28.1 24.8 / 29.2 
Molecules per ASU    
   HsPat-C 2 4 3 
   K/SCN/sulfate 2/4/0 0/0/0 0/0/4 
   Prot. atoms/ H2O /lig.s 3840/521/14 7682/8/0 5523/44/20 
B factor prot./H2O/lig.s (Å2) 32.8/35.0/37.7 77.9/50.2/- 51.0/26.0/75.1 
Ramachandran plot b 
(favored/allowed/outlier %) 
99.4/0.6/0 96.0/4.0/0 96.8/3.2/0 
R.m.s. deviations    
   bond lengths, (Å) 0.008 0.005 0.007 
   bond angles, (°) 0.921 
 
0.675 0.763 
a Numbers in parentheses are for the highest-resolution shell 
b Calculated using Molprobity 
c Values relate to unmerged Friedel pairs 
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Introduction
Eukaryotic mRNAs are degraded by two alternative pathways, 
both of which are initiated by a gradual shortening of the 
poly(A) tail by deadenylation. In one, the 3 to 5 decay path-
way, the poly(A) tail is first removed, and then the exosome and 
cofactors digest the mRNA exonucleolytically from the 3 end 
(Houseley et al., 2006). In the other, the 5 to 3 decay pathway, 
deadenylation is followed by the removal of the 5 cap structure 
by the decapping enzyme DCP2; decapped mRNA is then 
susceptible to 5 to 3 exonucleolytic degradation by XRN1 
(Bail and Kiledjian, 2006; Simon et al., 2006).
The decapping enzyme DCP2 requires additional proteins 
for full activity and/or stability (Bail and Kiledjian, 2006; Simon 
et al., 2006). Proteins that enhance decapping in Saccharomyces 
cerevisiae include DCP1, EDC1–3 (enhancer of decapping 1, 2, 
and 3), the heptameric LSm1–7 complex, Dhh1 (DExH/D-box 
RNA helicase 1; Me31B in Drosophila melanogaster), and Pat1 
(HPat in D. melanogaster). With the exception of EDC1 and -2, 
these proteins are conserved, yet most are not functionally char-
acterized in multicellular eukaryotes.
In S. cerevisiae, Pat1 interacts with the Lsm1–7 com-
plex and Dhh1 (Bonnerot et al., 2000; Bouveret et al., 2000; 
Fromont-Racine et al., 2000; Tharun et al., 2000; Coller et al., 
2001; Tharun and Parker, 2001; Fischer and Weis, 2002). The 
Pat1–LSm1–7 complex preferentially binds to the 3 ends 
of oligoadenylated mRNAs that have undergone deadenyl-
ation, thereby protecting them from 3 trimming and further 
degradation (He and Parker, 2001; Tharun and Parker, 2001; 
Chowdhury et al., 2007; Chowdhury and Tharun, 2008, 2009). 
This complex then activates decapping, most likely by recruit-
ing additional decapping activators and the decapping enzyme 
DCP2 (Hatfield et al., 1996; Bouveret et al., 2000; He and 
Parker, 2001; Chowdhury et al., 2007; Decker et al., 2007; 
Chowdhury and Tharun, 2008, 2009; Pilkington and Parker, 
2008; Tharun, 2009). Pat1 also associates with DCP1, DCP2, 
and EDC3 in yeast, which is consistent with a role in decapping 
(Fromont-Racine et al., 2000; Tharun et al., 2000; Tharun and 
Parker, 2001; Pilkington and Parker, 2008). Additionally, Pat1 
and the LSm1–7 complex copurify with Xrn1 (Bouveret et al., 
2000), suggesting a possible role for Pat in coupling decap-
ping to 5 to 3 mRNA degradation.
Like many components of the 5 to 3 mRNA decay 
pathway, Pat1 localizes to P bodies and, moreover, is required 
Decapping of eukaryotic messenger RNAs (mRNAs) occurs after they have undergone deadenyl-ation, but how these processes are coordinated is 
poorly understood. In this study, we report that Drosophila 
melanogaster HPat (homologue of Pat1), a conserved 
decapping activator, interacts with additional decapping 
factors (e.g., Me31B, the LSm1–7 complex, and the de-
capping enzyme DCP2) and with components of the 
CCR4–NOT deadenylase complex. Accordingly, HPat 
triggers deadenylation and decapping when artificially 
tethered to an mRNA reporter. These activities reside, 
unexpectedly, in a proline-rich region. However, this region 
alone cannot restore decapping in cells depleted of 
endogenous HPat but also requires the middle (Mid) and 
the very C-terminal domains of HPat. We further show 
that the Mid and C-terminal domains mediate HPat re-
cruitment to target mRNAs. Our results reveal an unprece-
dented role for the proline-rich region and the C-terminal 
domain of metazoan HPat in mRNA decapping and sug-
gest that HPat is a component of the cellular mechanism 
that couples decapping to deadenylation in vivo.
HPat provides a link between deadenylation and 
decapping in metazoa
Gabrielle Haas, Joerg E. Braun, Cátia Igreja, Felix Tritschler, Tadashi Nishihara, and Elisa Izaurralde
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Results
HPat coimmunoprecipitates Me31B, 
DCP2, and the LSm1–7 complex
To systematically investigate the network of interactions between 
HPat and decapping activators in metazoa, we coexpressed HA-, 
V5-, or GFP-tagged versions of these proteins in D. melanogas-
ter S2 cells and used anti-HA antibodies to coimmunoprecipi-
tate V5- or GFP-tagged proteins from cell lysates. We used this 
method to detect interactions with DCP1, DCP2, EDC3, EDC4, 
Me31B, Tral (trailer hitch), XRN1, and components of the 
LSm1–7 complex.
HPat coimmunoprecipitated with Me31B but not with 
DCP1, EDC3, or Tral (Fig. 1 A, lanes 7–10). Both EDC3 and 
Tral interact directly with Me31B (Tritschler et al., 2009), sug-
gesting that the interaction of HPat with Me31B mutually ex-
cludes an interaction with Me31B–EDC3 or Me31B–Tral (see 
Figs. 3 and 4). When coexpressed in Escherichia coli, recombi-
nant protein fragments of HPat and Me31B interact, showing 
the proteins bind each other directly (unpublished data).
In yeast, Pat1 associates with the LSm1–7 complex 
(Bonnerot et al., 2000; Bouveret et al., 2000; Fromont-Racine 
et al., 2000; Tharun et al., 2000; Tharun and Parker, 2001). 
Accordingly, we observed that HPat coimmunoprecipitated 
LSm1, -3, and -7 (Fig. 1 B). HPat interaction with LSm1 was 
insensitive to RNase A treatment (Fig. S1 A), suggesting that 
it is not mediated by RNA. LSm1 and -7 also coimmunopre-
cipitated with Me31B but not with any of the other proteins 
tested (Fig. 1 C; Tritschler et al., 2007, 2008). Finally, we observed 
that HPat coimmunoprecipitated DCP2 in an RNA-independent 
manner but not XRN1 or EDC4 (Fig. 1 D; Fig. S1, B and C; and 
not depicted). Thus, in addition to the interactions with Me31B 
and the LSm1–7 ring, which are conserved in S. cerevisiae, 
we detected an RNase A–insensitive interaction between HPat 
and DCP2. In contrast to our findings in this study, this inter-
action is sensitive to RNase A treatment in yeast (Tharun and 
Parker, 2001).
Me31B binds to the conserved N-terminal 
sequence of HPat
The interaction of HPat with Me31B is conserved in S. cerevisiae 
(Coller et al., 2001; Fischer and Weis, 2002). Despite conserva-
tion, the protein domains involved in this interaction were not 
defined. To identify them, we performed co-IP assays using 
different HPat and Me31B deletion mutants. Pat1 orthologues 
are characterized by a conserved N-terminal sequence of 50 
residues, a proline-rich region, a Mid domain, and a C-terminal 
domain termed Pat-C (Fig. 2, A and B). The boundary between 
the Mid domain and Pat-C was chosen on the basis of sequence 
alignments between Pat1 orthologues from various species.
We observed that Me31B interacted only with an 
N-terminal fragment of HPat (residues 1–499) but not with a con-
struct comprising the Mid domain and Pat-C (Fig. 2 C, lanes 
8 and 9). The N-terminal fragment contains the conserved 
N-terminal sequence (residues 1–56; Fig. 2 B) and the proline-rich 
region (13.6%), which is particularly long in the D. melanogaster  
protein and also rich in glutamine residues (16%; Fig. 2 A, 
for P-body integrity (Pilkington and Parker, 2008). A fraction 
of Pat1 is also found in polysomes (Bonnerot et al., 2000; 
Wyers et al., 2000), suggesting that it associates with ac-
tively translated mRNAs and may commit them to degrada-
tion in response to a triggering signal (Bonnerot et al., 2000). 
Intriguingly, Pat1 was reported to play dual roles in transla-
tion: it stimulates translation initiation (Wyers et al., 2000) 
but is also required for general translational repression dur-
ing glucose deprivation (Coller and Parker, 2005). Further-
more, Pat1 overexpression can repress translation and cause 
mRNAs to accumulate in P bodies (Coller and Parker, 2005). 
These and additional studies suggest that Pat1 is a key regula-
tor in the transition of mRNAs from a translationally active 
state associated with polysomes to a ribosome-free transla-
tionally repressed state that commits the mRNA to degrada-
tion (Coller and Parker, 2005; Pilkington and Parker, 2008). 
In this repressed state, mRNAs may aggregate into P bodies 
(Coller and Parker, 2005).
Pat1 is conserved in eukaryotes, and Pat1 orthologues in 
D. melanogaster and human cells (HPat and PatL1, respec-
tively) localize to P bodies (Eulalio et al., 2007a; Scheller et al., 
2007). The role of metazoan Pat1 orthologues in decapping is 
also conserved, as suggested by the observation that codeple-
tion of HPat and Me31B strongly inhibits decapping triggered 
by microRNAs or by tethered GW182 in D. melanogaster cells 
(Eulalio et al., 2007c). Nonetheless, the interactions of Pat1 
orthologues with additional decapping activators and the role 
of Pat1 orthologues in decapping remain largely unknown in 
multicellular eukaryotes.
Pat1 proteins are characterized by a conserved N-terminal 
sequence, a proline-rich region, a middle (Mid) domain, and 
a C-terminal domain (termed Pat-C). A study in S. cerevisiae 
showed that the Pat1 Mid domain interacts with the LSm1–7 
ring and is essential for decapping in vivo (Pilkington and 
Parker, 2008). Sequences located N- or C-terminally to the Mid 
domain stimulate but are not required for decapping. Further-
more, Pat-C is required for Pat1 to localize to P bodies and con-
fers the interaction with DCP1, EDC3, and RNA (Pilkington 
and Parker, 2008).
In this study, we analyzed HPat interactions and function 
in D. melanogaster using coimmunoprecipitation (co-IP) and 
complementation assays. In addition to the interaction between 
HPat and Me31B, DCP2 or the LSm1–7 complex, which are 
conserved in yeast, our study revealed that HPat interacts with 
the CCR4–NOT deadenylase complex. These findings suggest 
that HPat plays a role in coupling decapping to deadenylation. 
Accordingly, we observed that HPat promotes deadenylation 
and decapping of mRNAs in tethering assays. Unexpectedly, 
these activities are mediated by a proline-rich region, which 
we show is also required for P-body integrity. However, in 
contrast to results in yeast, we show that in addition to the Mid 
domain, both the proline-rich region and Pat-C are required to 
restore decapping in cells depleted of endogenous HPat. Our 
findings reveal that yeast and D. melanogaster differ signifi-
cantly as to which HPat domains are required for decapping, 
highlighting the importance of characterizing decapping com-
plexes in metazoa.
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fused to GFP could be coimmunoprecipitated from cell lysates 
using anti-HA antibodies. We observed that HA-Me31B coim-
munoprecipitated GFP-HPat and -EDC3, showing that Me31B 
does indeed interact with both proteins (Fig. 3 C, lanes 8–10). 
In contrast, HA-HPat coimmunoprecipitated GFP-Me31B but 
not GFP-EDC3 (Fig. 3 D, lanes 8–10), whereas HA-EDC3 co-
immunoprecipitated GFP-Me31B but not GFP-HPat (Fig. 3 E, 
lanes 8–10). Similar results were obtained when EDC3 was 
substituted by Tral in the co-IP assays (Fig. S2), suggesting that 
Me31B associates with HPat, Tral, and EDC3 to form distinct 
protein complexes.
EDC3 competes with HPat for binding  
to Me31B
The crystal structure of RCK (human Me31B orthologue) in 
complex with the FDF motif of EDC3 revealed surface residues 
on RCK (or Me31B) that are critical for the interaction with 
EDC3 and Tral (Tritschler et al., 2009). To determine whether 
HPat competes with EDC3 and Tral for this same binding 
surface, we tested whether an Me31B mutant that does not 
interact with EDC3 (or Tral) could still bind HPat. Specifically, 
we took advantage of an Me31B (Mut1) mutated at four surface 
residues involved in the interaction with the FDF motifs of 
EDC3 and Tral. We also tested an Me31B mutant (Mut2) that 
interacts with Tral but not with EDC3 (Tritschler et al., 2009). 
In IP assays, the two Me31B mutants interacted with HPat 
(Fig. 4 A, lanes 8–10), whereas Me31B-Mut1 did not interact 
with EDC3 as expected (Fig. 4 A, lane 12).
P-rich region). Because the interaction of HPat with Me31B is 
conserved, we hypothesized it could be mediated by the con-
served N-terminal sequence. Indeed, we observed that an HPat 
protein lacking the N-terminal sequence did not interact with 
Me31B (Fig. 2 C, lane 10). Conversely, a protein fragment com-
prising only the conserved N-terminal sequence was sufficient 
for the interaction with Me31B (Fig. 2 D, lane 9). Thus, the 
conserved N-terminal sequence represents the Me31B-binding 
site in HPat.
HPat, EDC3, or Tral assembles with 
Me31B into distinct protein complexes
Me31B is a DEAD-box helicase and, like all members of this 
protein family, consists of two RecA-like domains (Fig. 3 A). 
Previously, we showed that the C-terminal RecA-like domain 
interacts in a mutually exclusive manner with the FDF motifs of 
EDC3 and Tral (Tritschler et al., 2008, 2009). Surprisingly, in 
this study, we could also detect an interaction between the 
Me31B C-terminal RecA-like domain and full-length HPat 
(Fig. 3 B, lane 8) or with the HPat conserved N-terminal 
sequence (Fig. 2 D, lane 12). However, HPat did not interact 
with EDC3 or Tral (Fig. 1 A), suggesting that HPat, EDC3, and 
Tral may form mutually exclusive interactions with Me31B.
To investigate this possibility further, we cotransfected S2 
cells with mixtures of plasmids encoding three proteins: EDC3 
(or Tral), HPat, and Me31B. We used three different mixtures, 
each containing a plasmid expressing one HA-tagged and two 
GFP-tagged proteins. We then assayed whether the proteins 
Figure 1. HPat coimmunoprecipitates DCP2, 
Me31B, and the LSm1–7 complex. (A–D) GFP-, 
V5-, and HA-tagged proteins were coex-
pressed in S2 cells as indicated. Cell lysates 
were immunoprecipitated using a monoclonal 
anti-HA antibody. HA-tagged versions of GST 
or MBP served as negative controls. Inputs 
(1%) and immunoprecipitates (10%) were 
analyzed by Western blotting. In D, 30% of 
the IP fraction was loaded. Asterisks indicate 
cross-reactivity of the primary antibodies with 
an endogenous protein (input panels) or of the 
secondary antibody with the immunoglobulin 
heavy chain (IP panels). Molecular mass is 
indicated in kilodaltons.
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peptide also competes with Tral for binding to Me31B (Tritschler 
et al., 2009), we conclude that HPat, EDC3, and Tral interact 
with Me31B in a mutually exclusive manner.
The Mid domain of HPat confers 
interaction with the LSm1–7 complex
Next, we tested which HPat domains can interact with LSm1 and 
DCP2. We observed that a fragment of HPat containing the Mid 
domain plus Pat-C (residues 500–968) was necessary and suffi-
cient to interact with both LSm1 and DCP2 (Fig. 5, A–D). When 
the Mid domain and Pat-C were tested individually, we observed 
that both LSm1 and DCP2 interacted with the Mid domain but 
not with Pat-C (Fig. 5, B and D). However, the interaction of 
DCP2 with the Mid domain was less efficient than with the frag-
ment also containing Pat-C, suggesting that Pat-C contributes to 
DCP2 binding. These results, together with the observation that 
DCP2 does not interact with LSm1 (Fig. S1 D), suggest that DCP2 
binds HPat independently of the LSm1–7 ring.
Our results indicate that HPat binds to Me31B via surface 
residues different than those contacting EDC3 (or Tral); yet, the 
Me31B interaction with HPat and EDC3 (or Tral) appears to 
be mutually exclusive, suggesting that the binding surfaces 
partially overlap. Alternatively, EDC3 (or Tral) may interfere 
with HPat binding as the result of steric hindrance.
To further investigate whether EDC3, Tral, and HPat form 
mutually exclusive interactions with Me31B, we performed 
competition assays. In these assays, we tested whether a peptide 
containing the Me31B-binding domain of EDC3 (i.e., the FDF 
motif) competed with HPat for binding to Me31B when added 
to cell lysates before IP. Indeed, the peptide did interfere with 
HPat binding to Me31B, as expected for a mutually exclusive 
interaction (Fig. 4 B, lanes 9 and 10). As a control, we tested the 
corresponding peptide carrying alanine substitutions of the 
phenylalanine residues in the EDC3-FDF motif (ADA peptide); 
this peptide no longer binds Me31B and had no effect (Fig. 4 B, 
lanes 11 and 12; Tritschler et al., 2009). Because the EDC3-FDF 
Figure 2. The N-terminal conserved sequence mediates HPat interaction with Me31B. (A) Domain organization of HPat. HPat proteins contain a conserved 
N-terminal (N-ter) sequence, a glutamine/proline-rich region (P-rich), a Mid domain, and Pat-C. Numbers above the protein outline represent amino acid 
positions at fragment boundaries for the D. melanogaster protein. S. cerevisiae Pat1 is shown for comparison. (B) Sequence alignment of the N-terminal 
conserved sequence of Pat1 orthologues from Homo sapiens (Hs), Danio rerio (Dr), D. melanogaster (Dm), Caenorhabditis elegans (Ce), and S. cerevi-
siae (Sc). Asterisks indicate invariant residues. Hydrophobic, polar, and acidic residues are shaded in blue, green and magenta, respectively. Glycines 
are shaded orange. Unconserved acidic and basic residues are shaded light magenta and yellow, respectively. (C and D) Interaction between full-length 
GFP-HPat or HPat fragments with full-length Me31B or its C-terminal RecA-like domain. Cell lysates were immunoprecipitated and analyzed as described 
in Fig. 1. Molecular mass is indicated in kilodaltons.
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which interacts with Me31B, spread throughout the cell (Fig. 6 D). 
Moreover, when overexpressed, this protein fusion affected the 
integrity of endogenous P bodies, significantly reducing them 
in number and size (Fig. 6 D). In contrast, the proline-rich 
region accumulated in P bodies in 47% of the cells (Fig. 6 E), 
suggesting that the proline-rich region is sufficient for P-body 
localization. In line with this interpretation, we found that an 
HPat mutant lacking the proline-rich region was evenly dis-
tributed throughout the cell (Fig. 6 F). Furthermore, the over-
expression of this mutant affected the integrity of endogenous 
P bodies in a dominant-negative manner. We conclude that the 
proline-rich region of HPat plays a critical role in maintaining 
P-body integrity and promoting HPat accumulation in P bodies.
HPat promotes degradation  
of bound mRNAs
To better understand the function of HPat in decapping, we inves-
tigated whether binding of HPat to an mRNA was sufficient to 
promote degradation. To this end, we made use of the tethering 
The proline-rich region is required for  
P-body localization
HPat localizes to P bodies both in S. cerevisiae and in metazoa 
and is required for P-body integrity (Eulalio et al., 2007a,b; 
Parker and Sheth, 2007). This localization does not appear to be 
affected by a GFP tag (Fig. 6 A). Therefore, we sought to define 
which interactions are critical for HPat accumulation in P bod-
ies by examining where HPat fragments localize. A fragment 
of HPat comprising the N-terminal conserved sequence and the 
proline-rich region localized to P bodies in 37% of the cell 
population (Fig. 6 B), whereas a fragment comprising the Mid 
domain and Pat-C, which interacts with DCP2 and the LSm1–7 
ring, dispersed throughout the cytoplasm (Fig. 6 C). This sug-
gests that the N-terminal fragment retains the ability to localize 
to P bodies, although not as efficiently as full-length HPat, which 
localized to P bodies in 87% of the cell population (Fig. 6 A).
We next investigated whether the N-terminal conserved 
sequence or the proline-rich region were sufficient for P-body 
localization. A GFP fusion of the HPat N-terminal sequence, 
Figure 3. HPat interacts with the C-terminal 
RecA-like domain of Me31B. (A) Me31B 
consists of two RecA-like domains. Numbers 
above the protein outline represent amino 
acid positions at fragment boundaries for the 
D. melanogaster protein. N-ter, N-terminal; 
C-ter, C-terminal. (B) HA-tagged Me31B or 
the indicated Me31B protein fragments were 
coexpressed in S2 cells with GFP-HPat. Cell 
lysates were immunoprecipitated and analyzed 
as described in Fig. 1. (C–E) S2 cells were 
cotransfected with mixtures of three plasmids. 
In C, the plasmids encoded HA-Me31B, 
GFP-HPat, and GFP-EDC3; in D, the plasmids en-
coded HA-HPat, GFP-Me31B, and GFP-EDC3; 
in E, the mixture consisted of HA-EDC3, 
GFP-Me31B, and GFP-HPat. In all panels, 
HA-GST served as a negative control. Cell 
lysates were immunoprecipitated and ana-
lyzed as described in Fig. 1. Arrows indicate 
EDC3 or HPat protein degradation fragments. 
Asterisks indicate cross-reactivity of the pri-
mary antibodies with an endogenous protein 
(input panels) or of the secondary antibody 
with the immunoglobulin heavy chain (IP 
panels). (B–E) Molecular mass is indicated 
in kilodaltons.
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Together, these results indicate that HPat directs bound mRNAs 
to degradation.
The proline-rich region is required for HPat 
to degrade bound mRNAs
We next performed tethering assays using the aforementioned 
HPat deletion mutants. We observed that deleting the con-
served N-terminal sequence, which interacts with Me31B, re-
duced HPat activity in the tethering assay (Fig. 7 A, N-ter). In 
contrast, HPat mutants lacking either the Mid domain or Pat-C 
individually or simultaneously (Fig. 7, A and B, N-ter+P-rich) 
were fully active.
Unexpectedly, deleting the proline-rich region abolished 
HPat activity (Fig. 7, A and B, P-rich). Conversely, the proline-
rich region alone was more active than full-length HPat (Fig. 7, 
A and B, P-rich). All proteins were expressed at comparable 
levels (Fig. 7 C). We conclude that the proline-rich region 
is both necessary and sufficient to trigger degradation of 
bound mRNAs.
HPat triggers deadenylation and decapping
Given the role of HPat and orthologues in mRNA decapping, 
we next tested whether HPat-mediated mRNA degradation 
required the activity of decapping activators. To this end, we 
performed the tethering assay in cells codepleted of two de-
capping activators, DCP1 and EDC4. In such cells, decapping 
was efficiently inhibited, blocking mRNA degradation caused 
by tethered GW182 (Fig. 7, D and E [lane 2 vs. lane 1]). The 
accumulated transcripts were shorter, which is consistent with 
the observation that GW182 triggers mRNA deadenylation 
(Behm-Ansmant et al., 2006). We confirmed that these tran-
scripts lack a poly(A) tail by oligo (dT)–targeted RNase H 
cleavage (Fig. 7 F). Specifically, in cells expressing N-HA–
AGO1-F2V2, both the F-Luc reporter and the endogenous rp49 
mRNA (encoding ribosomal protein L32) migrated faster after 
oligo (dT)–directed RNase H cleavage had removed the poly(A) 
tail (Fig. 7 F, lane 2 vs. lane 1). In contrast, in cells expressing 
N-HA–GW182, RNase H treatment did not affect F-Luc 
reporter mobility, indicating that it was already deadenylated 
(Fig. 7 F, lane 4 vs. lane 3).
Codepletion of DCP1 and EDC4 also prevented HPat- 
mediated degradation of the reporter, which accumulated both 
in the poly- and deadenylated form (Fig. 7, E [lane 3] and F 
[lane 6 vs. lane 5]). The polyadenylated form corresponded 
to the fraction of the mRNA that was not degraded by HPat 
(Fig. 7 B, lane 3). The accumulation of the deadenylated form 
indicates that HPat promotes deadenylation. This finding might 
explain why luciferase activity is not restored despite restora-
tion of mRNA levels (Fig. 7 D) because deadenylated transcripts 
are translated less efficiently. Similar results were obtained for 
all HPat fragments containing the proline-rich region (Fig. 7, 
D and E).
We could not analyze the effect of codepleting DCP1 and 
EDC4 in cells expressing two HPat fragments (N-ter+P-rich 
and P-rich) because overexpressing these fragments had cyto-
toxic effects (i.e., low recovery of transfected cells). This was 
not observed in control cells, suggesting that in the background 
assay previously described (Gehring et al., 2005). This assay 
involves the expression of N fusion proteins that bind with 
high affinity to five BoxB hairpins (5BoxB) in the 3 untrans-
lated region of a firefly luciferase (F-Luc) reporter mRNA 
(F-Luc–5BoxB reporter).
S2 cells were transiently transfected with the F-Luc–5BoxB 
reporter, a plasmid expressing HPat fused to the N-HA pep-
tide, and a plasmid encoding Renilla luciferase (R-Luc). As 
negative control, we used an inactive mutant of the Argonaute-1 
protein (AGO1-F2V2) because this protein is comparable in 
size with HPat. Relative to cells expressing the AGO1-F2V2 
mutant, tethered N-HA–HPat reduced F-Luc activity 2.5-fold 
(Fig. 7 A). A stronger inhibitory effect was observed for 
GW182, which served as a positive control (Fig. 7 A; Behm-
Ansmant et al., 2006).
To determine whether HPat inhibits F-Luc activity by re-
pressing translation directly or indirectly by reducing mRNA 
levels, we analyzed by Northern blot the steady-state levels of 
the F-Luc–5BoxB mRNA. We found that N-HA–HPat par-
tially reduced reporter mRNA (Fig. 7, A and B [lane 3]) at 
a level that fully accounted for the decrease of F-Luc activity 
(Fig. 7 A, black vs. gray bars). HPat did not affect the expression 
of an F-Luc reporter lacking the BoxB elements (Fig. S1 E). 
Figure 4. Me31B establishes mutually exclusive interactions with HPat, 
EDC3, and Tral. (A) HA-tagged Me31B or the indicated Me31B mutants 
were coexpressed in S2 cells with GFP-HPat or -EDC3. Cell lysates were 
immunoprecipitated and analyzed as described in Fig. 1. Me31B mutants 
carry alanine substitutions of the following residues: Gln281, His284, 
Tyr288, and Lys292 (Mut1) or Phe405, His408, Glu411, and Lys412 
(Mut2). (B) HA-MBP or -Me31B was coexpressed with GFP-HPat in S2 
cells. Cell lysates were immunoprecipitated using a monoclonal anti-HA 
antibody. In lanes 3–6 and 9–12, increasing amounts (5 and 20 µg) of 
purified recombinant EDC3-FDF peptide or of the corresponding ADA 
mutant were added to the cell lysates before IP as indicated. (A and B) 
Molecular mass is indicated in kilodaltons.
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levels of F-Luc–5BoxB mRNA over time (as compared with the 
long-lived rp49 mRNA, which has a half-life >8 h). In cells ex-
pressing the AGO1-F2V2 mutant, the half-life of F-Luc–5BoxB 
mRNA was 2 h, whereas in cells expressing N-HPat or the 
proline-rich region, the half-life of this mRNA was 40 min or 
10 min, respectively (Fig. 7 I). Importantly, in cells expressing 
HPat or the proline-rich region, the F-Luc–5BoxB transcripts 
accumulating 15–90 min after adding actinomycin D were 
deadenylated (Fig. 7 I). These results further demonstrate that 
HPat-mediated decay is initiated by deadenylation. Collectively, 
our results indicate that HPat triggers deadenylation followed 
by decapping of bound mRNAs and that these activities reside 
in the proline-rich region.
of the double DCP1–EDC4 knockdown, these protein frag-
ments are toxic.
To further demonstrate that HPat triggers deadenylation 
followed by decapping, we performed two independent ex-
periments. First, we examined the F-Luc–5BoxB mRNA in 
cells expressing a dominant-negative mutant of DCP2 that 
strongly inhibits decapping in S2 cells partially depleted 
of endogenous DCP2. Again, in the presence of GW182 or 
HPat, the reporter accumulated in the deadenylated form, 
co-migrating with an F-Luc–5BoxB transcript lacking the 
poly(A) tail (Fig. 7 H).
In the second experiment, we exposed transfected cells to 
actinomycin D to inhibit transcription and then analyzed the 
Figure 5. The Mid domain and Pat-C interact with DCP2 and the LSm1–7 complex. (A–D) Interaction between full-length HPat or HPat fragments with GFP-
LSm1 or DCP2-V5. Protein interactions were analyzed as described in Fig. 1. Asterisks indicate cross-reactivity of the anti-HA antibody with an endogenous 
protein (input panels) or of the V5 antibody with the immunoglobulin heavy chain (IP panels). Note that in C, a degradation product arising from full-length 
HPat, an HPat fragment containing the N-terminal (N-ter) and proline-rich (P-rich) regions (in lanes 1–4), and the fragment containing the Mid domain and 
Pat-C (lanes 5 and 6) have a similar mobility (arrow). Molecular mass is indicated in kilodaltons.
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that HPat coimmunoprecipitated components of the CCR4–
NOT complex (including POP2, CCR4, NOT2, NOT3/5, and 
NOT4) in an RNA-independent manner (Fig. 8 A). These 
results suggest that HPat acts as an adaptor molecule, bridg-
ing the interaction between the deadenylation and decapping 
machineries. However, it is important to note that HPat is not 
required for deadenylation per se because depleting HPat 
causes deadenylated mRNAs to accumulate. Thus, in the ab-
sence of HPat, only decapping but not deadenylation is inhib-
ited (Fig. 9; Eulalio et al., 2007c), which is in agreement with 
the results reported previously in yeast (Bouveret et al., 2000; 
He and Parker, 2001; Tharun and Parker, 2001).
To define the domains of HPat required for the interaction 
with CCR4–NOT deadenylase complex components, we per-
formed co-IP assays with the aforementioned protein fragments. 
We observed that the Mid domain was both necessary and suffi-
cient for HPat to interact with CCR4 (Fig. 8, B and C).
The Mid domain and Pat-C are required for 
decapping in vivo
The tethering assay allows functional domains to be identified 
once HPat is artificially tethered to an mRNA, but additional 
domains may also be essential for HPat function because they 
mediate target binding. To further investigate the requirement 
for HPat domains in decapping, we established a complemen-
tation assay in which endogenous HPat was depleted using a 
double-stranded RNA (dsRNA) targeting HPat ORF. HPat frag-
ments were then tested for their ability to restore decapping in 
HPat-depleted cells. Transcripts encoding the recombinant pro-
teins were made resistant to the dsRNA by introducing muta-
tions that disrupt base pair interactions with the dsRNA without 
altering the protein sequence.
To monitor decapping, we used the F-Luc–5BoxB re-
porter tethered to GW182. The GW182 triggers deadenylation 
of the F-Luc–5BoxB reporter, which is then decapped, and 
subsequently, the mRNA body is digested exonucleolytically 
(Fig. 7; Behm-Ansmant et al., 2006). Inhibiting decapping 
prevents mRNA degradation by GW182, and so deadenylated 
decay intermediates accumulate (Fig. 7 E, lane 2 vs. lane 1). 
Therefore, the accumulation of the deadenylated F-Luc–5BoxB 
mRNA reflects a block in decapping.
As shown in Fig. 9 A, tethered N-HA–GW182 reduces 
mRNA levels threefold relative to that measured in cells ex-
pressing the N-HA peptide alone. Depleting HPat did not sig-
nificantly restore reporter mRNA levels (unpublished data). 
This result was expected because we previously showed that at 
least two decapping activators must be codepleted in S2 cells to 
inhibit decapping (Eulalio et al., 2007c).
We then tested whether we could inhibit decapping of the 
F-Luc–5BoxB reporter in cells depleted of HPat plus EDC4, 
DCP1, or Me31B and whether decapping could be restored by 
expressing a dsRNA-resistant form of HPat. To our surprise, 
although all combinations inhibited decapping, the dsRNA- 
resistant form of HPat restored decapping only in cells co-
depleted of HPat and Me31B (Fig. 9 B, lane 4 vs. lane 2). These 
observations indicate that, in this context and/or for this reporter, 
the HPat–Me31B interaction is dispensable for decapping. 
HPat interacts with components of the 
CCR4–NOT deadenylase complex
The finding that HPat triggers deadenylation followed by de-
capping of bound mRNA suggests that HPat interacts with com-
ponents of the deadenylase complex. Accordingly, we observed 
Figure 6. The proline-rich region is required for HPat accumulation in 
P bodies. (A–F) Confocal fluorescent micrographs of fixed S2 cells ex-
pressing GFP-tagged fusions of full-length HPat or the protein fragments 
indicated on the left. Cells were stained with affinity-purified anti-Tral anti-
bodies. The merged images show the GFP signal in green and the Tral sig-
nal in red. The fraction of cells exhibiting a staining identical to that shown 
in the representative panel was determined by scoring at least 100 cells 
per transfection in three independent transfections performed per protein. 
Mean values ± standard deviations are shown. N-ter, N-terminal; P-rich, 
proline-rich. Bar, 5 µm.
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by HPat mutants lacking Pat-C alone or in combination with the 
Mid domain, indicating that Pat-C is also required for decapping 
in vivo (Fig. 9, B [lanes 12 and 14] and C). Moreover, deleting 
the proline-rich region or the Mid domain also impaired decap-
ping (Fig. 9, B [lanes 8 and 10] and C). Finally, expressing the 
proline-rich region alone was not sufficient to restore decapping 
(Fig. 9, B [lane 16] and C). All proteins were expressed at 
comparable levels and had no dominant-negative effects when 
expressed in control cells (Fig. 9, A and E). Thus, with the 
We next tested whether HPat mutants could restore reporter 
mRNA degradation in the background of the double Me31B–HPat 
knockdown. Here, the HPat mutant lacking the Me31B-binding 
sequence restored mRNA degradation (Fig. 9 B, lane 6), which 
is consistent with a study in S. cerevisiae showing that deleting 
the N-terminal sequence of Pat1 only modestly affects decapping 
(Pilkington and Parker, 2008).
Unlike results obtained in yeast (Pilkington and Parker, 
2008), in our experiments, mRNA degradation was not restored 
Figure 7. HPat triggers deadenylation and 
decapping of bound mRNAs. (A–F) Control 
S2 cells (treated with GFP dsRNA) or cells 
codepleted of DCP1 and EDC4 were trans-
fected with a mixture of three plasmids, one 
expressing the F-Luc–5BoxB reporter, another 
expressing R-Luc, and a third expressing 
N-HA–AGO1-F2V2 (negative control) or 
N-HA fusions of wild-type HPat or fragments, 
as indicated. F-Luc activity and mRNA levels 
were normalized to those of the Renilla and 
set to 100 in cells expressing N-HA–AGO1-
F2V2. Mean values ± standard deviations 
from three independent experiments are 
shown. B and E show Northern blot analysis of 
representative RNA samples shown in A and D, 
respectively. (C) Full-length HPat and frag-
ments were expressed at comparable levels. 
(F) RNA samples shown in E (lanes 1–3) were 
treated with RNase H in the absence or pres-
ence of oligo (dT) and analyzed by Northern 
blot. rp49 mRNA served as a positive control 
for the RNase H treatment. (G) Western blot 
analysis of control and DCP1–EDC4-depleted 
cell lysates. -Tubulin served as a loading con-
trol. KD, knockdown. (C and G) Molecular 
mass is indicated in kilodaltons. (H) Tethering 
assay in cells expressing a dominant-negative 
mutant of DCP2 (E361Q). In lanes 1 and 2, 
samples isolated from cells expressing poly- 
and unadenylated F-Luc–5BoxB mRNA served 
as size markers. (I) S2 cells were transfected 
as described in A. 3 d after transfection, cells 
were treated with 5 µg/ml actinomycin D 
(ActD) and harvested at the indicated time 
points. The dashed line indicates the position 
of the deadenylated decay intermediate. N-ter, 
N-terminal; P-rich, proline-rich.
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HPat, previous studies showing that wild-type Pat1 coimmuno-
precipitates a variety of yeast mRNAs (Tharun et al., 2000; 
Tharun and Parker, 2001). We used real-time quantitative 
RT-PCR (RT-qPCR) to analyze the levels of an F-Luc mRNA 
reporter coimmunoprecipitating with HPat and observed that 
HA-HPat coimmunoprecipitated the F-Luc reporter 10-fold 
more efficiently than did HA-GST, which served as a back-
ground control for the IPs (Fig. 10 A). Furthermore, an HPat 
mutant lacking Pat-C was partially impaired in the association 
with the reporter mRNA, whereas deleting the Mid domain 
abolished association with the F-Luc mRNA (Fig. 10 A). All 
proteins were present in the immunoprecipitates at compara-
ble levels (Fig. 10 B). Thus, the Mid domain, which interacts 
with the LSm1–7 ring, CCR4, and DCP2, is required for HPat 
recruitment to mRNAs. This activity is likely stimulated by the 
contribution of Pat-C.
In yeast, Pat1 has been reported to associate with 
mRNAs via LSm1-dependent and -independent mechanisms 
and to exhibit RNA-binding activity (Tharun and Parker, 2001; 
Pilkington and Parker, 2008). Accordingly, we observed that 
HPat association with the F-Luc reporter was not affected in 
cells depleted of LSm1 (Fig. 10, A and B). These results sug-
gest that HPat could be recruited to mRNA targets via a 
redundant mechanism, including the interaction with the dead-
enylase complex, the interaction with the LSm1–7 ring, or direct 
RNA binding.
Discussion
Decapping of eukaryotic mRNAs depends on prior deadenyl-
ation, which ensures that functional, polyadenylated mRNAs 
are not decapped prematurely. However, little is known re-
garding the mechanisms that promote decapping of deadenyl-
ated mRNAs in vivo. In this study, we show that the protein 
HPat coimmunoprecipitates with decapping factors, including 
DCP2, Me31B, and the LSm1–7 ring as well as components of 
the CCR4–NOT deadenylase complex. These findings suggest 
that HPat acts as a bridging factor between the deadenylation 
and decapping machineries. Furthermore, the HPat proline-rich 
region is necessary and sufficient to trigger deadenylation and 
decapping of bound mRNAs. However, in addition to the pro-
line-rich region, both the Mid domain and Pat-C are required 
to restore decapping in cells depleted of endogenous HPat. 
Finally, we show that the Mid domain and Pat-C are required 
for HPat recruitment to mRNAs. Therefore, our work suggests 
a model whereby HPat associates with mRNAs undergoing 
deadenylation via interactions with the deadenylase complex or 
the LSm1–7 ring; subsequently, HPat recruits decapping fac-
tors, thereby committing deadenylated mRNAs to degradation 
through the 5 to 3 mRNA decay pathway.
HPat interacts with decapping activators 
and the CCR4–NOT deadenylase complex
In this study, we show that in D. melanogaster cells, HPat co-
immunoprecipitates Me31B, DCP2, the LSm1–7 ring, and com-
ponents of the CCR4–NOT deadenylase complex (Fig. 10 C). 
We mapped the domains on HPat that mediate these interactions 
exception of the N-terminal sequence, all domains of HPat 
contribute to decapping in vivo.
HPat recruitment to mRNAs is mediated 
by the Mid domain and Pat-C
The Mid domain and Pat-C were not required for HPat to 
promote mRNA degradation in tethering assays but were re-
quired for decapping in complementation assays, so we spec-
ulate that these domains contribute to target mRNA binding. 
To investigate this possibility, we confirmed and extended, for 
Figure 8. HPat interacts with components of the CCR4–NOT complex. 
(A–C) Interaction between HA-HPat wild type or mutants and GFP-tagged 
components of the CCR4–NOT complex. In lanes 13–18 of A and B, cell 
lysates were treated with RNase A before IP. F-Luc–GFP (A) or HA-GST 
(B and C) served as negative controls. The asterisk indicates cross-reactivity 
of the secondary antibody with the immunoglobin heavy chain. Molecular 
mass is indicated in kilodaltons. N-ter, N-terminal; P-rich, proline-rich.
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and showed that the Mid domain is required for HPat to interact 
with CCR4 and the LSm1–7 ring. Similarly, in S. cerevisiae, the 
corresponding region of Pat1 confers binding to the LSm1–7 
ring (Pilkington and Parker, 2008). Moreover, the Mid domain 
cooperates with Pat-C to mediate DCP2 binding, suggest-
ing that DCP2 binds HPat independently of the LSm1–7 ring. 
Future experiments will unravel whether HPat binds decapping 
and deadenylation factors simultaneously or consecutively and 
whether these interactions are direct.
We also show that a conserved N-terminal sequence 
of HPat interacts with the C-terminal RecA-like domain of 
Me31B. Surprisingly, this conserved sequence is dispensable 
for HPat activity in complementation assays, suggesting that 
mRNAs targeted for GW182-dependent degradation are effi-
ciently decapped even when HPat and Me31B do not interact 
directly. However, the HPat–Me31B interaction may play a role 
in decapping mRNAs degraded by pathways distinct from the 
microRNA pathway.
An important observation is that HPat also interacted with 
components of the CCR4–NOT deadenylase complex. Because 
HPat is not required for deadenylation per se (Eulalio et al., 
2007c; this study), an interaction with the CCR4–NOT complex 
most likely plays a role in recruiting HPat to mRNAs undergo-
ing deadenylation, providing a mechanism to couple decapping 
to the removal of the mRNA poly(A) tail.
Me31B is part of at least three distinct 
protein complexes
Previously, we showed that Me31B interacts with EDC3 and 
Tral to form distinct protein complexes (Tritschler et al., 2009). 
This study shows that a third complex exists, consisting mini-
mally of Me31B, HPat, and the LSm1–7 ring. The interaction 
between Me31B and HPat is also detected in yeast (Coller et al., 
2001; Fischer and Weis, 2002); however, our study revealed that 
EDC3, Tral, and HPat compete for binding to Me31B. Thus, 
Me31B establishes mutually exclusive interactions with EDC3, 
Tral, and HPat. The ability of Me31B and orthologues to estab-
lish mutually exclusive interactions with multiple partners 
provides a mechanistic explanation for the myriad functions 
performed by this protein and further supports the idea that 
Me31B and its orthologues act as remodeling subunits in di-
verse protein complexes (Tritschler et al., 2009). The role of 
these complexes in posttranscriptional mRNA regulation (e.g., 
decapping or translational repression) is specified by the addi-
tional components.
The proline-rich region is required for  
P-body assembly and mRNA decapping
In this study, we show that the proline-rich region of HPat 
promotes deadenylation and decapping of bound RNAs and 
is required for P-body localization, indicating that this region 
Figure 9. Complementation assay. (A–E) Control S2 cells (treated with 
GFP dsRNA) or cells codepleted of HPat and Me31B were cotransfected 
with a mixture of three plasmids, one expressing the F-Luc–5BoxB reporter, 
another expressing N-HA–GW182 or the N-HA peptide, and a third 
expressing R-Luc. Plasmids (5 ng) expressing HA-MBP, wild-type HA-HPat, 
or fragments (lacking the N tag) were included in the transfection 
mixtures, as indicated. RNA samples were analyzed by Northern blot. 
(C) F-Luc activity and mRNA levels were normalized to that of the R-Luc. 
For each condition, the normalized values of F-Luc activity and mRNA 
levels were set to 100 in control cells expressing the N-HA peptide and 
HA-MBP. Mean values ± standard deviations from three independent ex-
periments are shown. Dashed lines indicate F-Luc–5BoxB mRNA levels in 
cells expressing MBP and GW182. (D) Western blot analysis of control and 
HPat–Me31B-depleted cell lysates. -Tubulin served as a loading control. 
(E) Full-length HPat and fragments were expressed at comparable levels. 
(D and E) Molecular mass is indicated in kilodaltons. KD, knockdown; 
N-ter, N-terminal; P-rich, proline-rich.
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interacts with additional components of the mRNA decay pathway. 
However, in IP assays, the proline-rich region was dispensable 
for HPat interaction with decapping factors or deadenylase 
complex components, suggesting that the binding partners of 
this region remain to be identified.
How can a proline-rich region mediate such diverse ac-
tivities? Proline residues could play a structural role by keep-
ing this region in an extended conformation, rendering short 
sequence motifs accessible for interaction with protein part-
ners. In addition, proline-rich regions can also provide multi-
ple, nonspecific binding sites for protein–protein interactions, 
thereby contributing to the assembly of multiprotein com-
plexes (Williamson, 1994).
P-body components often contain low-complexity Q/N-
rich regions proposed to facilitate P-body formation via self-
 association or association with Q/N-rich domains on other 
proteins (Decker et al., 2007; Mazzoni et al., 2007; Reijns et al., 
2008). These regions are often rich in proline in addition to or 
instead of glutamine. The region of D. melanogaster HPat re-
quired for P-body localization is rich in proline and glutamine; 
however, the length and composition of this region varies among 
Pat1 orthologues from different species, suggesting that the 
physical interactions between decapping activators that are crit-
ical for P-body localization may not be conserved. This view is 
supported by evidence from S. cerevisiae in which Pat-C but not 
the proline-rich region is required for Pat1 to accumulate in 
P bodies (Pilkington and Parker, 2008).
The Mid domain is required for HPat 
binding to mRNAs
In addition to the proline-rich region, we show that the Mid 
domain and Pat-C are required to restore decapping in cells 
depleted of endogenous HPat. However, the Mid domain 
and Pat-C are dispensable for mRNA degradation when HPat 
is artificially tethered to an mRNA. One possible explanation 
for this difference is that the reporters used in these assays 
are decapped through distinct mechanisms. An alternative but 
not mutually exclusive explanation is that the Mid domain 
and Pat-C play a role in target binding and therefore are no 
longer required once HPat is tethered to an mRNA. Consis-
tent with this second possibility, we show that the Mid do-
main is essential for HPat to associate with mRNAs. The Mid 
domain may interact with mRNAs indirectly, via the LSm1–7 
ring, as shown in yeast (Tharun and Parker, 2001; Chowdhury 
and Tharun, 2008, 2009). However, our results indicate that 
HPat can associate with mRNAs in LSm1-depleted cells, sug-
gesting that HPat binds RNA either directly or through other 
interacting partners (e.g., the CCR4–NOT complex). In 
agreement with this, in S. cerevisiae, both the Mid domain 
and Pat-C exhibit RNA-binding activity (Pilkington and 
Parker, 2008).
What role might the Pat-C domain play in decapping? In 
S. cerevisiae, it exhibits RNA-binding activity. Accordingly, in 
D. melanogaster S2 cells, this domain contributes to target 
mRNA binding. However, the absolute requirement for this 
domain in complementation assays suggests that it may have 
additional functions in mRNA decapping.
Figure 10. The Mid domain is required for HPat recruitment to mRNA tar-
gets. (A) Control or LSm1-depleted S2 cells were transfected with a mixture 
of three plasmids, one expressing an F-Luc reporter, another expressing 
HA-GST, wild-type HA-HPat, or mutants, and a third plasmid expressing 
R-Luc. Cell lysates were immunoprecipitated using an anti-HA antibody. The 
levels of the F-Luc reporter in the immunoprecipitates (IP) were analyzed 
by RT-qPCR and normalized to the corresponding input sample. Mean 
values ± standard deviations from four independent experiments are shown. 
(B) The efficacy of the IPs was examined by Western blotting. Molecular 
mass is indicated in kilodaltons. (C) Schematic model summarizing the pro-
tein interactions described in this study. KD, knockdown; N-ter, N-terminal; 
P-rich, proline-rich.
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0.1 µg reporter plasmid (F-Luc–5BoxB or F-Luc), 0.4 µg pAc5.1–R-Luc as 
transfection control, and 0.025 µg of plasmids expressing N-HA–protein 
fusions. For the complementation assay, cells were depleted on days 0 and 
4, transfected on day 6, and collected on day 9. The transfection mixtures 
contained 0.1 µg reporter plasmid (F-Luc–5BoxB), 0.4 µg pAc5.1–R-Luc as 
transfection control, and 0.1 µg of plasmids expressing the N-HA peptide 
or N-HA–GW182. When indicated, 0.005 µg of plasmids expressing 
wild-type HPat or HPat fragments was cotransfected. HA–maltose-binding 
protein (MBP) served as a negative control. In all experiments, cells were 
collected 3 d after transfection. F-Luc and R-Luc activities were measured 
using the Dual-Luciferase reporter assay system (Promega). Northern blot-
ting was performed as described previously (Behm-Ansmant et al., 2006). 
RNase H (USB) digestion using a (dT)15 oligonucleotide was performed ac-
cording to the manufacturer’s instructions.
Reverse transcription and RT-qPCR
The interaction of HPat with mRNAs was tested as described by Zekri et al. 
(2009). In these experiments, the transfection mixtures contained 0.3 µg of 
an F-Luc reporter plasmid, 0.2 µg of the Renilla transfection control, and 
0.5 µg of plasmid expressing full-length HPat or fragments or HA-GST. 
S2 cells (10–12 × 106 cells) were collected 3 d after transfection, washed 
with PBS, and lysed in 0.5 ml of NET buffer (50 mM Tris, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, and 0.1% NP-40) supplemented with protease inhibi-
tors. Cells were lysed by three 30-s sonications, followed by a 15-min incu-
bation on ice. Cells were spun at 16,000 g for 15 min at 4°C. Anti-HA 
antibodies were added to the cleared lysates (2.5 µl/2 × 106 cells). After 
1 h at 4°C, aliquots (1/10) of the cleared lysates (input) were kept aside 
for both RNA extraction and Western blotting analysis, and 20 µl of pro-
tein G–agarose was added to the remaining lysate. Before addition to the 
lysates, protein G–agarose beads were preincubated with 0.5 mg of yeast 
RNA and 30 µg BSA for 1 h at 4°C. Lysates were rotated with protein G–
agarose beads for 1 h at 4°C. Beads were washed four times with NET 
buffer and once with NET buffer and eluted with 60 µl of 2× SDS-PAGE 
protein sample buffer. 40 µl of the eluate was used for RNA analysis. RNA 
was prepared from input and immunoprecipitates using TRIZOL-LS reagent 
(Invitrogen) according to the manufacturer’s protocol. DNase treatment 
was performed using the TURBO DNA-free kit (Applied Biosystems) for 
30 min at 37°C. RNAs were detected via cDNA synthesis and real-time quan-
titative PCR. cDNAs were synthesized with M-MuLV reverse transcription 
(Fermentas) and the F-Luc reporter–specific primer 5-TGTTTACATAACCG-
GACATAATCA-3, according to the manufacturer’s protocols. Quantitative 
PCR analysis was performed using gene-specific primer pairs (as indicated 
below) and SYBR green PCR master mix (Applied Biosystems). Each sam-
ple was analyzed in triplicate. mRNA levels in the immunoprecipitates 
were normalized to the respective input levels. Primer sequences for F-Luc 
reporter are 5-GGCCGAAGACGCCAAAAACATAAAG-3 (forward) and 
5-AATAACGCGCCCAACACCGGCA-3 (reverse).
Online supplemental material
Fig. S1 shows that HPat interacts with LSm1 and DCP2 in an RNA-independent 
manner. Fig. S2 shows that HPat and Tral interact with Me31B in a mutu-
ally exclusive manner. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200910141/DC1.
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A role for HPat in mediating the 
deadenylation dependence of decapping
Our findings suggest that in vivo HPat facilitates the deadenyl-
ation dependence of decapping. Several lines of evidence support 
this assertion. First, HPat may be preferentially recruited to deade-
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degradation via the 5 to 3 mRNA decay pathway.
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pAc5.1-EGFP vectors. For the complementation assay shown in Fig. 9, the 
N tag was deleted, and cDNAs were made resistant to HPat dsRNA, which 
targets mRNA sequences encoding aa 743–968 of HPat. Plasmids for the 
expression of deadenylase complex components were obtained by inserting 
the corresponding cDNAs in the pAc5.1–N-EGFP vector using the restriction 
sites EcoRV–Not1 (POP2, which is related to CAF1), EcoR1–Not1 (CCR4), 
HindIII–XbaI (NOT2), HindIII–Not1 (NOT3/5), and XhoI–BstBI (NOT4).
Co-IP assays, Western blotting, and fluorescence microscopy
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agent (QIAGEN). Protein co-IPs, Western blotting, and immunofluorescence 
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Figure S1.  HPat interacts with LSm1 and DCP2 in an RNA-independent manner. (A–D) Lysates from S2 cells coexpressing the indicated HA-, V5-, or GFP-
tagged proteins were immunoprecipitated using a monoclonal anti-HA or -V5 antibodies. In lanes 5 and 6 of panels A and B, cell lysates were treated with 
RNase A before IP. Inputs (1%) and immunoprecipitates (10%) were analyzed by Western blotting using anti-GFP, -V5, and -HA antibodies. In B and D, 
30% of the immunoprecipitate was loaded. HA-GST, R-Luc–V5, or HA-MBP served as negative controls. The asterisk indicates cross-reactivity of the second-
ary antibody with the immunoglobin heavy chain. Molecular mass is indicated in kilodaltons. (E) S2 cells were transfected with a mixture of three plasmids, 
one expressing the F-Luc reporter without 5BoxB, another expressing R-Luc, and a third expressing N-HA–AGO1-F2V2 (negative control) or N-HA fusions 
of GW182 or wild-type HPat, as indicated. F-Luc activity was normalized to that of the Renilla and set to 100 in cells expressing N-HA–AGO1-F2V2. 
Mean values ± standard deviations from three independent experiments are shown.
JCB S2 
Figure S2.  HPat and Tral interact with Me31B in a mutually exclusive manner. (A–C) S2 cells were cotransfected with mixtures of three plasmids. In A, the 
plasmids encoded HA-Me31B, GFP-HPat, and GFP-Tral; in B, the plasmids encoded HA-HPat, GFP-Me31B, and GFP-Tral; in C, the mixture consisted of 
HA-Tral, GFP-Me31B, and GFP-HPat. Cell lysates were immunoprecipitated using a monoclonal anti-HA antibody. In all panels, HA-GST served as a 
negative control. Inputs and immunoprecipitates were analyzed as described in Fig. 1. Asterisks indicate cross-reactivity of the primary antibodies with an 
endogenous protein (input panels) or of the secondary antibody with the immunoglobulin heavy chain (IP panels). The arrow indicates an HPat protein 
degradation fragment. Molecular mass is indicated in kilodaltons.
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DCP1 stimulates the decapping enzyme DCP2, which removes the
mRNA 5 cap structure committing mRNAs to degradation. In
multicellular eukaryotes, DCP1-DCP2 interaction is stabilized by
additional proteins, including EDC4. However, most information
on DCP2 activation stems from studies in S. cerevisiae, which lacks
EDC4. Furthermore, DCP1 orthologs from multicellular eukaryotes
have a C-terminal extension, absent in fungi. Here, we show that in
metazoa, a conserved DCP1 C-terminal domain drives DCP1 trim-
erization. Crystal structures of the DCP1-trimerization domain re-
veal an antiparallel assembly comprised of three kinked -helices.
Trimerization is required for DCP1 to be incorporated into active
decapping complexes and for efficient mRNA decapping in vivo.
Our results reveal an unexpected connectivity and complexity of
the mRNA decapping network in multicellular eukaryotes, which
likely enhances opportunities for regulating mRNA degradation.
DCP2  miRNAs  P-bodies  EDC4  Ge-1
In eukaryotes, removal of the mRNA 5 cap structure iscatalyzed by the decapping enzyme DCP2 (1, 2); to be fully
active and/or stable, DCP2 requires additional proteins (1, 2).
Yeast DCP2 interacts directly with DCP1 and this interaction is
required for decapping in vivo and in vitro (3–7). In humans, the
DCP2-DCP1 interaction requires additional proteins, which
together assemble into multimeric decapping complexes that
also include the enhancers of decapping 3 and 4 (EDC3 and
ECD4), and the DEAD-box protein DDX6/RCK (8, 9).
DCP2 is highly conserved and most information on DCP2
activation stems mainly from studies in S. cerevisiae and S. pombe
(3–7). Fungi, however, lack EDC4 as well as many extensions and
additional domains present in decapping activators of metazoan
orthologs (8–10). For example, all eukaryotic DCP1 proteins
contain an N-terminal EVH1 domain (3, 5, 6); however, DCP1
orthologs from metazoa and plants also have a proline-rich
C-terminal extension (9, 10). The sequence of this extension is
not conserved except for a 14-residue short motif (motif I, MI)
conserved in metazoa with the exception of C. elegans (Fig. 1A
and Fig. S1) and a C-terminal domain conserved in plants and
metazoa (Fig. 1A, referred to as TD).
The DCP1 C-terminal domain is predicted to adopt an
-helical conformation. In this work, we show that this domain
trimerizes in an asymmetric fashion. We solved the crystal
structure of the trimerized domain for both human and D.
melanogaster DCP1 and show that the trimer adopts an unprec-
edented fold, with no current similarities in the protein database.
We further show that DCP1 trimerization is required for the
assembly of active decapping complexes and for mRNA decap-
ping in vivo. The conservation of structurally critical residues
indicates that this domain adopts a similar fold in DCP1 or-
thologs of other multicellular eukaryotes. Consequently, within
mRNA decapping complexes in these organisms, the stoichiom-
etry of the protein components is likely more complex than
previously thought.
Results and Discussion
Crystal Structure of the Human DCP1a Trimerization Domain. To
investigate the role of the conserved C-terminal domain of human
DCP1a in mRNA decapping we expressed the domain in E. coli
(DCP1a residues S539 to L582). Using static light scattering mea-
surements coupled with size exclusion chromatography, we found
unexpectedly that the purified domain forms stable trimers in
solution (Table S1). We have termed this domain the DCP1-
trimerization domain (DCP1-TD). Furthermore, although the re-
combinant polypeptide contains 51 residues per monomer (i.e., 44
from DCP1a-TD and seven from the expression vector), NMR
spectroscopy yields 115 peaks in the 15N-HSQC spectrum (Fig.
S2), suggesting that in solution the trimers are asymmetric (assum-
ing a single trimeric assembly).
We determined the crystal structure of this unusual assembly
to a resolution of 2.3 Å (Rwork  20.8, Rfree  25.2, Table S2).
The structure reveals an unprecedented, antiparallel bundle of
three kinked -helices (two up, one down), in which the struc-
tural environment for a given side-chain differs for each of the
three molecules (Fig. 1 B–F). The central sequence (K544-L571)
of each molecule is -helical, with a strong kink at D558 that
separates helix 1 from helix 2 with an elbow angle of 90°
(Fig. 1F). At the kink, residue L554 from helix 1 makes van der
Waals contacts with F561 from helix 2, while D558 caps the N
terminus of helix -2 by hydrogen-bonding with the peptide
NH-groups of residues S560 and F561 (Fig. 1F). Alignment of
DCP1 sequences from various species shows only these three
residues are invariant (Fig. 2A, asterisks), indicating the elbow is
a conserved structural feature of DCP1 trimerization domains
from multicellular eukaryotes.
The three polypeptide chains (termed A, B, and C in Fig. 1
B–F) superimpose over the central sequence, with a maximal C
r.m.s.d. of 1.15 Å (chain A and B, residues 544–571). To
assemble the trimer, chain B interacts with chains A and C in an
antiparallel fashion, causing helices 1 of chain A and 2 of chain
C to interact in parallel. Chains A and B are thus related by a
pseudotwofold axis close to F561 (Fig. 1D), while chains C and
B are related by a pseudotwofold axis close to I552 (Fig. 1E).
This arrangement places most hydrophobic side chains into a
densely packed core (Figs. 1B and 2A, residues shaded in blue),
explaining the stability of the trimer. The resulting DCP1a
trimerization domain could be characterized as a novel fold if the
chains were connected in cis.
Using the structural information, we constructed three mu-
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tants designed to either disrupt the interface with chain A
(Mutant-1, L554S, F561R, L565S; Fig. 2A, green triangles), or
chain C (Mutant-2, I552S, I555R, L562E; Fig. 2A, red triangles)
or to completely prevent oligomerization (Mutant-3, L551R,
I555S, F561R, L565S; Fig. 2A, blue triangles). Static light
scattering shows all mutants remain monomeric (Table S1).
Notably, we did not detect dimeric assemblies suggesting that the
DCP1 C-terminal domain oligomerizes as trimer exclusively.
Crystal Structure of the Drosophila melanogaster DCP1 Trimerization
Domain. Despite the apparent stability of this unusual asymmet-
ric homotrimeric assembly, we could not formally rule out the
possibility that this particular protein sequence causes a unique
artifact. Therefore, we crystallized the trimerization domain of
D. melanogaster DCP1 (residues L328 to D366), which is only
36% identical to the human DCP1a trimerization domain (iden-
tity calculated over the central sequence of the TDs: HsDCP1a
544–571, DmDCP1 331–358; Fig. 2A). We found it also trim-
erizes with the same topology but in a different crystal packing
environment and with two independent copies in the asymmetric
unit (Fig. 1C, Fig. S3, and Table S2). Moreover, when D.
melanogaster DCP1 is mutated at structural positions equivalent
to those in human DCP1a mutants (Mut-1, Mut-2, and Mut-3),
trimerization is again disrupted (Table S1). We therefore con-
clude that the C terminus of DCP1 contains a trimerization
domain, which is conserved in metazoa but absent in fungi.
Functional Analysis of the Human and D. melanogaster DCP1 Trimer-
ization Domain. Further analysis showed DCP1 also oligomerizes
in vivo. In human HEK293 cells, we coexpressed hemagglutinin
(HA)-tagged DCP1a with green fluorescent protein (GFP)-
tagged wild-type or mutant DCP1a, and then performed coim-
munoprecipitations with anti-GFP antibodies. HA-DCP1a co-
immunoprecipitated withGFP-DCP1a, but not with the negative
control protein GFP-MBP (Fig. 2B, lane 9 vs. 8). As expected,
the trimerization domain (GFP-DCP1a-TD) is sufficient for
oligomerization (Fig. 2C, lane 6); while for DCP1a mutants 1, 2
and 3 oligomerization is strongly impaired (Fig. 2B, lanes 10–12).
Accordingly, deleting the trimerization domain prevents DCP1a
oligomerization (Fig. 2B, lane 13). Similarly, we confirmed that
the trimerization domain of D. melanogaster DCP1 is also
sufficient for oligomerization in vivo (Fig. 2D).
Because we were able to disrupt oligomerization in vivo using
information from the crystal structure, we infer DCP1 in human
and D. melanogaster cells exist as asymmetric trimers. Accord-
ingly, the possibility that the observed DCP1a self-association is
indirect and results from the incorporation of several monomeric
DCP1a copies into larger decapping complexes can be ruled out,
as it is inconsistent with the crystal structures and with the
findings described below.
We next showed human DCP1a trimerization is required for
assembly of active decapping complexes. We immunopurified
GFP-DCP1a (wild-type and mutants) from HEK293 cells and,
using an m7G-capped RNA substrate, tested for decapping
activity in vitro. Decapping activity coimmunopurified with
GFP-DCP1a as reported before (8, 10) (Fig. 2E, lane 3). This
activity likely comes from the associated DCP2 (as a positive
control, compare an immunoprecipitation of GFP-DCP2, Fig.
2E, lane 9) since adding nucleotide diphosphate kinase converts
the m7GDP product to m7GTP (8, 10) (Fig. 2E, lanes 10 and 11).
Strikingly, trimerization-defective mutants of DCP1a or DCP1a-
TD did not copurify with decapping activity (Fig. 2E, lanes
4–7), although the amounts of these proteins in the decapping
assay were comparable to those of wild-type DCP1a (Fig. 2F).
Trimerization Is Required for DCP1a to Interact with DCP2 and EDC4.
Two scenarios can explain why DCP1a trimerization-defective
mutants fail to copurify with decapping activity: either these
mutants are not incorporated into DCP2-containing complexes,
or they fail to stimulate DCP2 decapping activity. To discrimi-
nate between these possibilities, we examined the association of
DCP1a with additional components of the decapping complex
(i.e., EDC4, DCP2, EDC3, and DDX6/RCK). These all coim-
munoprecipitated with DCP1a, as reported before (8, 11–14)
(Fig. 3 A–D, lanes 9). DCP1-DCP2 association is likely stabilized
by endogeneous EDC4 or other components (8, 9, 12, 14). We
found DCP1a trimerization-defective mutants 1, 2, and 3 and
Fig. 1. Structure of the DCP1-trimerization domain. (A) Domain organiza-
tion of human DCP1a (HsDCP1a), indicating the EVH1 domain, motif I (MI), and
the trimerization domain (TD). (BandC) Crystal structures of human DCP1a-TD
and of the D. melanogaster orthologue, respectively. Chains A, B, and C are
shown in green, blue, and red, respectively, with the N-termini of chains A and
C in the front and the N terminus of chain B in the back. Residues from the
hydrophobic core are shown as sticks. A total of 4,700 Å2 is buried by the
interfaces of the three chains in HsDCP1a-TD. (D and E) Asymmetric arrange-
ment of the chains. Views down the two pseudodyads of HsDCP1a-TD, relating
chains A and B or chains C and B, respectively. (F) Superposition and compar-
ison of the three chains of HsDCP1a-TD with a close-up of the helix elbow.
Interhelical angles are 86°, 95°, 86°, for chains A, B, and C, respectively. Strictly
conserved side chains are shown as sticks.
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DCP1a-TD were strongly impaired in the interaction with
EDC4 and DCP2 (Fig. 3 A and B, lanes 10–13). Therefore, the
fact that DCP1a mutants that cannot trimerize also lack decap-
ping activity can be explained by the failure to associate with
DCP2 and EDC4. Notably, the trimerization domain itself is not
sufficient to coimmunoprecipitate EDC4 or DCP2 (Fig. 3 E and
F, lane 6). These results show that the oligomerization of
DCP1-TD in vivo does not require an association with EDC4 or
DCP2 and that additional sequences in DCP1 are necessary for
binding EDC4 and DCP2.
EDC3 and DDX6/RCK assemble with DCP1a independently
of DCP2 and EDC4. Indeed, loss of trimerization does not affect
the interaction of DCP1a with EDC3 and DDX6/RCK (Fig. 3 C
andD, lanes 10–13). However, EDC3 and DDX6 do not interact
with a DCP1a mutant that lacks the conserved motif MI (Fig. 3
C and D, lane 14), while DCP2 and EDC4 still do (Fig. 3 A and
B, lane 14). Despite the lack of interaction with EDC3 and
DDX6, DCP1a-MI still oligomerizes (Fig. 2B, lane 14), dem-
onstrating once again that the observed self-association of DCP1
is independent of other decapping factors and occurs by an
asymmetric trimerization. Furthermore, immunopurified
DCP1a-MI complexes retain decapping activity in vitro, while
immunopurified DCP1a-TD complexes do not (Fig. 2E, lanes
8 vs. 7). Consequently, a minimal decapping complex consisting
of DCP1, DCP2 and EDC4 may be sufficient for decapping
activity.
Specificity of DCP1 Trimerization In Vivo. Human cells express two
DCP1 orthologs, DCP1a and DCP1b, whose trimerization do-
mains exhibit 50% identity over the central sequence (HsDCP1a
544–571, HsDCP1b 580–607; Fig. 2A). It was therefore of
interest to investigate whether human DCP1a and DCP1b
heteromerize. We observed that HA-DCP1b coimmunoprecipi-
tated with GFP-DCP1a, indicating that DCP1a and DCP1b can
indeed heteromerize (Fig. 4A, lane 6). Consistently, we found
heteromerization required the trimerization domain (Fig. 4A,
lane 7).
To investigate the specificity of this interaction further, we
substituted the trimerization domain of human DCP1a with the
equivalent domain from D. melanogaster DCP1 and examined
whether the chimeric protein (DCP1a-DmTD) oligomerized and
interacted with wild-type DCP1a and DCP1b. As expected, the
chimeric protein homomerized, indicating that D. melanogaster
DCP1-TD trimerizes independently of the additional f lanking
sequences (Fig. 4B, lane 8). In contrast, we observed no inter-
action between the chimeric DCP1a-DmTD and DCP1a or
DCP1b (Fig. 4 A and C, lane 8, and B, lane 6). Thus, hetero-
merization is observed only between highly related sequences.
Furthermore, BLAST searches using the trimerization domains
of DCP1a and DCP1b failed to identify any significantly similar
sequence in the human genome. Thus, we conclude that DCP1a
and DCP1b are unlikely to heteromerize with alternative, un-
related proteins.
Trimerization Enhances DCP1a Accumulation in P-Bodies.DCP1a and
partners localize to P-bodies (8, 9, 15–17). We therefore tested
the localization of DCP1a mutants, to define what interactions
Fig. 2. DCP1 trimerization occurs in vivo and is required for the assembly of active decapping complexes. (A) Structure-based alignment of the trimerization
domain (TD) of DCP1 orthologs fromHomo sapiens (Hs),Xenopus laevis (Xl),Danio rerio (Dr);Drosophilamelanogaster (Dm),Aedes aegypti (Aa),Caenorhabditis
elegans (Ce), Arabidopsis thaliana (At), and Oryza sativa (Os). Residues from the hydrophobic core of the trimerization domain are shaded blue, residues
mediating conserved intrachain hydrogen bonds are shaded green. The portion of the sequence that is -helical in all three chains of HsDCP1a-TD is indicated.
Triangles mark mutated residues in mutant-1 (green), mutant-2 (red) and mutant-3 (blue). Gray letters indicate residues with variable conformation, likely to
be affected by crystal packing. (B and C) DCP1 trimerization in vivo. GFP- and HA-tagged proteins were coexpressed in human cells as indicated. Cell lysates were
immunoprecipitated using anti-GFP antibodies. GFP-tagged maltose binding protein (GFP-MBP) served as a negative control. Protein samples were analyzed by
Western blotting using anti-HA and anti-GFP antibodies. (D) Lysates from D. melanogaster (Dm) S2 cells expressing HA-GST or HA-GST-DmTD together with
GFP-tagged DmTD, were immunoprecipitated using anti-HA antibodies. Inputs and immunoprecipitates were analyzed as described above. The asterisk indicates
cross-reactivity of the anti-HA antibody with an endogenous protein. (E) GFP-tagged proteins were expressed in human cells, as indicated. Cell lysates were
immunoprecipitated using anti-GFP antibodies. The immunoprecipitates were tested for decapping activity using in vitro synthesized 32P-labeled capped mRNA.
(F) Samples corresponding to panel (E) were analyzed by Western blot to ensure that equivalent amounts of DCP1a wild-type and mutants were used for the
decapping assay.
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are critical for P-body accumulation. As reported (8, 9), GFP-
DCP1a accumulates in cytoplasmic foci corresponding to en-
dogenous P-bodies (Fig. 5A). Deleting the conserved motif MI
did not affect this pattern (Fig. 5B). In contrast, the trimeriza-
tion-deficient mutants and DCP1a-TD dispersed throughout
the cytoplasm, although some signal was still detectable in
P-bodies (Fig. 5 C and D and Fig. S4). The isolated trimerization
domain did not localize to P-bodies (Fig. 5E). Importantly, the
chimeric DCP1a protein containing the D. melanogaster trimer-
ization domain did localize to P-bodies in human cells (Fig. 5F).
We conclude that trimerization per se, independently of the
sequence of the trimerization domain, is required for DCP1a to
efficiently accumulate in P-bodies.
DCP1 Trimerization Is Important for Efficient Decapping in Vivo. To
test the biological significance of the identified DCP1 trimer-
ization domain and its functional relevance in mRNA decapping
we established a complementation assay inD. melanogaster cells,
which express a single DCP1 paralog. In the complementation
assay, endogenous DCP1 was depleted using a dsRNA targeting
the DCP1 ORF. A dsRNA targeting GFP was used as a negative
control. Wild-type DCP1 and a DCP1 mutant lacking the
trimerization domain were then tested for the ability to restore
decapping in DCP1-depleted cells. Transcripts encoding the
proteins were made resistant to the dsRNA by introducing
mutations that disrupt base pair interactions with the dsRNA
without altering the protein sequence.
To assay mRNA decapping we monitored miRNA-mediated
Fig. 3. Role of trimerization in the interactions of DCP1 with partner
proteins. (A–F) GFP- and HA-tagged proteins were expressed in human cells as
indicated above the panels. Cell lysates were immunoprecipitated using anti-
GFP antibodies. GFP-MBP served as a negative control. Protein samples were
analyzed by Western blotting using anti-GFP and anti-HA antibodies. DCP1a
interaction with EDC4 (A). DCP1a interaction with DCP2 (B). DCP1a interaction
with EDC3 (C). DCP1a interaction with DDX6/RCK (D). Interaction of DCP1a
and DCP1a-TD with EDC4 (E) or DCP2 (F).
Fig. 4. Specificity of DCP1 trimerization. (A–C) GFP- and HA-tagged proteins
were expressed in human cells as indicated above the panels. Cell lysates were
immunoprecipitated using anti-GFP antibodies. GFP-MBP served as a negative
control. Protein samples were analyzed by Western blotting using anti-GFP
and anti-HA antibodies.
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mRNA degradation. We previously showed that miRNA targets
are degraded by exonucleolytic digestion of themRNAbody only
after they are first deadenylated and then decapped (18, 19).
Therefore, we could prevent miRNA targets from being de-
graded by inhibiting decapping (18, 19). In our assay, we used the
F-Luc-CG3548 reporter consisting of the firefly luciferase (F-
Luc) ORF fused to the 3 UTR of the D. melanogaster gene
CG3548, which is silenced by miR-12 (19). Each transfection
mixture included either a plasmid encoding the primary miR-12
transcript or the corresponding control vector without an insert,
plus a transfection control plasmid expressing Renilla luciferase
(R-Luc).
Our results showed the F-Luc-CG3548 mRNA is degraded in
a miR-12-dependent manner (Fig. 6A, lane 2 vs. 1). Depleting
DCP1 did not restore reporter mRNA levels. This result is
expected since we previously showed that, in S2 cells, at least two
decapping activators must be codepleted to restore the levels of
miRNA reporters (19). Accordingly, codepletion of endogenous
DCP1 plus EDC4 from S2 cells strongly inhibited decapping of
the F-Luc-CG3548 reporter, leading to the accumulation of
F-Luc-CG3548 mRNA as a fast migrating deadenylated form
(Fig. 6A, lane 4). We therefore performed the complementation
assay in this sensitized background.
We thus tested whether in cells codepleted of DCP1 and
EDC4, we could restore mRNA degradation by expressing
wild-type DCP1 or the DCP1 mutant lacking the trimerization
domain.We restored target mRNA degradation in cells depleted
of the endogenous DCP1 by expressing the dsRNA-resistant
version of wild-type DCP1 (Fig. 6A, lane 6). In contrast, the
DCP1-TD mutant was impaired in restoring mRNA degrada-
tion indicating that decapping is still inhibited in these cells (Fig.
6A, lane 8). DCP1 and DCP1-TD were expressed at compa-
rable levels (Fig. 6B). Notably, in control cells, neither DCP1 nor
DCP1-TD inhibited mRNA degradation in a dominant nega-
tive manner (Fig. S4). Finally, the changes in steady state levels
of F-Luc-CG3548 mRNA in cells depleted of DCP1 and EDC4
were accompanied by corresponding changes in the half-life of
the mRNA (Fig. 6C). We conclude that DCP1 trimerization is
required for efficient mRNA decapping in vivo.
Concluding Remarks. In this study, we identified a protein trim-
erization domain in the DCP1 protein. In metazoa, this domain
is physiologically important for DCP1 to be incorporated into
active mRNA decapping complexes and for mRNA decapping in
vivo. This is remarkable, not only because trimers are rare among
homomeric protein assemblies, but particularly because such an
entirely asymmetric arrangement has not been described before
in a physiological context (20).
Trimerization of DCP1 reveals an unexpected connectivity
and complexity of the decapping network in multicellular eu-
karyotes, as both EDC3 and EDC4 are known or presumed to
form homodimers (11, 13, 15, 21). We find that DCP1a can
interact with DCP2 and EDC4 independently of the interaction
with EDC3 and DDX6/RCK. Therefore, we can now conceive of
multimeric assemblies consisting of (i) DCP1, EDC4, and DCP2,
(ii) DCP1, EDC3, and DDX6 or (iii) combinations of both.
Presently, we do not know precisely how DCP1 trimers associate
with EDC3 and EDC4 dimers and why DCP1 oligomerizes in a
F
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Fig. 5. Trimerization enhances accumulation of DCP1a in P-bodies. (A–F)
Representative confocal fluorescent micrographs of fixed human HeLa cells
expressing wild-type GFP-DCP1a or the mutants indicated on the left. Cells
were stained with antibodies cross-reacting with EDC4 and a nuclear human
antigen (23). The merged images show the GFP signal in green and the EDC4
signal in red. The fraction of cells exhibiting a staining identical to that shown
in the representative panel was determined by scoring at least 100 cells in
three independent transfections performed per protein. (Scale bar, 10 m.)
Fig. 6. Trimerization is required for efficient decapping in vivo (A–C) D.
melanogaster S2 cells were treated with dsRNA targeting the ORF ofDCP1and
EDC4 mRNAs. Control cells were treated with GFP dsRNA. These cells were
subsequently transfected with a mixture of three plasmids: one expressing the
F-Luc-CG3548 reporter; another expressing miR-12 primary transcripts (miR-
12) or the corresponding empty vector (-); and a third expressing Renilla
luciferase (R-Luc). Plasmids (5 ng) encoding wild-type HA-DCP1, HA-DCP1TD
or HA-MBP were included in the transfection mixtures, as indicated. RNA
samples were analyzed by Northern blot. Firefly luciferase mRNA levels were
normalized to those of the Renilla luciferase. For each condition, the normal-
ized values of F-Luc mRNA were set to 100 in the absence of miR-12. (B) Shows
that HA-DCP1, HA-DCP1TD and HA-MBP are expressed at comparable levels.
(C) The decay of F-Luc-CG3548 mRNA was monitored in the presence (black
lines) or absence (red lines) of miR-12 in depleted cells following inhibition of
transcription by actinomycin D. The levels of the F-Luc-CG3548 mRNA were
normalized to rp49 mRNA and plotted against time. mRNA half-lives (t1/2)
calculated from the decay curves are indicated in minutes.
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nonsymmetric fashion. It shall be challenging to determine the
structural details of such assemblies and their possible signifi-
cance for regulating mRNA decapping or for promoting P-body
formation.
Methods
Detailed experimental procedures are given in the SI Text. Briefly, the trim-
erization domains of human DCP1a (residues 539–582) and D. melanogaster
DCP1 (residues 328–366), N-terminally tagged with GST, were expressed in the
E. coli strain BL21 Gold (DE3) (Stratagene) at 25 °C overnight. The proteins
were purified by glutathione affinity step (GSTrap HP column; GE Healthcare).
After cleaving the GST with PreScission protease, the complexes were further
purified by gel filtration (HiLoad 26/60 Superdex 75 columns; GE Healthcare).
The structure of the human protein was solved using single-wavelength
anomalous dispersion data, collected from a crystal with selenomethionine-
substituted protein. The structure of the D. melanogaster protein was solved
by molecular replacement using the structure of the human protein as search
model. Coimmunoprecipitation assays and immunofluorescence were per-
formed as described in ref. 22. Decapping assays were performed as described
in ref. 10, with the modifications indicated in the SI Text.
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SI Text
Protein Expression, Purification, and Crystallization. cDNA se-
quences encoding the trimerization domains of H. sapiens
DCP1a (Q9NPI6; Ser-539 to Leu-582) and D. melanogaster
DCP1 (Q9W1H5; Leu-328 to Asp-366) were amplified from
oligo(dT)15-primed cDNA libraries obtained from human HeLa
cells or D. melanogaster S2 cells, respectively. The amplified
cDNA fragments were inserted into a modified pRSFDuet-1
vector (Novagen) downstream of the GST ORF. The GST-
tagged proteins were expressed in the E. coli strain BL21 Gold
(DE3) (Stratagene) at 25 °C overnight. The proteins were pu-
rified from cleared cell lysates by a glutathione affinity step
(GSTrap HP column; GE Healthcare ). After cleavage of the
GST with PreScission protease, the proteins were further puri-
fied by gel filtration (HiLoad 26/60 Superdex 75 pg; GE Health-
care).
Diffraction quality crystals were grown by hanging drop vapor
diffusion. Drops containing 1 L of protein solution [16 mg/mL
(human protein) or 7 mg/mL (D. melanogaster protein) in 10 mM
Na-Hepes, pH 8.0, 50 mM NaCl, and 1 mM DTT] plus 1 L of
reservoir solution were equilibrated at 19 °C over 500 L of
reservoir [50 mM Mes, pH 6.0, and 1.2 M Na-Malonate (human
protein) or 100 mM Mes, pH 6.5, 1.2 M ammonium sulfate, and
5% 1,4-Dioxane (D. melanogaster protein)]. Crystals of the
human protein grew to a size of at least 200 50 30m3 within
1 day. Crystals were flash-frozen in liquid nitrogen after cryo-
protection in 50 mM Mes, pH 6.0, and 2.3 M Na-Malonate.
Crystals of the D. melanogaster protein grew to a size of
approximately 150  40  20 m3 within 12 h and were
cryoprotected in 100 mMMes, pH 6.5, 1.2 M ammonium sulfate,
5% 1,4-dioxane, and 25% glycerol.
Structure Determination and Refinement. Diffraction data were
collected on beamline X10SA of the Swiss Light Source (SLS).
Diffraction images of selenomethionine-substituted human pro-
tein (one methionine per molecule, resulting from the 5-cloning
site) were processed with XDS (1) to 2.4 Å resolution. According
to XTRIAGE (2) the crystal was merohedrally (-h,-k, l) twinned
(twinning fraction 24%). The structure was solved using single-
wavelength anomalous dispersion. We used AutoSHARP (3) to
identify (SHELX D) and refine (SHARP) selenium sites, fol-
lowed by automatic density modification (SOLOMON). Assum-
ing one molecule per asymmetric unit (67% solvent) and search-
ing for three selenium sites (resolution cutoffs 30–2.8 Å) resulted
in an electron density map that displayed distinct protein and
solvent regions. After phase extension and further statistical
phase improvement with PIRATE as part of the CCP4 Suite (4)
the density was good enough to directly place six -helical
fragments using COOT (5). After rigid body refinement (REF-
MAC) using native data (2.3-Å resolution, twinning fraction
18%), this model was good enough to prime autobuilding (121
out of 132 final residues) with flex-wARP (6). The model was
completed manually using COOT and REFMAC (7) for refine-
ment. A twin-specific target function did not improve the map
any further. At least one of the three selenium sites refined by
SHARP seems to have been an artifact of the twinning. Crystals
of the D. melanogaster protein were untwinned and diffracted to
2.8 Å resolution. The structure was solved by molecular replace-
ment using PHASER (8) and a polyalanine model of a truncated
version of the human protein as search model. The model for the
two monomers in the asymmetric unit (74% solvent) was (re-
)built manually using COOT and REFMAC for refinement.
Stereochemical properties were analyzed with MOLPROBITY
(9) and WHATCHECK (10).
Analytical Size Exclusion Chromatography and Static Light Scattering.
Proteins were prepared as described for crystallization, except
that the preparative gel filtrations were done in chromatography
buffer (10 mM Hepes, pH 8.0, 150 mM NaCl, and 1 mM DTT).
Approximately 250 g of each protein in a volume of 500 L was
injected onto a Superdex 75 10/300 GL analytical gel filtration
column (15 °C equilibrated in chromatography buffer) at a flow
rate of 0.4 mL/min. Multiangle static laser light-scattering was
done online with analytical gel filtration chromatography using
miniDAWN TREOS and Optilab rEX instruments (Wyatt
Technologies) and the associated software (AstraV) for molec-
ular weight determination.
NMR Measurements. The 2D 1H-15N HSQC spectrum of human
DCP1a was measured at 291 K on a Bruker AV III-800 spec-
trometer, processed and analyzed using the Topspin (Topspin V.
2.1.1, Bruker) software. The spectrum was recorded with 1,024
(t1) 128 (t2) complex points using 128 scans per increment and
a relaxation delay of 0.8 s.
Coimmunoprecipitation Assays and Western Blotting. Plasmids al-
lowing the expression of DCP1a, DCP2, DDX6/RCK, EDC3,
and EDC4 in human cells were generated by cloning the
corresponding cDNAs into the pEGFP-C1 vector (Clontech) or
the pCI-neo-N-HA vector (11). Human DCP1b was cloned
between the XhoI and EcoR1 sites of the pN-HA-C1 vector.
DCP1 mutants were generated by site-directed mutagenesis
using the QuikChange mutagenesis kit from Stratagene and the
appropriate oligonucleotide sequences. In DCP1-MI residues
155 to 168 are deleted. In DCP1-TD, residues 539–582 are
deleted. In the chimeric DCP1a-DmTD protein, residues 539–
582 of human DCP1a are substituted with residues 329–372 of
D. melanogaster DCP1.
For coimmunoprecipitation assays, HEK293 cells were grown
in 10-cm plates and transfected using Lipofectamine 2000 (In-
vitrogen). The transfection mixtures contained 7 g of the GFP-
and HA-constructs. Two days after transfection, cells were
washed with PBS and lysed for 15 min on ice in NET buffer (50
mM Tris at pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% Triton
X-100, and 10% glycerol) supplemented with protease inhibitors
(1 mL NET buffer/plate). Cell lysates were spun at 18,000  g
for 15 min at 4 °C. Polyclonal anti-GFP antibodies were added
to the supernatants (dilution 1:100). Samples were incubated for
1h at 4 °C, 25 L Protein G-agarose (Roche) were added and the
mixtures were rotated for an additional hour at 4 °C. Beads were
washed three times with NET buffer and once with NET buffer
without Triton X-100. Bound proteins were eluted with 100 L
protein sample buffer and analyzed by Western blotting. For the
GFP-tagged proteins we analyzed 2% of the inputs and 10% of
the immunoprecipitates. For HA-tagged EDC3, EDC4, RCK,
and DCP1 we analyzed 1.5% of the input and 20% of the
immunoprecipitates. For HA-DCP2 we analyzed 1% of the input
and 40% of the immunoprecipitates. HA-tagged proteins were
detected by Western blot analysis using horseradish peroxidase
linked anti-HA high affinity (3F10) antibodies (Roche, Catalog
no. 12013819001 dilution 1:5,000). GFP-tagged proteins were
detected using a mixture of two monoclonal anti-GFP antibodies
(Roche, catalog number 11814460001, dilution 1:2,000) and a
secondary horseradish peroxidase linked anti-mouse IgG anti-
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body (GE Healthcare, NA931V). Western blots were developed
using ECL PlusWestern Blotting Detection System (GEHealth-
care).
Decapping Assays.Decapping assays were performed as described
before (12), using an in vitro synthesized RNA (127-
nucleotides). The RNA probe was labeled with [-32P]GTP
using the ScriptCap m7G Capping System and the ScriptCap
2-O-Methyltransferase kit (EPICENTRE Biotechnologies).
Human HEK293 cells were transfected with plasmids expressing
GFP-tagged proteins (10 g plasmid/10-cm dish). Two days after
transfection, cells were washed with PBS and lysed as described
above for the immunoprecipitation assays. Samples were pro-
cessed as described for the immunoprecipitation assays, with the
exception that the last washing step was performed with NET-2
buffer (50 mM TrisHCl, pH 7.5, 150 mM NaCl, 0.05% Triton
X-100, and 0.1 mg/mL BSA). Aliquots of the beads (5 L of a
1:2 slurry in NET-2 buffer) were incubated for 30 min at 30 °C
in a thermomixer (at 700 rpm) with approximately 50 ng RNA
substrate in a final volume of 10 L in decapping buffer [50 mM
TrisHCl, pH 7.9, 30 mM ammonium sulfate, 1 mM MgCl2, and
0.1 mM cap structure analog (NEB)]. When indicated 1 U of
nucleoside 5-diphosphate kinase (Sigma) and ATP (0.5 mM
final concentration) were added, and samples were incubated for
an additional 30 min. Reactions were stopped by adding up to 50
mM EDTA and analyzed on PEI cellulose TLC plates (Merck)
in 0.75 M LiCl (1 L/sample). Unlabeled GDP, m7GMP,
m7GDP, and m7GTP were used as markers.
Fluorescence Microscopy. For fluorescence microscopy, human
HeLa cells were grown on coverslips in 24-well plates and
transfected using Lipofectamine 2000 (Invitrogen). The trans-
fection mixtures contained either 0.3 g (for DCP1 wild-type) or
0.5 g (for DCP1 mutants) of plasmids expressing GFP-protein
fusions.
Two days after transfection, cells were fixed with 4% para-
formaldehyde in PBS for 10 min, and permeabilized for 10 min
with PBS containing 0.5% Triton X-100. Endogenous P-bodies
were detected using a monoclonal antibody (sc-8418, Santa Cruz
Biotechnology), which cross-reacts with EDC4 (13) at a 1:1,000
dilution in PBS containing 0.1% Tween-20, and 10% FBS (FBS).
Alexa Fluor 594-coupled goat-anti-mouse secondary antibody
(Molecular Probes) was used at a 1:1,000 dilution. Cells were
mounted using Fluoromount-G (Southern Biotechnology Asso-
ciates, Inc.). Images were acquired using a Leica TCS SP2
confocal.
Immunoprecipitations, RNA Interference, and Complementation As-
say in D. melanogaster S2 Cells. Protein coimmunoprecipitations in
S2 cells were performed as described before (14, 15). Luciferase
reporters and plasmids for expression of miRNAs and HA-
tagged proteins were described before (14, 15). Mutants of D.
melanogasterDCP1 were generated by site-directed mutagenesis
using the plasmid pAc5.1B-N-HA-DCP1 (dsRNA resistant) as
template, using the QuikChange mutagenesis kit from Strat-
agene. Plasmid pAc5.1B-NHA-DCP1 (dsRNA resistant) car-
ries mutations that prevent the interaction with DCP1-dsRNA
without changing the protein sequence. RNA interference was
performed as described before (14) with the exception that cells
were depleted on days 0 and 4, transfected on day 7 and collected
on day 10. Transfections of S2 cells were performed in six-well
plates, using Effectene transfection reagent (Qiagen). For
miRNA-mediated silencing assays, the transfection mixtures
contained 0.1 g of firefly luciferase reporter plasmid, 0.4 g the
Renilla transfection control, and 0.4 g plasmids expressing
miRNA primary transcripts or the corresponding vector without
insert. When indicated, 0.025–1 g of plasmids expressing
recombinant proteins were cotransfected. Firefly and Renilla
luciferase activities were measured 3 days after transfection
using the Dual-Luciferase Reporter Assay System (Promega).
Total RNA was isolated using TriFast (Peqlab Biotechnologies)
and analyzed as described before (14).
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Fig. S1. Sequence alignment of conserved motif MI of DCP1 orthologs from Homo sapiens (Hs), Xenopus laevis (Xl), Danio rerio (Dr), Drosophila melanogaster
(Dm), and Aedes aegypti (Aa). This motif is not conserved in DCP1 orthologs from Caenorhabditis elegans and plants. Conserved residues are shaded blue
(hydrophobic) or red (charged).
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Fig. S2. 2D-1H-15N HSQC spectrum of human DCP1a-TD measured at 291 K. The spectrum shows at least 115 well-resolved NH-peaks. A pure and symmetric
homotrimer, however, would yield only a single set of backbone resonances (51 peaks). The molecular diffusion coefficient of the protein [0.74 ( 0.02)1010
m2/s] is in perfect agreement with the molecular mass of the homotrimer at 291 K and excludes significant exchange between higher or lower oligomeric forms.
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Fig. S3. Crystal structure of the DCP1-trimerization domain from D. melanogaster (DmDCP1-TD). The two crystallographically independent trimers are shown
side by side. Left side: Trimer 1 with chains A (green), B (blue), and C (red). Right side: Trimer 2 with chains D (green), E (blue), and F (red). (A) Top view with the
N-termini of chains A and C (D and F in trimer 2) in the front and the N terminus of chain B (E in trimer 2) in the back. Residues from the hydrophobic core are
shown as sticks. A total of 4,200 Å2 (4,000 Å2 in trimer 2) is buried by the interfaces of the three chains. (B) Asymmetric arrangement of the chains, oriented like
in Fig. 1 D and E, with corresponding residues labeled. The pseudodyad relating chains A and B in the human protein is absent in DmDCP1-TD due to a partial
unwinding of the N-terminal turn in helix A2 (D2 in trimer 2). (C) Superposition of helix 1 and comparison of the three chains of DmDCP1-TD with a close-up
on the helix elbow. Strictly conserved side-chains are shown as sticks. Note that helix A2 (D2 in trimer 2) is shifted in its relative position when compared to
the other two chains of the DmDCP1 trimer or to the human ortholog (Fig. 1F).
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Fig. S4. Trimerization enhances accumulation of DCP1a in P-bodies and is required for decapping in vivo. (A–C) Representative confocal fluorescent
micrographs of fixed human HeLa cells expressing GFP-DCP1a wild-type or the mutants indicated on the left. Cells were stained with an antibody that cross-reacts
with EDC4 and a human nuclear antigen. The merged images show the GFP signal in green and the EDC4 signal in red. The fraction of cells exhibiting a staining
identical to that shown in the representative panel was determined by scoring at least 100 cells in three independent transfections performed per protein. (Scale
bar, 10m.) (D)D.melanogaster S2 cells were treated with dsRNA targeting the ORF of DCP1 and EDC4 mRNAs. Control cells were treated with GFP dsRNA. These
cells were subsequently transfected with a mixture of three plasmids: one expressing the F Luc-CG3548 reporter; another expressing miR-12 primary transcripts
(miR-12) or the corresponding empty vector (); and a third expressing Renilla luciferase (R Luc). Plasmids (5 ng) encoding wild-type HA-DCP1, HA-DCP1TD,
or HA-MBP were included in the transfection mixtures, as indicated. The panel shows RNA samples isolated from control cells.
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Table S1. Molecular weight of wild-type human or D.
melanogaster DCP1 trimerization domains and corresponding
mutants as determined by static light scattering
Human
DCP1a-TD
D. melanogaster
DCP1-TD
MWkDa	 MWkDa	
Wild-type 16.3 15.1
Theoretical trimer 17.4 15.6
Mut-1 7.4 3.8
Mut-2 7.1 5.6
Mut-3 5.3 5.6
Theoretical monomer 5.8 5.2
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Table S2. Data collection, phasing and refinement statistics
HsDCP1a-TD HsDCP1a-TD DmDCP1-TD
Se-Met Native Native
Data collection
Space group P3221 P3221 P6122
Cell dimensions
(a/b/c), Å 64.2, 64.2, 103.3 64.7, 64.7, 103.0 120.9, 120.9, 134.5
(//) ° 90.0, 90.0, 120.0 90.0, 90.0, 120.0 90.0, 90.0, 120.0
Wavelength, Å 0.9792 1.0688 1.0643
Resolution, Å 38–2.8 80–2.3 50–2.8
(2.87–2.80) (2.37–2.31) (2.87–2.80)
Rmerge, % 6.6 (25.5) 8.0 (55.7) 10.7 (80.0)
I/ (I) 22.0 (7.3) 11.9 (2.5) 13.0 (2.0)
Completeness, % 99.8 (100.0) 98.9 (95.7) 98.2 (96.0)
Completeness, anomalous, % 99.6 (96.9) — —
Redundancy 8.3 (6.3) 3.5 (3.5) 4.8 (4.4)
Redundancy, anomalous 4.6 (3.5) — —
Phasing
Rcullis 0.929 — —
Phasing power 0.552 — —
Mean figure of merit 0.192 — —
Refinement
Resolution, Å — 2.3 2.8
No. reflections — 10708 13830
Rwork/Rfree, % — 20.8/25.2 21.5/26.7
No. atoms
Protein — 1050 2053
Ligand/ion — 0 25
Water — 54 54
B-factors
Protein, Å2 — 33.1 42.5
Ligand/ion, Å2 — — 101.7
Water, Å2 — 40.0 41.1
Ramachandran plot
Most favoured regions, % 98.4 96.7
Disallowed regions, % 0.0 0.0
R.m.s. deviations
Bond lengths, Å — 0.0183 0.0113
Bond angles, ° — 1.648 1.272
*Values in parentheses are for the highest-resolution shell.
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The DEAD box helicase DDX6/Me31B functions in
translational repression and mRNA decapping. How
particular RNA helicases are recruited specifically to
distinct functional complexes is poorly understood.
We present the crystal structure of the DDX6
C-terminal RecA-like domain bound to a highly
conservedFDF sequencemotif in the decapping acti-
vator EDC3. The FDF peptide adopts an a-helical
conformation upon binding to DDX6, occupying a
shallow groove opposite to the DDX6 surface
involved in RNA binding and ATP hydrolysis. Muta-
genesis of Me31B shows the relevance of the FDF
interaction surface both for Me31B’s accumulation
inPbodies and for its ability to repress the expression
of bound mRNAs. The translational repressor Tral
containsasimilarFDFmotif. Togetherwithmutational
and competition studies, the structure reveals why
the interactions of Me31B with EDC3 and Tral are
mutually exclusive andhow the respectivedecapping
and translational repressor complexes might hook
onto an mRNA substrate.
INTRODUCTION
DEAD box proteins are RNA-dependent ATPases that partici-
pate in most, if not all, steps of cellular RNA metabolism (Linder
and Lasko, 2006). They are thought to unwind short RNA
duplexes in a nonprocessive manner and/or disrupt RNA-protein
interactions (Jankowsky and Bowers, 2006). DEAD box proteins
are characterized by 11 evolutionarily conserved motifs (Q, I, Ia,
GG, Ib, II, III, IV, QxxR, V, and VI), including the signature
sequence DEAD (motif II), from which the name of the family is
derived. The 11 motifs define the conserved core of the protein
family, which consists of two globular RecA-like domains con-
nected by a flexible hinge (Caruthers et al., 2000).
The human DEAD box protein DDX6 (also known as RCK/p54)
and its orthologs in X. laevis (Xp54), D. melanogaster (Me31B),
C. elegans (CGH-1), and S. cerevisiae (Dhh1p) play a critical
role in posttranscriptional gene regulation by mediating both
translational repression and mRNA decapping (reviewed by
Weston and Sommerville, 2006). DDX6 and Me31B in humanMand D. melanogaster cells, respectively, are also implicated in
the miRNA pathway (Chu and Rana, 2006; Eulalio et al., 2007).
DDX6 and its orthologs associate with multiple partners to
form distinct protein complexes that may repress translation
and/or enhance decapping, depending on which other proteins
are in these complexes. In S. cerevisiae, Dhh1p interacts with
Pat1, the LSm1–7 complex, and EDC3 (Coller et al., 2001; Coller
and Parker, 2005; Decker et al., 2007); in human cells, DDX6
coimmunoprecipitates with the decapping enzyme DCP2 and
the decapping activators DCP1, EDC3, and Ge-1 (also known
as EDC4; Fenger-Grøn et al., 2005). These interactions are
conserved. Indeed, we recently showed that D. melanogaster
Me31B coimmunoprecipitates with EDC3, the related protein
Trailer hitch (Tral), and the S. cerevisiae Pat1 ortholog (HPat;
Eulalio et al., 2007; Tritschler et al., 2007, 2008).
EDC3and Tral (also known as vertebrateRAP55 orS.cerevisiae
Scd6p) share a domain organization consisting of a divergent
N-terminal LSm domain and a central FDF motif (Albrecht and
Lengauer, 2004; Anantharaman and Aravind, 2004; Tritschler
et al., 2007, 2008). They are thought to act as molecular scaffolds,
using their modular domain organization to bridge multiple protein
interactions. Indeed, Tral coimmunoprecipitates with DCP1 and
the translational regulator CUP, whereas EDC3 coimmunopreci-
pitates with DCP1 and DCP2 (Decker et al., 2007; Fenger-Grøn
et al., 2005; Tritschler et al., 2007, 2008). Moreover, both EDC3
and Tral interact with the C-terminal RecA-like domain of Me31B,
via regions encompassing the FDF motifs (Decker et al., 2007;
Tritschler et al., 2008).
We aimed to gain insight into how the FDF motifs of EDC3
and Tral interact with DDX6 and its orthologs to form complexes
with functions in translational repression and/or mRNA decapp-
ing. To this end, we determined the crystal structure, at 2.3 A˚
resolution, of the C-terminal domain of human DDX6 in complex
with an EDC3-FDF peptide. The structure reveals a tight heter-
odimer, with the EDC3-FDF peptide adopting a helical confor-
mation upon binding to DDX6. In orthologous proteins from
different species, residues critical for heterodimerization are
conserved. We show that these residues are involved in the
interaction between the D. melanogaster proteins Me31B and
DmEDC3. We further show that Me31B uses the same surface
to interact with the FDF motif of Tral. Thus, DDX6/Me31B inter-
acts with EDC3 and Tral in a mutually exclusive manner to form
distinct protein complexes, thereby providing a mechanistic
explanation for the functional diversity of the DDX6/Me31B
helicase.olecular Cell 33, 661–668, March 13, 2009 ª2009 Elsevier Inc. 661
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Structural Insight into the DDX6-EDC3 HeterodimerRESULTS
Structure of the DDX6 C-Terminal Domain in Complex
with an EDC3-FDF Peptide
The C-terminal RecA-like domain of Me31B coimmunoprecipi-
tates with EDC3 and Tral protein fragments encompassing the
FDF motifs (Tritschler et al., 2008). Hence, we looked for direct
interactions between the bacterially expressed proteins. We
found that a small fragment of human EDC3 that contains the
FDF motif (residues Phe192–Arg228, referred to as EDC3-FDF;
Figure 1A) was sufficient to efficiently copurify with the C-terminal
RecA-like domain of DDX6 (residues Lys296–Pro472, referred to
as DDX6-C; Figure 1A and data not shown). We purified the het-
erodimeric complex and obtained two unrelated crystal forms,
each containing two heterodimers per asymmetric unit (Table 1).
The four refined DDX6-C–EDC3-FDF complexes superpose well,
with a maximum pairwise root-mean-square deviation (rmsd) of
0.77 A˚ (see Figure S1 available online).
The EDC3-FDF Peptide Binds DDX6-C Opposite
to the Catalytically Important Interface
DDX6-C adopts a typical RecA-like a/b fold, characterized by
a central six-stranded parallel b sheet (b8–b13, in Dhh1p
numbering) sandwiched between a helices (a10–a14) that alter-
nate with strands in the protein sequence (Figures 1B and 2A).
When compared to yeast Dhh1p (Cheng et al., 2005), DDX6-C
superimposes with an rmsd of 0.80 A˚.
Figure 1. Structure of the DDX6-C/EDC3-
FDF Heterodimer
(A) Domain organization of DDX6 and EDC3. The
structured part of the DDX6 C-terminal domain is
shown in gray, with the conserved helicase motifs
in purple. The EDC3-FDF peptide is highlighted in
salmon. Numbers correspond to the human
proteins.
(B) Ribbon diagrams of the complex colored as in
(A). Side chains for the EDC3-FDF and EDC3-FDK
motifs and for DDX6-His312 are shown as sticks.
(C and D) Electrostatic potentials were mapped
onto the respective molecular surface and con-
toured from 5 kT/e (red) to +5 kT/e (blue). In
(C), EDC3-FDF is represented as sticks (carbons
in yellow, oxygens in red, nitrogens in blue) on
the molecular surface of DDX6-C. (D) shows the
molecular surface of the complex and changes in
charge distribution.
The EDC3-FDF peptide binds across
the b8-edge of the b sheet in a shallow
groove between a helices a10 and a14
(Figure 1B; for difference electron density,
see Figure S2). As inferred from the struc-
tures of Dhh1p and the DEAD box
helicase Vasa in complex with RNA and
an ATP analog, the peptide binds oppo-
site to the helicase motifs IV, QxxR, V,
and VI and thus opposite to the catalyti-
cally important interface that is formed
between DDX6-C and the DDX6 N-terminal RecA-like domain
(Figures 1B and 2B; Cheng et al., 2005; Sengoku et al., 2006).
We could not, however, test whether EDC3 binding affects
DDX6 catalytic activity, because purified recombinant DDX6
does not exhibit detectable ATPase activity in vitro (data not
shown).
The EDC3-FDF Peptide in Complex with DDX6-C Adopts
a Helical Conformation
When the EDC3-FDF peptide is bound to DDX6-C, it folds into
two consecutive a helices (H1 and H2; Figures 1B and 2C).
The helices are preceded and connected by the FDF motif and
a related FDK sequence, respectively, motifs that share a strik-
ingly similar structure (Figure 1B). The N-terminal residues of
the EDC3-FDF peptide (residues Glu197–Asp203) form a struc-
tured loop that wraps around His312, which protrudes from
a helix a10 of DDX6-C (Figure 1B, side view).
The FDF motif adopts a particularly interesting conformation
that represents an unusual recognition element: the aromatic
rings of phenylalanines Phe204 and Phe206 stack perpendicu-
larly to each other in an edge-to-face orientation and are accom-
modated by DDX6-C in a complementary hydrophobic pocket
(Figures 1B, 3A, and 3B). Consequently, the aspartate Asp205
bulges out from between them and caps a helix H1 (Figures 3A
and 3B), both neutralizing the positive helix dipole and forming
a stabilizing hydrogen bond with the main-chain nitrogen of
Gly208 (in H1). Similarly, a helix H2 is capped by Asp214 of the662 Molecular Cell 33, 661–668, March 13, 2009 ª2009 Elsevier Inc.
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bulges out from between the two flanking residues, probably due
to their intimate interaction with DDX6-C (Figure 3C).
An Intertwined Network of Interactions Anchors
the EDC3-FDF Peptide to DDX6
Approximately 31% (1000 A˚2) of the total EDC3-FDF surface
area is buried in the complex. Much of this is due to hydrophobic
contacts, which exploit complementary shapes; but the interface
also contains a buried water molecule and numerous direct
hydrogen bonds (Figures 3A–3C and Figure S3).
Among the specific hydrogen bonds, most contacts come
from a helix a10 of DDX6-C, contacts which constrain the struc-
ture of the FDF motif and fix its orientation. On DDX6-C, the side
chains of His312 and Thr316 fix the backbone (the carbonyl
oxygen of Thr202 and the nitrogen of Asp203, respectively) of
the EDC3 N-terminal loop that precedes the FDF motif. Further-
more, the side chain of the conserved EDC3 Asp203 is fixed by
a salt bridge to DDX6-C Arg320, and the conserved EDC3
Asn209 (in a helix H1) is contacted by DDX6-C Gln309 (Figures
3A and 3B and Figure S3).
The structure of the FDK motif is similarly stabilized by a water-
mediated contact of DDX6-C Tyr302, which fixes the main-chain
Table 1. Crystallographic Statistics
Form I Form II
Space group C2 P212121
Unit cell
dimensions (a/b/c) (A˚)
172.6, 47.9, 65.8 46.9, 80.0, 110.3
Unit cell angles (a/b/g), () 90.0, 96.4, 90.0 90.0, 90.0, 90.0
Wavelength (A˚) 0.978 0.978
Rmerge (%)
a 10.1 (55.5) 6.6 (36.1)
Completeness (%)a 98.4 (99.7) 95.5 (98.2)
I/s(I)a 10.8 (2.6) 16.5 (4.2)
Number of unique
reflections
22482 17392
Multiplicitya 2.9 (2.8) 4.6 (4.5)
Resolution range (A˚)a 46.1–2.3
(2.36–2.3)
45.5–2.3
(2.36–2.3)
Rcryst/Rfree (%) 19.0/26.0 21.0/27.5
Molecules per asymmetric
unit
DDX6-C/EDC3-FDF 2/2 2/2
CAPS/glycerol/phosphate 6/0/4 0/4/0
Number of protein
atoms/waters
3144/235 2952/111
Average B factor
for protein atoms (A˚2)
26.1 33.3
Ramachandran plot
(favored/allowed/outlier %)
97.1/2.9/0 98/2/0
Rmsd from ideal geometry
Bond lengths, (A˚) 0.019 0.019
Bond angles, () 1.73 1.78
a Numbers in parentheses are for the highest-resolution shell.Mcarbonyls of EDC3 Phe213 and Leu210 (Figure 3B). Additionally,
Lys215 from the FDK motif is fixed in a specific pocket on
DDX6-C and provides one hydrogen bond to Glu439 on a helix
a14 and another hydrogen bond to the carbonyl oxygen of
Ile446 in the DDX6-C C-terminal extension (Figure 3C). Finally,
the C-terminal end of a helix H2 is fixed by EDC3-Asp223, which
accepts a hydrogen bond from DDX6-Lys436 (Figure 3C).
Specificity of the DDX6-EDC3-FDF Interaction
To understand how EDC3-FDF discriminates between DDX6
and other RNA helicases that are structurally closely related,
we aligned and superimposed (core rmsd in brackets) the struc-
tures of DDX6-C, human UAP56 (1.2 A˚; Shi et al., 2004; Zhao
et al., 2004), D. melanogaster Vasa (1.5 A˚; Sengoku et al.,
2006), S. cerevisiae eIF4A (1.6 A˚; Caruthers et al., 2000), human
eIF4AIII (1.7 A˚; Andersen et al., 2006; Bono et al., 2006), and
human DDX3X (1.6 A˚; Ho¨gbom et al., 2007). We found that the
critical side chains of Tyr302, Gln309, His312, and Thr316 are
conserved as a group only among DDX6 orthologs (Figure 2A;
red boxes). Furthermore, in Vasa and DDX3X, the C-terminal
extension would clash with the EDC3-FDF peptide. Conse-
quently, other RNA helicases should not interact with EDC3-
FDF. In agreement with this, we observed that EDC3 and Tral
interact with Me31B (the D. melanogaster DDX6 ortholog), but
not with the related DEAD box proteins UAP56, eIF4A, Belle
(DDX3), or p68 (Figure S4A).
A Coupled Binding-Folding Mechanism for FDF
Peptide-DDX6 Recognition
The binding surface of DDX6-C in complex with the EDC3-FDF
peptide is very similar to that of yeast Dhh1p in the absence of
binding partners. In contrast, the EDC3-FDF peptide is unlikely
to be structured in the unbound form, because the N-terminal
loop as well as the FDF and FDK motifs would lose their stabilizing
interactions. Consequently, the short a helices H1 and H2 would
also be significantly destabilized in the unbound conformation,
since the capping aspartates from the FDF and FDK motifs would
not be kept in a fixed position without DDX6-C.
To determine experimentally whether the structure of the
EDC3-FDF peptide is induced by the rigid conformation of the
DDX6-C binding surface, we took NMR measurements of the iso-
lated peptide in solution. In the absence of DDX6, we found no
significant a-helical content (Figure S5). Consistent with this,
the crystal structure of the C-terminal domain of human EDC3
(residues 203–508) shows that the region encompassing the
FDF motif is disordered (Ling et al., 2008). Together, these obser-
vations suggest that a coupled binding-folding mechanism oper-
ates when the EDC3-FDF peptide interacts with DDX6 (Dyson
and Wright, 2005).
The resulting complex is significantly different from the free
DDX6 helicase and shows a markedly more negative surface
potential (Figures 1C versus Figure 1D). Indeed, in the a-helical
conformation adopted by the EDC3-FDF peptide bound to
DDX6, a whole series of acidic EDC3-FDF side chains becomes
clustered and oriented toward the solvent, creating a large nega-
tively charged patch, which may exclude or favor the recruitment
of additional factors (Figures 1C, 1D, and 2C; Asp205, Glu207,
Asp214, Glu220, Glu221).olecular Cell 33, 661–668, March 13, 2009 ª2009 Elsevier Inc. 663
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Structural Insight into the DDX6-EDC3 HeterodimerFigure 2. Structure-Based Alignments of DDX6 and EDC3
(A) Sequence alignment of DDX6 orthologs (group I) from H. sapiens (DDX6), D. melanogaster (Me31B), C. elegans (CGH-1), and S. cerevisiae (Dhh1) with func-
tionally distinct helicases (group II), UAP56 (H. sapiens), eIF4AIII (H. sapiens), Vasa (D. melanogaster), and DDX3X (H. sapiens). Positions involving side-chain
interactions between DDX6 and EDC3 are boxed red (specific hydrogen bonds) or yellow (hydrophobic contacts). Boxes are filled if the residues are highly
conserved. Boxes are extended to group II if the residues are conserved in both groups. Positions involving specific main-chain contacts are marked with an
asterisk. Triangles indicate residues mutated in this study (red triangles indicate residues mutated in DDX6-CMut-1 or Me31BMut-1, blue triangles indicate residues
mutated in Me31BMut-2). Conserved helicase motifs are shaded in purple. Secondary structure assignment and numbering correspond to DDX6.
(B) Structural superposition of DDX6-C (purple) bound to EDC3-FDF (salmon) with Vasa (pale cyan; Sengoku et al., 2006) bound to RNA (magenta) and an ATP
analog (orange).
(C) Sequence alignment of EDC3 orthologs (group I) with orthologs of Tral (group II) from H. sapiens (Rap55), D. melanogaster (Tral), C. elegans (CAR-1), and
S. cerevisiae (Scd6p). The region that aligns best between EDC3 and Tral is underlined. Helix-capping residues are boxed in green. For the remaining symbols, see (A).The FDF Motif Is Essential for DDX6-EDC3
Heterodimerization
To identify contacts that are essential for the DDX6-EDC3 inter-
action, we performed binding assays in vitro using recombinant
DDX6-C and minimal, synthetic EDC3-FDF peptides with an
N-terminal fluorescein label (EDC3 residues 197–224). We tested
both a wild-type peptide (EDC3-FDFFluo) and a peptide in which
the two phenylalanines of the FDF motif were replaced with
alanines (EDC3-ADAFluo).
When mixed with an excess of wild-type EDC3-FDFFluo, the
bulk of DDX6-C shifts to a lower elution volume, consistent with
the formation of a well-behaved globular complex (Figure S6A).
In contrast, the EDC3-ADAFluo peptide does not detectably
interact with DDX6-C (Figure S6B), demonstrating that, in vitro,
the FDF motif is essential for heterodimerization.664 Molecular Cell 33, 661–668, March 13, 2009 ª2009 Elsevier IncTo identify similarly important residues on the side of DDX6-C,
we substituted Gln309, His312, Thr316, and Arg320 with alanines
(DDX6-CMut-1). In the crystal structure, these residues interact
with residues surrounding the FDF motif and represent specificity
determinants, as suggested by a phylogenetic comparison
(Figures 2A and 3A; boxed residues). As expected, DDX6-CMut-1
no longer interacted with EDC3-FDFFluo in the gel filtration assay
(Figure S6C). It eluted at the same position as the isolated protein
(wild-type or mutant) in the absence of peptide, also indicating
that the mutations do not affect the protein fold.
The DDX6-EDC3 Heterodimerization Interface
Is Conserved
The human and D. melanogaster (Dm) proteins are highly
conserved (83% and 50% sequence identity for the structured.
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Structural Insight into the DDX6-EDC3 Heterodimerparts of DDX6-C and EDC3-FDF, respectively); thus, mutations
based on the structure of the human DDX6-EDC3 complex can
be easily mapped onto the D. melanogaster Me31B-DmEDC3
proteins (Figures 2A and 2C). This enabled us to investigate
the effect of such mutations in the context of the full-length
proteins in D. melanogaster Schneider cells (S2 cells), where
these interactions were previously characterized (Tritschler
et al., 2007, 2008).
To examine how DmEDC3 mutations affect Me31B binding,
HA-tagged wild-type or mutant DmEDC3 was expressed in S2
cells, together with a green fluorescent protein (GFP) fusion of
Me31B. We then tested whether anti-HA antibodies could coim-
munoprecipitate GFP-Me31B from cell lysates. We found that
alanine substitution of Phe345 in the FDF motif of DmEDC3
Figure 3. Molecular Interface between DDX6-C and EDC3-FDF
DDX6-C (gray) and EDC3-FDF (salmon) are shown as ribbons with selected
side-chain and main-chain atoms as sticks (oxygens in red, nitrogens in
blue, sulfurs in yellow). Fixed water molecules are shown as red spheres and
hydrogen bonds and salt bridges as dotted lines.
(A) Interactions of the N-terminal loop, the FDF motif, and a helix H1. The four
residues mutated in DDX6-CMut-1 have boxed labels.
(B) Interactions of the N-terminal loop, the FDF motif, and a helix H1. b strand
b8 is drawn as a loop for clarity.
(C) Interactions of the FDK motif and a helix H2. Equivalent residues mutated in
Me31BMut-2 have boxed labels.(corresponding to Phe204 in human EDC3, Figure 2C) strongly
impaired the interaction with Me31B (Figure 4A, lane 10). Surpris-
ingly, alanine substitution of Phe347 had only a modest effect
(Figure 4A, lane 11). Consistently, when the two phenylalanines
in the FDF motif were substituted with alanines, it did not exacer-
bate the effect of the single Phe345Ala substitution (Figure 4A,
lane 12 versus lane 10); this indicates that the first phenylalanine
of the FDF motif, which reorients the peptide backbone, is critical
for the interaction with Me31B. Similarly, substituting the phenyl-
alanine of the FDK motif with alanine strongly reduced the inter-
action with Me31B (Figure S4B, lane 9), indicating that both the
FDF and FDK motifs play a crucial role in this interaction.
Interestingly, substituting the bulged aspartate (DmEDC3
Asp346) in the FDF motif with either alanine or lysine strongly
impaired binding to Me31B (Figure 4A, lanes 13 and 14, respec-
tively), yet this residue does not contribute directly to the hetero-
dimerization interface. Because Asp346 caps and stabilizes helix
H1, this result suggests that the absence of Asp346 prevents the
EDC3-FDF peptide from adopting the conformation required for
binding to Me31B.
On the Me31B heterodimerization surface, double or
quadruple substitutions of conserved residues strongly reduced
binding to DmEDC3. In particular, an HA-tagged Me31B carrying
alanine substitutions of residues surrounding the FDF motif
(Gln281, His284, Tyr288, and Lys292; referred to as Me31BMut-1,
and corresponding to DDX6-CMut-1; Figure 2A, red triangles)
abolished binding to DmEDC3 (Figure 4B, lane 13). These results
agree with those obtained for the interaction between human
DDX6 and EDC3 in vitro (Figure S6). Furthermore, HA-Me31B
carrying alanine substitutions of residues interacting with EDC3
helix H2 (Phe405, His408, Glu411, and Lys412; referred to as
Me31BMut-2; Figure 2A, blue triangles) failed to interact with
DmEDC3 (Figure 4B, lanes 14–16), indicating that in addition to
the FDF and FDK motifs, helix H2 strongly contributes to the
affinity of the interaction.
Tral and EDC3 Use a Similar Mode to Interact
with Me31B
Previously, we showed that a Tral fragment comprising the FDF
motif coimmunoprecipitates with the C-terminal RecA-like
domain of Me31B, suggesting that Tral and EDC3 use a similar
mode to interact with Me31B (Tritschler et al., 2008). If this
were the case, the Tral-Me31B interaction should be abolished
by mutating Tral residues located at positions similar to EDC3
residues mediating the interaction with Me31B.
Using the coimmunoprecipitation assays described above, we
found that alanine substitutions of any residue in the FDF motif of
Tral, or of the phenylalanine in the FEE motif, prevented Tral from
binding to Me31B (Figure 4A and Figure S4B). As for EDC3-FDF,
the substitution of the bulged aspartate in the FDF motif of Tral
abolished Me31B binding, suggesting that the Tral-FDF peptide
adopts a similar helical conformation upon binding to Me31B (Fig-
ure 4A, lane 27). Consistently, and as expected for a mutually
exclusive interaction, a DmEDC3-FDF peptide, but not the corre-
sponding ADA mutant, competed with Tral for binding to Me31B
whenadded tocell lysates before immunoprecipitation (Figure 4C).
Nevertheless, the exact mode of interaction of Tral and EDC3
with Me31B likely differs. Indeed, for Me31B mutations atMolecular Cell 33, 661–668, March 13, 2009 ª2009 Elsevier Inc. 665
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Residues
(A) HA-tagged maltose-binding protein (MBP),
wild-type EDC3 or Tral, and the indicated EDC3
or Tral mutants were coexpressed in S2 cells with
GFP-Me31B, as indicated. Cell lysates were immu-
noprecipitated using an anti-HA antibody. The
KFKF mutants carry lysine substitutions of aspar-
tate residues preceeding and within the FDF motifs
of EDC3 and Tral. Inputs (1%) and immunoprecip-
itates (10%) were analyzed by western blotting
using anti-HA and anti-GFP antibodies. Asterisks
indicate crossreactivity of the anti-HA antibody.
(B) HA-tagged MBP, wild-type Me31B, or Me31B
mutants were coexpressed in S2 cells with
GFP-EDC3 or GFP-Tral, as indicated. Cell lysates
were immunoprecipitated and analyzed as
described in (A).
(C) HA-MBP or wild-type HA-Me31B was
expressed in S2 cells. Cell lysates were immuno-
precipitated by using anti-HA antibodies. The
presence of endogenous Tral in the immunopre-
cipitates was analyzed by western blot using
anti-Tral antibodies. In lanes 3–8 and 11–16,
increasing amounts (0.5, 5, and 10 mg) of purified
recombinant EDC3-FDF peptide or of the corre-
sponding ADA mutant were added to the cell
lysates prior to immunoprecipitation. Samples
were analyzed as described in (A).
(D and E) Confocal fluorescent micrographs of
fixed S2 cells expressing GFP-Me31B wild-type
or mutant. Cells were stained with anti-Tral anti-
bodies. The fraction of cells exhibiting a staining
similar to that shown in the representative panel
was determined by scoring at least 100 cells in
two independent transfections performed per
protein. The merged images show the GFP signal
in green and the Tral signal in red.
(F–I) S2 cellswere transfectedwith the F-Luc–5BoxB
or F-Luc reporters, a plasmid expressing Renilla
luciferase, and vectors expressing lN-HA fusions
of wild-type or mutant Me31B and EDC3, as indi-
cated. Firefly luciferase activity was normalized to
that of the Renilla and set to 100 in cells expressing
themutant proteins.Meanvaluesandstandarddevi-
ations from three independent experiments are
shown. Mutant proteins have a comparable effect
as the lN-HA peptide alone (data not shown).residues surrounding the FDF motif (Me31BMut-1), we observed
that if a mutation impaired the interaction with EDC3, then it
also impaired the interaction with Tral (Figure 4B, lanes 27–29).
In contrast, mutating Me31B residues that interact with helix
H2 (Me31BMut-2) abolished binding to EDC3, but not to Tral
(Figure 4B, lanes 14–16 versus 30–32). These results suggest
that the highly conserved FDF and FDK motifs of Tral and EDC3
probably compete for the same binding pocket on the helicase;
in contrast, the sequences corresponding to the less conserved
helix H2 may play a different role in RAP55/Tral (Figure 2C).
Me31B Interaction with EDC3 or Tral Is Required for P
Body Localization
To test whether disrupting EDC3 binding would also affect the
accumulation of Me31B in P bodies, we visualized the localiza-666 Molecular Cell 33, 661–668, March 13, 2009 ª2009 Elsevier Inction of Me31BMut-1. We observed that 90% of cells expressing
wild-type GFP-Me31B displayed GFP foci (Figure 4D and
Figure S7A). These foci correspond to endogenous P bodies,
as judged by the staining with anti-Tral antibodies or by the accu-
mulation of HA-Ge-1. In contrast, only 24% of cells expressing
GFP-Me31BMut-1 displayed foci comparable to those observed
with the wild-type protein (Figure 4E), whereas 75% of cells
expressing the mutant protein had no detectable GFP foci
(Figure 4E).
In cells in which GFP-Me31BMut-1 was dispersed throughout
the cytoplasm, the number of endogenous P bodies was reduced
(Figure 4E and Figure S7B). Because Tral (and Ge-1) accumulate
in P bodies independently of Me31B (Tritschler et al., 2008), these
results suggest that overexpressing GFP-Me31BMut-1 inhibits
P body formation in a dominant-negative manner..
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P bodies independently of Me31B (Tritschler et al., 2007, 2008).
Consistently, the DmEDC3ADA and TralADA mutants (which do
not interact with Me31B) accumulated in endogenous P bodies
as efficiently as the wild-type proteins (Figures S7C–S7F).
Me31B Interaction with EDC3 or Tral Is Required
to Repress the Expression of Bound mRNAs
Previous studies in Xenopus oocytes showed that DDX6
represses the expression of bound mRNAs (Minshall et al.,
2001; Minshall and Standart, 2004). To determine whether
repression required the interaction with EDC3, we adopted the
tethering assay used in these studies (Minshall et al., 2001; Min-
shall and Standart, 2004). This assay involves the expression of
a lN-HA fusion of Me31B that binds with high affinity to five
BoxB sites (5BoxB) in the 30UTR of a firefly luciferase reporter
mRNA. Renilla luciferase served as transfection control. We
observed that Me31B repressed firefly luciferase expression,
as reported before for Xenopus RCK (Figure 4F; Minshall et al.,
2001; Minshall and Standart, 2004). In contrast, the Me31B
mutant that no longer interacts with Tral and EDC3 did not
have a significant effect on firefly luciferase levels (Figure 4F).
Similarly, when EDC3 is tethered to the firefly luciferase mRNA,
luciferase expression is inhibited relative to the activity measured
in cells expressing the lN-HA peptide alone or the EDC3 mutant
that does not interact with Me31B (Figure 4G). None of the
proteins affected the expression of an F-Luc reporter lacking
BoxB elements (F-Luc; Figures 4H and 4I). These results indicate
that Me31B and EDC3 must interact to repress the expression of
bound mRNAs.
DISCUSSION
The crystallographic analysis of DDX6-C in complex with the
EDC3-FDF peptide reveals that these proteins interact viaa highly
conserved interface. In DDX6, the surface required for heterodi-
merization is preformed; in contrast, the EDC3-FDF peptide is
unstructured in solution and adopts an a-helical conformation
only upon binding to DDX6.
The association of EDC3 with DDX6 may represent an impor-
tant step in the assembly of a multimeric complex dedicated to
mRNA decapping. Indeed, EDC3 also interacts with the decapp-
ing enzyme DCP2 and the decapping activator DCP1 (Decker
et al., 2007; Tritschler et al., 2007, 2008) and may enhance
decapping by positioning the catalytic subunit of the decapping
complex (DCP2) in proximity to DCP1. The interaction with the
FDF peptide thus anchors the decapping activity onto DDX6,
which, as a helicase, could bind the mRNA substrate in an
ATP-dependent manner.
DDX6 and its orthologs also play a fundamental role in regu-
lating translation of maternal mRNAs during oogenesis and early
embryogenesis (reviewed by Weston and Sommerville, 2006). In
agreement with this, Xenopus DDX6 represses the expression of
bound mRNAs (Minshall et al., 2001; Minshall and Standart,
2004). We show that this repressive activity requires the interac-
tion with EDC3 or Tral. Nevertheless, the precise molecular
mechanism by which DDX6 orthologs exert their repressive
functions remains to be established.DEAD box proteins are highly specific despite having
a conserved helicase core, and they cannot be mutually inter-
changed. Their specificity is governed by interactions with other
protein partners and/or RNPs (Linder and Lasko, 2006). We
show here that DDX6/Me31B achieves specificity, at least in
part, through mutually exclusive interactions with partners
such as EDC3 and Tral; these partners associate with the heli-
case to form distinct protein complexes (Tritschler et al., 2008).
In these alternative complexes, when RNA stimulates the ATP
hydrolysis activity of DDX6 orthologs, the RNP substrate may
be remodeled to facilitate the action of other components in
these complexes (e.g., DCP2). In this scenario, DDX6 orthologs
would function as ‘‘blind’’ remodeling subunits in diverse protein
complexes. The final outcome of their action would thus be
specified by both the additional proteins they associate with
and the composition of the mRNP target. Therefore, to under-
stand the precise molecular function of DDX6 orthologs, the
biochemical, functional, and structural properties of the
complexes in which they are assembled should be characterized
further.
EXPERIMENTAL PROCEDURES
Protein Expression, Purification, and Crystallization
N-terminally tagged His6-RCK-C and GST-EDC3-FDF were coexpressed in
the E. coli strain Rosetta 2(DE3) (Novagen) at 25C overnight. Complexes
were purified by consecutive Ni2+ and glutathione affinity steps. After cleaving
the tags with 3C protease, complexes were further purified by ion exchange
chromatography and gel filtration (Mono Q 5/50 GL and HiLoad 26/60 Super-
dex 75 columns (GE Healthcare)). A detailed description of crystallization
conditions is provided in the Supplemental Data.
Structure Determination and Refinement
Diffraction data were collected on beamline PXII of the Swiss Light Source
(SLS), Villigen, Switzerland. For both crystal forms, the structure was solved
independently by molecular replacement using the C-terminal domain
(K256-A420) of Dhh1p (PDB-ID 1s2m) as a search model. Additional informa-
tion is provided in the Supplemental Data.
Coimmunoprecipitation Assays, Western Blotting,
and Fluorescence Microscopy
Plasmids expressing GFP- or lN-HA-tagged EDC3, Tral, and Me31B in S2 cells
have been described (Tritschler et al., 2007, 2008). Mutants were generated by
site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis
Kit from Stratagene and the appropriate oligonucleotide sequences. Transfec-
tions, coimmunoprecipitations, western blotting, and immunofluorescence
were performed as described before (Tritschler et al., 2007, 2008).
Tethering Assays
Plasmids for performing the tethering assay in S2 cells were described before
(Rehwinkel et al., 2005). Transfections of S2 cells were performed in 6-well
plates, using Effectene transfection reagent (QIAGEN). The transfection
mixtures contained 0.1 mg reporter plasmid (F-Luc-5BoxB or F-Luc), 0.4 mg
pAc5.1-R-Luc as transfection control, and 0.01 mg (Me31B) or 0.1 mg (EDC3)
of plasmids expressing lN-HA-protein fusions. Firefly and Renilla luciferase
activities were measured 3 days after transfection using the Dual-Luciferase
Reporter Assay System (Promega).
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DNA constructs 
cDNA sequences encoding the FDF peptide of H. sapiens EDC3 (gi:18204641; 
Phe192 to Arg228) and H. sapiens DDX6-C (gi:458727; Lys296 to Pro472) were 
amplified from an oligo (dT)15-primed human cDNA library, and cloned into a 
modified pRSFDuet-1 (Novagen) vector. 
 
Crystallization  
Diffraction quality crystals were grown by sitting drop vapor diffusion. Drops 
containing 0.4 µl protein solution (at 12 mg/ml in 10 mM Na-HEPES pH 7.5, 5 mM 
DTT and 100 mM NaCl) plus 0.4 µl reservoir solution were equilibrated at 19°C over 
75 µl of reservoir. After two weeks crystal form I (clustered plates of 80 x 80 x 10 
µm3) was obtained over 100 mM N-cyclohexyl-3-aminopropanesulfonic acid pH 
10.5, 1.2 M NaH2PO4, 0.8 M K2HPO4 and 200 mM Li-SO4. Crystal form II (a single 
rod of 50 x 10 x 10 µm3) was obtained over 40 mM KH2PO4, 16% PEG8000 and 20% 
glycerol. For crystal form II, the single rod was directly flash-frozen in liquid 
nitrogen. For crystal form I, single fragments were broken from the clusters and 
cryoprotected in 1.8 M NaH2PO4, 1.2 M K2HPO4 and 200 mM Li-SO4 before flash-
freezing. 
 
Structure determination and refinement 
Diffraction images were processed with XDS (Kabsch 1993). Due to poor diffraction 
quality of crystal form II in one particular orientation, data were cut at 2.3 Å 
resolution and are only 95.5 % complete. The structure was solved for both crystal 
forms independently by molecular replacement using PHASER (McCoy, 2007). As a 
search model, we took the C-terminal domain (K256-A420) of Dhh1p (PDB-ID 
1s2m). For each crystal form two copies of the search model were placed per 
asymmetric unit. After an initial NCS-restrained refinement (REFMAC, Murshudov 
et al., 1997) of the adjusted DDX6-C model, the EDC3-FDF peptide could be built 
unambiguously in COOT (Emsley and Cowtan, 2004), guided for the sequence 
register by the well-defined aromatic side-chains. Further refinement without NCS 
restraints was done in REFMAC and COOT iteratively. Data collection and structure 
refinement statistics are shown in Table S1. According to MolProbity (Davis et al., 
2007) the geometry of the structures is excellent. All three-dimensional 
representations are done with PyMOL (http://www.pymol.org). Electrostatic 
potentials were calculated using the Adaptive Poisson-Boltzmann Solver software 
(Baker et al., 2000). 
 
Analytical size exclusion chromatography 
Components were mixed in chromatography buffer (10 mM HEPES, pH 7.5, 300 mM 
NaCl, 1 mM DTT) using a protein concentration of 30 µΜ, and a peptide 
concentration of approximately 60 µM. After 30 min at 15 °C, 100 µl were injected 
onto the column (15 °C) at a flow rate of 0.4 ml/min. UV absorption was monitored 
simultaneously at 280 nm (E280) and 490 nm (E490). Protein concentrations of 
DDX6-C and DDX6-CMut-1 were estimated from the theoretical molar extinction 
coefficient ε280 at 280 nm. Synthetic peptides (EDC3-FDFFluo: Fluorescein-
EEIPDTDFDFEGNLALFDKAAVFEEIDT; EDC3-ADAFluo: Fluorescein-
EEIPDTDADAEGNLALFDKAAVFEEIDT; EMC Microcollections, Tübingen, 
Germany) were monitored at 490 nm, via N-terminal fluorescein groups. Due to the 
lack of an exact molar extinction coefficient (ε490) for the labeled peptide we chose to 
normalize peptide absorption based on a pilot experiment, where we assumed a 
saturated 1:1 complex of DDX6-C and EDC3-FDF. For calculating protein 
concentrations in the presence of labeled peptide the contribution of the peptide to the 
value of E280 was first subtracted.  
 
NMR measurements 
1H-NOESY and 1H -TOCSY spectra of EDC3-FDF were acquired at 291K on a 
Bruker AV III-600 spectrometer, processed and analyzed using the Topspin (Topspin 
V. 2.1.1, Bruker, Karlsruhe) software. Both spectra were recorded with 1024 (t2) × 
512 (t1) complex points using 128 scans per increment and a relaxation delay of 1 s. 
The 1H -NOESY spectrum was recorded with an NOE mixing time of 120 ms and the 
1H -TOCSY spectrum was recorded with a spin lock mixing time of 70 ms. 
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Supplemental Figure S1
Figure S1. Superposition of the four crystallographically independent DDX6-C 
/ EDC3-FDF complexes (stereo). 
The structures of the four complexes, IA (gray), IB (blue), IIA (red) and IIB (green), 
were superimposed by secondary-structure matching (SSM) and are shown as 
tubes. Selected side-chains are drawn as sticks.
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Figure S2. Difference density for the EDC3-FDF peptide 
(stereo). 
Difference electron density ((|Fo|-|Fc|)eiα(c)) is contoured around 
the EDC3-FDF peptide at 2.0 sigmas over the mean, where |Fo| are 
the observed structure factor amplitudes and |Fc| and α(c) are 
structure factor amplitudes and phases calculated from a model 
lacking this EDC3-FDF peptide. EDC3-FDF is shown as sticks 
(magenta) over the surface of DDX6-C (gray).
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Figure S3. Molecular interface between DDX6-C and the EDC3-FDF pep-
tide including the EDC3 N-terminal loop, the FDF motif and α-helix H1. 
DDX6-C (gray) and EDC3-FDF (salmon) are shown as ribbons with selected 
side-chain and main-chain atoms as sticks (oxygens in red, nitrogens in blue, 
sulfurs in yellow). Fixed water molecules are shown as red spheres, hydro-
gen bonds and salt bridges as dotted lines. β-strands β8 and β14 are drawn 
as loops for clarity. This view is identical to that shown in Figure 3B, but 
includes the DDX6-C C-terminal extension, which contributes to the interface 
with residues Pro448 and Ile449. 
β14
Input IP (anti-HA)
anti-HA
anti-DmEDC3
HA
-M
BP
HA
-M
e3
1B
HA
-B
el
le
HA
-e
IF4
A
1 2 3 4 5 6
HA
-U
AP
56
HA
-p
68
7 8 9 10 11 12
175
83
62
47.5
HA
-M
BP
HA
-M
e3
1B
HA
-B
el
le
HA
-e
IF4
A
HA
-U
AP
56
HA
-p
68
anti-Tral
83
83
Tritschler et al.
Supplemental Figure S4
A
Input
1 2 3 4 5 6 7 8 9 10
IP (anti-HA)
M
BP
ED
C3
ED
C3
-F
AK
ED
C3
-A
DK
ED
C3
-A
AK
M
BP
ED
C3
ED
C3
-F
AK
ED
C3
-A
DK
ED
C3
-A
AK
Input
11 12 13 14 15 16 17 18 19 20
IP (anti-HA)
M
BP
Tr
al
Tr
al
-F
AE
Tr
al
-A
EE
ED
C3
-A
AE
M
BP
Tr
al
Tr
al
-F
AE
Tr
al
-A
EE
Tr
al
-A
AE
HA-DmEDC3 or HA-Tral + GFP-Me31BB
GFP-Me31B
HA-MBP
HA-EDC3
GFP-Me31B
HA-MBP
HA-Tral
Figure S4.
(A) Interaction between EDC3 and Tral with various DEAD-box proteins. HA-tagged 
fusions of maltose binding protein (MBP), wild-type Me31B or the indicated DEAD-box 
proteins were expressed in S2 cells. Cell lysates were immunoprecipitated using a mono-
clonal anti-HA antibody. Inputs (1%) and immunoprecipitates (10%) were analyzed by 
Western blotting using polyclonal anti-HA antibodies. The presence of endogenous EDC3 
or Tral in the immunoprecipitates was detected using anti-EDC3 or anti-Tral antibodies.
(B) Functional analysis of residues in the FDK and FEE motifs of EDC3 and Tral, respec-
tively. HA-tagged MBP, wild-type EDC3 or Tral, and the indicated EDC3 or Tral mutants 
were coexpressed in S2 cells with GFP-Me31B, as indicated. Cell lysates were immuno-
precipitated using anti-HA antibodies. Inputs (1%) and immunoprecipitates (10%) were 
analyzed by Western blotting using anti-HA and anti-GFP antibodies. 
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Figure S5. NOESY and TOCSY spectra of free EDC3-FDF. 
NOESY (A) and TOCSY (B) spectra of unlabeled EDC3-FDF are shown. As expected for an 
unfolded peptide, a very low chemical shift dispersion is observed in the region of the amide 
protons (dispersion from 7.75 to 8.35 ppm), thus excluding the possibility for the peptide to 
adopt a β-stranded structure. Closer examination of the spectra also shows that the peptide 
does not adopt a helical structure due to the lack of strong sequential HN – HN contacts (red, 
dashed box) as well as strong intraresidue HN – Hα contacts. Comparison of the HN – Hα 
peak positions of the TOCSY- to those of the NOESY-spectrum (see zoomed region) shows 
that most of the larger NOESY crosspeaks are not similarly located, meaning they are 
sequential. (For a helical peptide, each TOCSY HN – Hα peak would be expected to have a 
strong NOESY equivalent). Finally the lack of structural information in the NOESY spectra 
such as methyl-methyl and methyl-aromatic contacts further shows that the EDC3-FDF is 
unfolded in solution. For additional information see Supplemental Experimental Procedures.
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Figure S6. Heterodimerization of DDX6-C and EDC3-FDFFluo in vitro.
Analytical gel filtration experiments were done with variants of DDX6-C, either in the absence 
of EDC3 peptides (black dashed lines), or with an excess of fluorescein-labeled EDC3 pep-
tides (black solid lines). DDX6-C concentrations are shown in black (left axis). Relative 
EDC3-peptide absorption is shown in green (right axis), normalized to the amount in the com-
plex. Elution volumes of the free components and of the complex are indicated by arrows and 
dashed gray lines. For additional information see Supplemental Experimental Procedures. 
(A) Complex formation between DDX6-C and the EDC3-FDFFluo peptide. 
(B) Mutation of the EDC3-FDFFluo peptide and disruption of the complex. The free EDC3-
ADAFluo peptide elutes earlier than the free EDC3-FDFFluo peptide. 
(C) Mutation of the DDX6-C domain and disruption of the complex. The elution of the free 
DDX6-CMut-1 quadruple mutant is unaffected, compared to the wild-type.
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Figure S7. Me31B interaction with EDC3 (or Tral) is required for P-body localization. Confocal 
fluorescent micrographs of fixed S2 cells expressing the indicated HA and GFP protein fusions. 
Cells were stained with anti-HA antibodies. The fraction of cells exhibiting a staining similar to that 
shown in the representative panel was determined by scoring at least 100 cells in three independent 
transfections performed per protein. The merged images show the GFP signal in green and the HA 
signal in red.
(A,B) S2 cells expressing HA-tagged Ge-1 and GFP-fusions of full length Me31B (wild-type, A) or 
mutant (B). 
(C,D) S2 cells expressing GFP-Ge-1 and HA-fusions of full length EDC3 wild-type or the ADA 
mutant.
(E,F) S2 cells expressing GFP-Ge-1 and HA-fusions of full length Tral wild-type or the ADA 
mutant.
